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Healthcare settings are dangerous places. Individuals who receive healthcare may be subject 
to unintended harm as a consequence. One potential adverse event is a ‘healthcare associated 
infection’. This contemporary term refers to any infection which is acquired in healthcare 
facilities or any infection that occurs as a result of healthcare interventions. This thesis is 
concerned with the topic of healthcare associated infections. The effects of healthcare 
associated infections are felt not only by individual patients through increased morbidity and 
mortality but also by health services faced with higher costs associated with infections. The 
prevention of infection requires a multifaceted approach which is underpinned by healthcare-
associated infection surveillance. Surveillance is used to influence practice and policy as well 
as to evaluate the effectiveness of strategies to reduce healthcare associated infections. 
Surveillance of healthcare associated infections is a critical element of any infection control 
program and it is crucial that healthcare-associated infection surveillance data are reliable and 
valid. In this thesis, three individual studies are presented.  
 
The three studies focus on two specific healthcare-associated infections: Staphylococcus 
aureus bacteraemia and Clostridium difficile infection. The aim of this thesis is to explore the 
epidemiology of these two infections and, in doing so, to examine methodological influences 
on reliable and valid healthcare associated infection data collection and analysis.  
 
The first study – an examination of the epidemiology of Staphylococcus aureus bacteraemia 
in Tasmania, Australia – used a descriptive, observational, population-based study design. 
This is the first known Australian study to capture and analyse data from all cases of SAB at 
a population-based level and represent this as an incidence. Four key findings can be 
identified from this study. First, the incidence of Staphylococcus aureus bacteraemia at a 
population level was accurately determined for the first time in Australia and was found to be 
21.26 per 100,000 population, with 42% of Staphylococcus aureus bacteraemia being 
healthcare associated. Second, 55% of healthcare associated Staphylococcus aureus 
bacteraemia was associated with intravascular device management. Third, case definitions for 
healthcare associated Staphylococcus aureus bacteraemia have an influence on detection. 
Sixty-eight per cent of healthcare associated Staphylococcus aureus bacteraemia occurred in 
persons hospitalised less than 48 hours but had other criteria which resulted in them being 
XX 
 
defined as healthcare associated. Therefore, in cases where no criteria other than timeframe 
are used to define cases of SAB, approximately 30% of cases of SAB would be incorrectly 
identified as community associated. Fourth, 11% of Staphylococcus aureus bacteraemia were 
identified in private hospitals which fall outside the scope of almost all Staphylococcus 
aureus bacteraemia surveillance programs in Australia.  
 
The second study examined mortality following Clostridium difficile infection in hospitalised 
persons at the Royal Hobart Hospital, Tasmania. Results from this study indicated that 
Clostridium difficile infection was associated with increased mortality, when compared to a 
comparable population who did not have Clostridium difficile infection. More specifically, 
mortality following Clostridium difficile infection was found to be statistically significant at 
180 days post-admission to hospital, compared to persons who did not have Clostridium 
difficile infection, using a conditional logistical regression model. One potential explanation 
for the delayed effect was the manner in which exclusion criteria, more specifically the 
management of two or more positive laboratory tests, were applied to the study population. 
This is an important finding in itself, as this study highlights not only the impact of a 
Clostridium difficile infection on individuals but also the potential influence that case 
definitions may have on valid and reliable results. 
 
The third study examined both the incidence of Clostridium difficile infection at Royal 
Hobart Hospital over a four year period and its impact on the prolongation of length of stay. 
The calculated incidence of 2.68 per 1000 admissions was higher than that found in other 
published Australian data but lower than internationally reported incidences. This study used 
multistate data analysis techniques to determine the potential prolongation of length of stay 
due to Clostridium difficile infection and is, to the best of the author’s knowledge, the first 
study to do so. From the findings, it can be inferred that Clostridium difficile infection does 
not significantly contribute to a longer hospital length of stay, (p = 0.51). Conversely, the 
influence of CDI in a proportional hazard model was found to be statistically significant, with 
acquisition of CDI significantly reducing the discharge hazard (p<0.001). In essence, the 
findings of this study demonstrate limitations of both existing and relatively new data 
analysis techniques. An unpublished model for multistate data analysis is proposed which 




Each of the three studies presented in this thesis provided a significant and unique 
contribution to the literature. In conducting these studies, an improved understanding of the 
epidemiology of these infections in Australian settings was achieved and four influences on 
reliable and valid data collection and analysis were identified. A new model summarising 
these influences is presented which has implications for future healthcare associated infection 
surveillance planning and evaluation. 
1 
 
Chapter 1: Introduction 
 
1.1 Origins of the thesis: patient safety and healthcare 
 
Healthcare settings are dangerous places. For those receiving care, the risk of unintended 
harm from healthcare failures continues to be excessive. The elderly fall and suffer fractures 
and other injuries; incorrect medications are administered with sometimes serious 
consequences; patients unable to move independently develop pressure injuries; and 
clinicians fail to respond to people whose condition deteriorates quickly enough to prevent 
further morbidity or sometimes death; healthcare associated infection (HAI) can cause 
increased morbidity and mortality. These adverse events have spawned an entire industry 
charged with attempting to keep people safe from the dangers associated with being the 
consumers of health care. These points are demonstrated in a landmark paper “To Err is 
Human: Building a Safer Health System” published in 1999 by the Institute of Medicine 
(IOM) (Kohn, 1999). Patient safety studies informing the IOM report suggested that the most 
frequent types of adverse events affecting hospitalised patients include adverse drug events 
and HAI (Brennan et al., 1991; Leape et al., 1991). 
 
 
The IOM paper focussed the attention of policy makers, the public and healthcare workers on 
improving patient safety in healthcare facilities (Kohn, 1999; Yokoe & Classen, 2008). The 
authors reported that adverse events affected approximately two million patients each year in 
the United States, resulting in 90,000 deaths and an estimated $4.5–5.7 billion per year in 
additional costs for patient care at that time (Kohn, 1999). Following the IOM report, the 
‘blame game’ and the search for how to fix the problem commenced in the United States 
(Donaldson, 2008). Congressional hearings were subsequently held, while government 
agencies, professional groups, accrediting organisations and insurers responded with plans to 
define events and develop reporting systems (Donaldson, 2008). 
 
 
In Australia, the themes of the IOM report and patient safety studies are evident through the 




Health Care (ACSQHC). The ACSQHC is an independent statutory authority, under the 
National Health and Hospitals Network Act 2011. The purpose of the ACSQHC is to lead 
and coordinate improvements in safety and quality in health care across Australia. The remit 
of the ACSQHC includes medication safety, falls prevention, recognising and responding to 
clinical deterioration and the prevention of HAIs. This thesis is particularly concerned with 
one patient safety activity the prevention and control of HAIs. 
 
1.1.1 The emergence of healthcare associated infections in patient safety 
 
Healthcare associated infection is the contemporary term used to refer to infections acquired 
in healthcare facilities and infections that occur as a result of healthcare interventions 
(National Health and Medical Research Council, 2010). The effect of HAIs are not only felt 
by individual patients through increased morbidity and mortality, but also by a health service 
through higher costs associated with infections. The magnitude of the effect of HAIs on 
patients is evidenced by a report from the World Health Organisation, which suggests that 
7.6% of hospitalised patients will acquire a HAI (World Health Organisation, 2011b).  
 
Following the publication of the IOM report, further reports were published and strategies 
were developed to raise awareness across the world about the specific importance of HAIs 
and patient safety. In addition, there was a growing consensus that many HAIs were largely 
preventable (Adams, Corrigan, & Institute of Medicine Committee on Identifying Priority 
Areas for Quality Improvement, 2003; Department of Health, 2002, 2004; Yokoe & Classen, 
2008). These developments led to an increase in interest in the area of HAIs from patients, 
the media, politicians, healthcare workers, regulators and government bodies (Flanagan, 
Welsh, Kiess, Hoke, & Doebbeling, 2011; H. Humphreys, Smyth, E T M., 2006; R. A. 
Weinstein, Edmond, & Eickhoff, 2008). In the United States, infection control programs have 
been regulated via legislative mandates and 32 states have HAI reporting laws (Association 
of Professionals in Infection Control and Epidemiology, 2011; Weinstein et al., 2008). In the 
United Kingdom, there has been extensive coverage of HAIs in the media (Turner, 2008). A 
British Broadcasting Corporation health reporter has stated, “There is probably no subject in 





In Australia, accreditation standards for hospitals have been strengthened in the area of 
infection control and new standards will be implemented in 2012 (Australian Commission on 
Safety and Quality in Health Care, 2011e); while public reporting of limited infection control 
data commenced during 2011 and 2012 (Australian Institute of Health and Welfare, 2012; B. 
Mitchell, McGregor, A., Brown, S., Wells, A., 2011b). Nationally, public reporting on hand 
hygiene compliance rates and reports on healthcare associated rates of Staphylococcus aureus 
bacteraemia (SAB) occurs, while in Tasmania data on other HAIs, such as Clostridium 
difficile infection (CDI), are recorded. At the time of writing, Tasmania is the only state in 
Australia that mandates public reporting of HAI data, additional to those that are required 
nationally. More broadly, on the issue of public reporting an expert advisory committee to the 
Centres for Disease Control and Prevention (CDC), the Healthcare Infection Control 
Practices Advisory Committee (HICPAC), argue that patients do have a right to know this 
information, but note concerns that the reliability of public reporting systems may be 
compromised by the variability in the definitions used for HAIs, or in the methods and 
resources used to identify HAIs (McKibben et al., 2005). The concerns raised by the 
HICPAC are themes that emerge through the three studies undertaken in this thesis and are 
discussed in more detail in Chapter 6. 
 
The decision to move to public reporting in Tasmania came after considerable media and 
political attention on the issue. Patient advocate groups applaud the fact that politicians have 
legally mandated reporting of infection prevention and control measures, for example, the 
requirement of formal governance arrangements incorporating the role of senior level 
managers and executives in healthcare organisations. Conversely, others “lament the forced 
creation of more layers of bureaucracy instead of focusing on resolving root causes, root 
causes created by the same political forces that created these new requirements” (Birnbaum, 
2004, p. 256). Regardless of individual views on political involvement in infection control, 
one key element in any infection prevention strategy, mandated or not, is the need to inform 







1.2 Surveillance of healthcare associated infections 
 
To influence practice and policy and to evaluate the effectiveness of strategies to reduce 
HAIs, there is a need to collect HAI data and use these through a wider system of quality 
management, as demonstrated through the Study of the efficacy of nosocomial infection 
control project, often referred to as the SENIC study (Haley et al., 1985). As a consequence 
of the SENIC study and the IOM report, HAI surveillance programs have been established in 
numerous countries to monitor and control the occurrence of HAIs through internal quality 
improvement efforts (Cruickshank, 2009; Health Protection Agency, 2007; Jarvis, 2003; 
Yokoe & Classen, 2008). HAI surveillance data can be integrated into a quality improvement 
cycle, such as the ‘plan-do-check-act’ cycle developed by Shewhart (Cleghorn & Headrick, 
1996). This cycle shares basic features of well-accepted theory about individual and 
organisational learning, including the concepts of change and action and or reflection 
(Cleghorn & Headrick, 1996). Surveillance for quality improvement in the area of HAIs can 
measure outcomes such as infections, or processes that are linked to outcomes, for example 
hand hygiene compliance (Collins, 2008). Regardless of whether outcome or process data are 
used, a critical element in using surveillance data for quality improvement is the need for it 
be of high quality (Clezy, 2008). Erroneous conclusions about healthcare problems in a given 
population may be drawn from poor quality data.  
 
In this thesis, I undertake three individual pieces of research, referred to as studies. As well as 
providing new clinical findings related to the infection themselves, I demonstrate 
methodological challenges in common approaches to HAI surveillance. The themes relating 
to the methodological challenges are synthesised at the end of the thesis and a new 
framework is proposed incorporating the influences on reliable and valid HAI surveillance 
data. 
 
The three studies in this thesis focus on two specific HAIs, namely, SAB and CDI. Each 
study is an individual piece of research that makes a significant contribution to the 
understanding and effect these two infections have in Australia. In addition the findings of 





1.3 Setting for the studies in this thesis 
 
The geographical location of the three studies is the Australian State of Tasmania. The State 
of Tasmania consists of an archipelago of more than 300 islands. It is located 240 kilometres 
south-east of mainland Australia. The state is home to a population of approximately 500,000 









Figure 1. Map of Australia indicating Tasmania. 
 
The first study is conducted at a population level, while the setting for studies two and three 
is the Royal Hobart Hospital (RHH). The RHH, located in Tasmania’s capital city, Hobart, is 
a tertiary hospital and is Tasmania’s largest public hospital. Like other Australian states and 
territories, Tasmania is facing the challenges of an ageing population, an increase in chronic 
disease and an increase in the costs of healthcare (Department of Health and Human Services, 
2007; Taylor, 2008). 
 
1.4 Background of the author 
 
My interest in conducting this research emanated from 13 years of experience as a practising 





Assistant Director of Nursing at the Tasmanian Infection Prevention and Control Unit 
(TIPCU), a departmental unit of the Department of Health and Human Services. In this role I 
take a lead in the strategic planning and management of HAI prevention in the Tasmanian 
public health system. As a result, many aspects of my work as Assistant Director and the 
research undertaken as part of this thesis are intrinsically linked. This is demonstrated by my 
involvement in Australia’s national hand hygiene initiative, the development of the first HAI 
strategy for Tasmania, the development of national surveillance implementation guides, and 
my work on the National Health and Medical Research Committee (NHMRC) responsible for 
oversighting the national infection control guidelines (L. Grayson, Russo, R., Cruickshank, 
M., Bear, J., Gee, C., Hughes, C., Johnson, P., McCann, R., McMillan,  A., Mitchell, B., 
Selvey, C., Smith, R., Wilkinson, I., 2011; B. Mitchell, Brown, S., Wells, A., McGregor, A., 
2009; B. Mitchell, McGregor, A., Coombs, G., 2009; National Health and Medical Research 
Council, 2010). In each of the studies in this thesis, a clear delineation between my work as a 
researcher and my work in the TIPCU is made where necessary.  
 
In my role as Assistant Director, I have developed and implemented a range of HAI 
strategies, including the establishment of surveillance programs in Tasmania. I am a current 
member on national committees, including the National Hand Hygiene Advisory Committee 
and the National Technical Surveillance Group (Australian Commission on Safety and 
Quality in Health Care, 2011c, 2011d). My work in the latter group required the translation of 
a concept, namely national surveillance of two HAIs into reality. This experience has 
provided me with insight into the current challenges in implementing national HAI 
surveillance programs. More specifically, I was faced with the dilemma of providing a 
national surveillance program that could be implemented across Australia in a variety of 
settings and at the same time attempting to maintain high quality, reliable and valid HAI 
surveillance data. This experience led me to question how I could build on existing 
Tasmanian HAI surveillance data to address key clinical questions relating to SAB and CDI, 






1.5 Aims of the thesis 
 
There are two overarching aims for this thesis: 
1. To explore the epidemiology of two serious HAIs namely SAB and CDI 
2. To examine methodological influences on reliable and valid HAI data collection and 
analysis  
 
1.6 Structure of the thesis 
 
The thesis contains three studies on two HAIs, namely SAB and CDI. Each of these three 
studies has specific objectives that relate to the aims of the thesis. In addition, each study has 
specific research questions to address the stated objectives. The thesis contains six chapters, 
including this chapter. A brief summary of each of the chapters will now be provided. 
 
The next chapter, Chapter 2, provides an introduction to the topic of HAIs, including a 
description of what HAIs are and the common types of infection that are implicated. The 
effects that HAIs have on an individual and on health services as a whole are also explored, 
in addition to current strategies to prevent HAIs in Australia. Theoretical frameworks and 
elements of HAI prevention programs, both of which underpin infection prevention activities, 
are then discussed. 
 
The third chapter is concerned with SAB. This chapter provides a background to S.aureus 
infection generally and SAB, before a literature review analysing the epidemiology of SAB 
and elements of a SAB surveillance program are detailed. Following the literature review, the 
methods, results and interpretation of the first study are presented. The objectives for the first 
study are to describe the epidemiology of SAB in Tasmania and to understand the 





The fourth chapter is concerned with CDI. This chapter initially provides background about 
the organism C.difficile and CDI, before a literature review analysing mortality and CDI is 
presented. Following the literature review, the second study of this thesis is described. The 
objectives for the second study are to describe the risk of mortality associated with CDI and 
to explore potential limitations in estimating mortality associated with CDI, when current 
international surveillance definitions for CDI are applied.  
 
The fifth chapter is again concerned with CDI; however this chapter further explores the 
epidemiology of CDI in more detail, by examining the potential effect it has on prolonging 
the length of stay in hospital in persons who had this infection. As a background to CDI was 
provided in the previous chapter, it is not repeated again. A literature review analysing 
studies that have examined CDI and the prolongation of length of stay in hospital is provided. 
Then, the third and final study of this thesis is presented. The objectives of this piece of 
research were to explore the incidence of CDI and prolongation of length of stay due to CDI 
and to analyse potential influences of differing data analysis methods in the calculation of any 
prolongation of length of stay.  
 
The final chapter, Chapter 6, commences by summarising and synthesising the key findings 
of the three studies presented in this thesis. In doing so, a model explaining the influences on 
reliable and valid HAI data—as identified through the studies conducted for this thesis—is 
presented and the implications for the proposed model discussed. The contribution to 




This chapter has provided an overview on the origins of this thesis, an introduction to the 
study setting for the three studies contained in the thesis and a summary of the structure of 
the thesis. Information on the background of the author of this thesis was presented to provide 




activities of the author. The next chapter of the thesis will introduce the topic of HAIs and 
includes strategies for their prevention. 
10 
 
Chapter 2: An introduction to healthcare associated infections  
 
2.1 Introduction to the chapter 
 
While Chapter 1 painted an overall picture regarding HAIs, this chapter will provide 
comprehensive information about the topic. Initially, an explanation of what HAIs are, 
including common types of infections is provided. The impact that HAIs have on an 
individual and on health services as a whole will then be explored. Strategies for HAI 
prevention and the role of HAI surveillance are subsequently discussed. Then, existing 
theoretical frameworks for infection prevention and control will be presented. An extension 
of an existing theoretical framework that incorporates the role of surveillance will then be 
proposed with supporting arguments.  
 
2.2 What are healthcare associated infections? 
 
The prevention of infection in persons receiving healthcare stretches back over a century to 
the time of Ignaz Semmelweis in 1847 and Florence Nightingale in 1863. Semmelweis, a 
Hungarian physician, discovered that using chlorine in hand washing practice dramatically 
reduced the incidence of puerperal fever and mortality in obstetric practice (Pittet & Boyce, 
2001). Similarly, Nightingale’s ideas about infection were formed through improving 
environmental hygiene and sanitation (Nightingale, 1863). In the past hundred years, hand 
hygiene, environmental cleanliness and other practices—such as isolation of patients with 
specific conditions—as methods of preventing infection have been reinforced repeatedly. 
Regardless of the known efficacy of these practices, however, compliance with infection 
prevention activities by healthcare workers remains sporadic, which continues to contribute 
significantly to the incidence of HAIs.  
 
‘Healthcare associated infection’ is the current term used to refer to infections acquired in 
healthcare facilities and infections that occur as a result of healthcare interventions (National 
Health and Medical Research Council, 2010). The terms ‘nosocomial infection’ and ‘hospital 




infection and nosocomial infection are terms that are used to reflect a subcategory of HAIs, 
i.e. those that have arisen during a hospital stay. For the purpose of this thesis, the term ‘HAI’ 
is used in a manner consistent with that defined by Australia’s main research body, the 
National Health and Medical Research Council (National Health and Medical Research 
Council, 2010). In this thesis, when other terms are used to describe subsets of HAIs, these 
terms are initially defined and subsequently used consistently throughout (see Glossary of 
common terms used in the thesis). 
 
Healthcare associated infections are common and can be caused by a variety of organisms, 
triggering a range of symptoms and infections in various human systems. One of the most 
commonly cited prevalence studies was undertaken in the United Kingdom. Findings from 
this study suggested that in hospitals, the prevalence of HAIs is approximately 8% (D. 
Gravel, Taylor, G., Ofner, M., Johnston, L., Loeb, M., Roth, V., Stegenga, J., Bryce, E., 
2007; H. Humphreys, Newcombe,  R., Enstone, J., Smyth, E., McIlvenny, G., Fitzpatrick, F., 
Fry, C., Spencer, R., 2008; Smyth et al., 2008). The types and frequency of HAIs identified in 
this point prevalence survey of 75,694 persons in England, Wales, Northern Ireland, and the 
Republic of Ireland are listed in Table 1 and grouped by anatomical location of the infection 















Frequency and causative agents of healthcare associated infections 
Infection Type / Anatomical location % of all 
HAIs 
Main causative agent(s) 
Gastrointestinal  20.6% C.difficile 
Urinary tract  19.9% Gram negative bacteria 
Surgical site  14.5% S.aureus, Gram negative bacteria 
Pneumonia 14.1% S.aureus, Acinetobacter species 
Skin and soft tissue 10.4% S.aureus 
Other (bone, joints, eyes, nervous system, 
cardiovascular, reproductive tract) 
7.2% Various 
Bloodstream (bacteraemia) 7% E.coli, S.aureus 
Lower respiratory tract (other than 
pneumonia) 
6.3% S.aureus 
Note: Adapted from Smyth et al. (2008). The information regarding main causative agents 
was adapted from the National Audit Office (2009), from data from the study conducted by 
Smyth et al. (2008). Gastrointestinal system includes gastroenteritis, hepatitis, and intra-
abdominal infections. HAIs = healthcare associated infections. 
 
The results of the study undertaken by Smyth et al. (2008) as presented in Table 1 not only 
demonstrate the distribution of HAIs by anatomical location, but also highlight that HAIs can 
be caused by a range of pathogens. Having provided background information, a description 
of the impact that HAIs have at individual and healthcare service levels will now be explored.  
 
 
2.3 The impact of healthcare associated infections on individuals and the 
health service 
 
Healthcare associated infections have a significant impact on patients through associated 
morbidity and mortality, and on the population as a whole through a negative effect on health 
services. These infections are deemed the most frequent adverse events threatening patients’ 




Donaldson, 2005). It is important to note that the impact of HAIs on individuals varies 
significantly, due to the nature of the illness caused by the infection. For example, as a 
general rule, a urinary tract infection would not be considered as serious as a bacteraemia, 
because the former is localised and the latter is systemic. The variation in effect of an 
infection on a person is also influenced by the causative agent. Some microorganisms are of 
greater concern due to their high level of virulence or because antibiotic resistance reduces 
our ability to treat them. With this background in mind, the impact that bloodstream 
infections have on individuals will be used as an example of the seriousness of HAIs.  
 
Bloodstream infections with bacteria (bacteraemia) or fungi (fungaemia) are common, and 
they are associated with significant morbidity and mortality. Although these are not the most 
common HAI, they are among the most important contributors to morbidity and mortality 
caused by HAIs (P. Collignon, Dreimanis, D., Ferguson, J., van Gessel, H., Taylor, P., 
Wilkinson, I., Worth, L, 2008). Many people who develop a healthcare associated 
bloodstream infection die during their hospital stay (Higuera et al., 2007; Pittet & Wenzel, 
1995; Wey, Mori, Pfaller, Woolson, & Wenzel, 1988). Those who do survive often develop 
complications and stay in hospital longer than persons who do not contract an infection 
(Saint, 2000). To explore this more fully in an Australian context, a prospective cohort study 
over three years examined the mortality and health status of persons who had a bloodstream 
infection (Gardner, 2003). In this study, 9% died by the end of the first week, and 34.5% died 
by six months. Survivors were followed up post-discharge. The two main findings from this 
study were that bloodstream infections are important in contributing to the probability of 
death, and that survivors continued to have reduced health when followed up for six months 
(P. Collignon, Dreimanis, D., Ferguson, J., van Gessel, H., Taylor, P., Wilkinson, I., Worth, 
L, 2008; Gardner, 2003). The example of morbidity and mortality associated with 
bacteraemia is one way to demonstrate the impact HAIs have on patients. There are other 
instances in the literature, including the effects of surgical site infections  (Bull, 2008; 
Kirkland, Briggs, Trivette, Wilkinson, & Sexton, 1999), urinary tract infections (Foxman, 
2002), and pneumonia (Kollef et al., 2005). 
 
A different approach to examining the impact that HAIs have on individuals is to explore the 




an example of a multi resistant organism (Engemann et al., 2003). For example, a 
retrospective cohort study evaluated the risk of subsequent MRSA infection and death among 
patients known to have harboured MRSA for at least one year (Datta & Huang, 2008). The 
study identified 281 carriers of MRSA, 23% of whom went on to develop discrete and 
unrelated MRSA infections in the year following their identification as prevalent carriers. 
The most common infections were pneumonia (39%), soft tissue infection (14%), and central 
venous catheter infection (14%) (Datta & Huang, 2008). 
 
The impact of HAIs is not limited to individuals. Treatment of HAIs consumes additional 
healthcare costs, through need for additional diagnostic procedures; interventions, such as 
surgery and antibiotic therapy; and longer lengths of stay in hospital (Rosenthal, Guzman, 
Migone, & Crnich, 2003). Additional length of stay is a major contributor to cost. One review 
identified 254 separate estimates of the length of stay attributable to a HAI and found that 
additional length of stay due to HAI varies according to infection type and causative agent, 
but it was clear that infections played a role in increased lengths of stay in hospital (N. 
Graves, Halton, K., Robertus, L., 2008). Costs associated with HAIs, however, are not 
limited to hospitals. The cost of HAIs also extends beyond the hospital, with post-discharge 
costs of persons with surgical site infections being one example. There has been one estimate 
that the post-discharge cost of surgical site infections in Australia is $21 million per year (N. 
Graves, Halton, K., Robertus, L., 2008). 
 
It is clear from the examples provided in this section that HAIs have a negative impact on 
individual patient outcomes, in addition to contributing to additional costs of a health service. 
With this in mind, the importance of preventing HAIs becomes clearer. The next section 
provides an overview of infection prevention activities and the role that surveillance plays in 






2.4 The prevention of healthcare associated infections and the role of 
surveillance 
 
In Australia, access to healthcare is universal through Medicare, Australia’s publically funded 
healthcare system, which provides free or subsidised medical, optical, and hospital care. 
Private healthcare is also available; however, there are close links between public and private 
facilities. For example, a patient may choose to receive private healthcare, but be physically 
located in a public hospital. Australian state and territory governments are responsible for the 
governance and management of public hospitals, whilst private hospitals are managed by the 
relevant funding organisation. Until recently, strategies to prevent HAIs were solely 
undertaken by individual hospitals or led by state or territory government bodies, such as the 
Centre for Healthcare Related Infection Surveillance and Prevention in Queensland and the 
TIPCU (Centre for Healthcare Related Infection Surveillance and Prevention, 2012; B. 
Mitchell, Brown, S., Wells, A., McGregor, A., 2009). Professional organisations, such as the 
Australasian College for Infection Prevention and Control (formally Australian Infection 
Control Association) and the Australasian Society for Infectious Disease, have also played 
key roles in infection control activities. The establishment of the ACSQHC in 2006 has 
changed the focus of HAI prevention in Australia to a more national and collaborative 
direction. The ACSQHC identified the prevention of HAIs as one of its key pieces of work, 
and commissioned a review of the infection control programs in Australia as part of the 
background work (Tropea, 2008).  
 
The ACSHQC set five individual pieces of work as part of a strategy to reduce the risk of 
HAIs: 1) improvement in surveillance of HAIs (a main focus of this thesis), 2) the 
establishment of a national hand hygiene initiative, 3) commissioning of the National Health 
and Medical Research Council (NHMRC) to develop national guidelines for infection 
control, 4) building clinical capacity, and 5) antimicrobial stewardship (Australian 
Commission on Safety and Quality in Health Care, 2011a). At the time of the writing of this 
thesis, the national hand hygiene initiative was in progress, with the participation of over 500 
hospitals in Australia, as well as agreement to the program by all state and territory health 
ministers (Russo, Pittet, & Grayson, 2012). In addition, the NHMRC has published national 




Council, 2010). Furthermore, there have been publications on surveillance and antimicrobial 
stewardship, with agreement on national definitions for SAB and CDI, and agreement by all 
states and territories to undertake surveillance of these two infections (Australian 
Commission on Safety and Quality in Health Care, 2010; Duguidm, 2011). Clinical capacity 
has been expanded, through the development of a national committee and the provision of 
education through online learning modules and ‘road shows’. 
 
On 1 July 2011, the ACSQHC became a permanent independent Statutory Authority under 
the National Health and Hospitals Network Act 2011. The ACSHQC’s primary function is to 
lead and coordinate improvements in safety and quality in healthcare across Australia. In 
September 2011, Australian Health Ministers endorsed new National Safety and Quality 
Healthcare Service Standards. These standards include infection prevention and control 
standards that are consistent with and support the work led by the ACSHQC (Australian 
Commission on Safety and Quality in Health Care, 2011b, 2011e). Infection prevention and 
control activities are monitored through approved accreditation agencies in Australia. Some 
of these initiatives are referred to throughout the thesis.  
 
The prevention of infection requires a multifaceted approach. These various approaches are 
often summarised in an infection control management plan or program used to facilitate the 
prevention and control of HAIs through internal quality improvement efforts (Yokoe & 
Classen, 2008). In 2010, the World Health Organisation (WHO) summarised the core 
components of an infection control program (Seto, Otaíza, & Pessoa Silva, 2010). These 
components as outlined by the WHO are consistent with those subsequently suggested by the 
ACSQHC, the NHMRC, and Australian state and territory government led infection control 
units. The WHO and the ACSQHC have listed surveillance as a key component of an 
infection control program. Surveillance is the collection, collation, analysis, and 
dissemination of data regarding a health related event for action to reduce morbidity and 
mortality and improve health (Guidelines Working Group, 2001). The WHO suggested that 
surveillance programs include surveillance of infections and assessment of compliance with 





There have been calls nationally and internationally for improved surveillance of HAIs so 
that the size, burden, and impact can be reduced, and to monitor the effect of interventions 
(Allegranzi et al., 2011). Likewise, there have been suggestions that surveillance itself can 
lead to a reduction in HAIs (Allegranzi et al., 2011; Gastmeier et al., 2006; Haley et al., 
1985). Surveillance has an important role in healthcare as it can serve as an early warning 
mechanism, provide essential data for monitoring the effectiveness of interventions, detect 
trends, provide information for designing and planning future programs, provide a measure 
for evaluating interventions or programs, and provide a framework for performance 
management (M. Cruickshank, Jorm, C., 2008; Gregg, 2002). Furthermore, it has been 
suggested by Nelson (2007) that key attributes of an effective surveillance program include 
sensitivity, timeliness, representativeness, yielding a high positive predictive value, and being 
simple, acceptable, and flexible.  
 
This section has provided a brief overview on HAI prevention strategies and introduced the 
importance of HAI surveillance. Surveillance, in the context of a revised theoretical 
framework for infection prevention and control, will be discussed in more detail later in this 
chapter. First, it is important to consider the current theoretical frameworks that underpin 
infection prevention activities. This is the focus of the next section.  
 
2.5 Theoretical frameworks in infection prevention and control 
 
Two frameworks related to infection prevention and control are explored in this section. The 
first, chain of infection, is a commonly cited framework used to describe methods of 
controlling and preventing infection as in the Australian Guidelines for the Prevention and 
Control of Infection in Healthcare (National Health and Medical Research Council, 2010). 
The second framework discussed in this section describes a biopsychological approach to 






2.5.1 Chain of infection 
 
Three processes are required for infectious agents to cause infection. These processes are 
often grouped together and referred to as the chain of infection (Figure 2). The chain of 
infection describes the elements for transmission of infections: the presence of an infectious 
agent (source), a mode of transmission, and a susceptible host (National Health and Medical 
Research Council, 2010). The term ‘cross infection’, is often used to describe the spread of 
infection from one person to another.  
 
Figure 2. The chain of infection. This figure describes the elements required for a person to 
acquire an infection. 
The sources of infectious agents primarily transmitted in healthcare settings are patients, 
healthcare workers, and visitors. The presence of an infectious agent on a human, however, 
does not necessarily mean infection. Individuals may carry an organism but display no 
symptoms for several reasons: the incubation period for the organism may be long, the 
carriage may be temporary, or the individuals may be chronic carriers without any symptoms. 
The term ‘colonisation’ is used to describe a sustained presence of replicating infectious 
agents on or in the body, without the production of an immune response or disease. 
Conversely, infection is the invasion of infectious agents into the body, resulting in an 
immune response, with or without symptomatic disease (National Health and Medical 
Research Council, 2010). There are two other sources of infectious agents: first, the 
endogenous flora of patients, and second, environmental sources, such as air, medical 
equipment, and other inanimate objects that have been contaminated. More detail regarding 











Infectious agents can be transmitted from their sources to a susceptible host by a variety of 
methods, which include direct spread on the hands of healthcare workers, carriage on 
equipment, and through airflow. The prevention of transmission via these methods can be 
routinely prevented in healthcare settings using standard precautions. A more detailed 
description of standard precautions is provided in Appendix B. Other modes of transmission 
for infectious agents are via direct or indirect contact, mucous membrane contact with 
respiratory secretions (droplet transmission) or inhalation of infectious agents suspected in 
the air (airborne transmission) (National Health and Medical Research Council, 2010). These 
three processes fall under the umbrella term ‘transmission based precautions’ and more 
information is provided in Appendix C. 
 
If transmission of an infectious agent does occur, infection is not necessarily certain. 
Infection is the result of a complex interrelationship between a host and an infectious agent 
and people vary in their response; not all people exposed to an infectious agent will develop 
symptomatic disease (National Health and Medical Research Council, 2010). The term 
‘susceptible host’ is used in the chain of infection framework to describe this stage (Figure 2). 
A number of factors influence an individual’s outcome following exposure. These factors 
include age, immune status, existing co-morbidities, the presence of wounds and devices, and 
the pathogenicity of the infectious agent. Pathogenicity is further characterised by the 
organism’s virulence and invasiveness (Brachman, 1996). 
 
The chain of infection has been referred to as using a biomedical or physical approach to 
infection prevention and control (Elliott, 2009). The terms ‘physical’ and ‘biomedical’ are 
often used interchangeably in the literature to describe the chain of infection approach. For 
the purpose of this thesis, the term ‘physical’ is used for consistency. The physical approach 
to health focuses on risk behaviours, emphasises health education, targets individual 
responsibility, and treats people in isolation. Considering the chain of infection approach and 
the examples of standard and transmission based precautions provided earlier, the suggestion 
that the chain of infection is physical in its orientation has some merit. However, there have 




(Elliott, 2009). In the next section, the potential limitations of the chain of infection model are 
explored in the context of a different theoretical approach to infection prevention. 
 
2.5.2 Biopsychosocial approach to infection prevention  
 
A biopsychosocial approach, that is, an approach that considers the physical, social and 
psychological aspects to infection prevention, was documented by Elliott (2009). He 
considered that the chain of infection model was no longer an adequate framework. The basis 
for his suggestion was that the chain of infection is out-dated and that it is “biomedical in its 
orientation and in the absence of any empirical findings to substantiate it as a holistic and 
rigorous measure capable of contributing to long term reductions in healthcare-acquired 
infection, it must be concluded that the chain is neither valid nor reliable” (Elliott, 2009, p. 
68). To elaborate further, he explained that this model is, at best, tenuous in its ability to 
purport what it is meant to, because they are developed by health and social care 
professionals who consistently demonstrate a propensity for being susceptible to dissonance 
effects, cognitively economic thinking and unrealistically optimistic beliefs in failing to 
recognise the necessity of adopting a biopsychological approach (Elliott, 2009). Examples of 
why the chain of infection has limitations as a physical approach, suggested by Elliott (2009), 
are provided in Appendix D. Elliott (2009) recognising the need to embrace a new theoretical 
framework for infection control proposed a biopsychosocial or united approach to infection 





Figure 3. A biopsychosocial approach to the causal nature of cross infection and the number 
of HAIs. This model was proposed by Elliott (2009, p. 69). Failure to acknowledge and 
reflect upon all three aspects equally will serve to increase the risk of cross infection and the 
number of HAIs. The physical aspects approach in this figure refers to a biomedical approach 
(i.e. the chain of infection).  
 
Elliott (2009) provides examples of each of the three aspects in the above model. Examples 
of the physical aspects reflect those in the chain of infection, i.e. reservoir, susceptible host, 
and mode of transmission. Psychological aspects include: rationalised beliefs, arrogance, 
stress, poor morale, and egocentric attitudes; while the social aspects include: elements of 
workload, management issues, fatigue, and peer pressure. In considering how infections are 
transmitted and the potential roles of social and psychological influences, theoretical 
frameworks for infection prevention and control and the subsequently developed programs 
need to be multifaceted. Such an argument is supported by Pittet, who suggested that “based 
on behavioural theories and reported experiences, multimodal intervention strategies have 
more chance of success than single approaches or promotion programmes focusing on one or 
two elements alone” (2004, p. 12). Despite this, explicit frameworks for infection prevention 
and control are rarely used or discussed in the infection control literature, as noted in a review 
conducted by Zimmerman, Yeatman and Jones (2012).  
 













The authors of this review concluded that “there is an absence of literature on studies that 
have applied conceptual frameworks to describe and analyse the adoption of comprehensive 
infection control programs within healthcare settings” (Zimmerman et al., 2012, p. 130). The 
authors go on to suggest that frameworks which dominated the literature, “focussed on 
continuous quality improvement and diffusion of innovations” (Zimmerman et al., 2012, p. 
130). The review identified four studies that used a diffusion of innovation theory (Abbott, 
Dremsa, Stewart, Mark, & Swift, 2006; Farrell & Petrik, 2009; Larson, Quiros, & Lin, 2007; 
Leu, 1995). Diffusion of innovation theory describes “the process by which an innovation is 
communicated through certain channels over time among the members of a social system” 
(Rogers, 1983, p. 5). Zimmerman et al. (2012), having identified four studies that used the 




2.6 A conceptual framework for infection control that incorporates the role of 
surveillance   
 
Miles and Huberman (1994) defined a conceptual framework as a product that explains, 
either graphically or in narrative form, the main factors, concepts, or variables to be studied, 
as well as the presumed relationships. A conceptual framework, therefore, could be 
considered a group of concepts or ideas, broadly described and systematically organised to 
provide a guide for the interpretation of information. The successful use of conceptual 
frameworks to translate evidence into practice in various healthcare disciplines is well 
recognised in the literature (Atun, de Jongh, Secci, Ohiri, & Adeyi, 2010; Biron, Richer, & 
Ezer, 2007;  Donaldson, Rutledge, & Ashley, 2004; Drolet & Lorenzi, 2011; Sudsawad, 
2005). In the context of infection prevention and control, use of a conceptual framework has 
been supported by evidence suggesting that organisations with surveillance programs have 
seen a reduction in HAIs (Gastmeier et al., 2006; Haley et al., 1985). In this section I 
introduce an extension of the framework proposed by Elliott (2009) detailed in Figure 3 by 
incorporating the role of surveillance. Rationale for why surveillance should be included in a 





As discussed earlier, HAI surveillance programs and, to a broader extent, HAI research, 
allow for the collection, collation, analysis, and dissemination of data. Further, analysis of 
HAI data through surveillance and research enables evaluation of interventions (Gaynes, 
1997). In Section 2.5.2, Elliott’s theoretical model describing biopsychosocial influences on 
the number of HAIs was presented (Figure 3). The model, however, does not include of the 
role of HAI surveillance. Surveillance programs for HAIs usually focus on infections that 
occur most frequently in healthcare settings and on the types of infections that pose the 
greatest risks to patients, through increased morbidity and mortality. Other infections are 
monitored because they are validated indicators of a range of important healthcare processes, 
such as hand hygiene and environmental cleanliness. The results of surveillance programs 
provide measures of the standards of infection control practices in hospitals and other 
healthcare facilities (Gaynes & Platt, 2006). Reliable surveillance data and continuous 
monitoring can provide useful information for clinicians and patients alike, by identifying 
areas for improvement and demonstrating the effectiveness of interventions, such as a 
reduction in infection rates and, subsequently, patient morbidity and mortality (K. Guerin, 
Wagner, J., Rains, K., Bessesen, M., 2010; Haley, et al., 1985; Pronovost et al., 2006). With 
these concepts in mind, a conceptual framework that includes the role of surveillance in HAI 
prevention is presented in Figure 4. 
 
Surveillance of HAI





Figure 4. Conceptual framework incorporating the role of HAI surveillance in infection 
prevention and control. Surveillance refers to the collection, collation, analysis, and 





In the framework depicted in Figure 4, a relationship is shown between surveillance of HAIs 
and the physical, social, and psychological aspects influencing the risk of infection. The 
argument for the developed framework is that surveillance can be used to inform, influence, 
and evaluate all three aspects of infection prevention described by Elliott (2009). The 
evaluation component is represented by the broken line in Figure 4. Examples that 
demonstrate the rationale for inclusion of HAI surveillance in the framework proposed in 
Figure 4 will now be explored.  
 
Psychological aspects and role of HAI surveillance 
 
The term ‘unrealistic optimism’ is used to describe a process whereby individuals behave in 
ways that put themselves or others at risk. In the context of infection control, an example may 
be failure to perform hand hygiene or failure to prepare a skin site appropriately prior to 
insertion of a device. In unrealistic optimism, an individual has a distorted belief of the risks 
involved in a type of behaviour. Using hand hygiene as an example, a healthcare worker may 
believe that either a) their practice is consistent with best practice, or b) failure to perform 
hand hygiene will not result in a person acquiring an infection. This statement is supported by 
a study that examined self-reported against observed hand hygiene compliance in healthcare 
workers (Jenner et al., 2006). The results indicated that observed hand hygiene practice was 
not predicted by self-reported measures of practice. Interpreting these findings, the authors 
propose that if people believe that their hand hygiene is much better than it is, then they are 
likely to be oblivious to current campaigns aimed at increasing hand hygiene compliance by 
changing their attitude (Jenner et al., 2006). Surveillance data can be used to correct the 
assumptions that individuals may have about their own practices or the way in which 
interventions affect patient outcomes. One example of this is the national hand hygiene 
initiative currently underway in Australia. Hand hygiene compliance data are used to inform 
healthcare workers of their level of adherence to correct hand hygiene, with early findings 
from the national hand hygiene initiative in Australia suggesting a reduction in SAB 
associated with improved hand hygiene compliance (L. Grayson, Russo, R., Cruickshank, M., 
Bear, J., Gee, C., Hughes, C., Johnson, P., McCann, R., McMillan,  A., Mitchell, B., Selvey, 





Another aspect of a psychological approach to infection prevention is the concept of 
cognitive economy, where it is argued that individuals develop ‘tunnel vision’ and fail to take 
into account the wider implications of their behaviour. As stated by Reason, “humans, if 
given the choice, would prefer to act as context-specific pattern recognisers rather than 
attempting to calculate or optimize” (Reason 1998, p. 44). It is postulated that individuals 
prefer to be task orientated as opposed to considering the wider context and being person 
centred, with the reason being that being task orientated requires less cognitive effort; hence, 
the term cognitive economy (Elliott, 2009). The development and success of care bundles in 
reducing HAIs can be used as an example of how cognitive economy can be positively 
applied to the framework proposed in Figure 4. A care bundle approach is defined as the 
“bundling together of several scientifically grounded elements essential to improving clinical 
outcome” (Aboelela, Stone, & Larson, 2007, p. 105). One example used in infection control 
is a central line care bundle which specifies the key components required to reduce the risk of 
infection (Institute for Healthcare Improvement, 2012). Each component of the care bundle 
should be well defined and based on strong evidence from at least one systematic review of 
multiple well designed, randomised, controlled trials or from at least one properly designed, 
randomised, controlled trial (Fulbrook & Mooney, 2003). Evidence provided through HAI 
surveillance and research is used in development of care bundles as well as evaluating the 
effect of care bundles on reducing HAIs, as evidenced by studies showing a reduction in 
central line associated bacteraemia ( Guerin, Wagner, Rains, & Bessesen, 2010; Schulman et 
al., 2011) and ventilator associated pneumonia (Resar et al.; Westwell, 2008).  
 
Social aspects and role of HAI surveillance 
 
Elliott (2009) suggests that social aspects include workload, management issues and peer 
pressure, and the presence of infection control professionals. On the issue of workload, there 
is evidence that inadequate staffing can increase the risk of HAIs (Hugonnet, Chevrolet, & 
Pittet, 2007). The purpose of these studies was to demonstrate to colleagues and policy 
makers the importance of workload in relation to safe, quality care. These studies were only 





A different example of the role surveillance plays in social strategies to prevent HAIs is the 
use of social cognitive theory. Social cognitive theory provides a framework for 
understanding, predicting, and changing human behaviour, and the theory identifies human 
behaviour as an interaction of personal factors, behaviour, and the environment (Bandura, 
1977). The theory suggests that people learn not only through their own experiences, but also 
by observing others’ actions and the results of those actions, as well as through modelling 
(Pittet, 2005). Such a theory supports strategies to engage clinical leaders and enrol senior 
management support in infection prevention strategies (Department of Health, 2003; B. 
Mitchell, Brown, S., Wells, A., McGregor, A., 2009; Welsh Assembly Government, 2004). 
 
Using the framework of social cognitive theory, Pittet (2005) also suggests that social 
networks can play a role in infection prevention. He explains this further by stating that “the 
conceptual framework of community organization models is based on social networks and 
support, focusing on the active participation and development of communities that can help 
evaluate and solve health problems” (Pittet, 2005, p. 265). An example of community 
involvement is an initiative funded by the Department of Health in England called Service 
Users Research Forum (SURF). The purpose of SURF is to encourage greater patient and 
public involvement in infection research (Healthcare Associated Infection Research Network, 
2012) .  
 
Physical aspects and role of HAI surveillance 
 
Surveillance plays a key function in the physical approach to HAI prevention. There are 
numerous studies that use surveillance to inform and evaluate interventions. The role of hand 
hygiene in infection prevention best demonstrates this point. Hand hygiene is used to prevent 
the transmission of infection. Transmission has already been identified as an element of the 
chain of infection (Figure 2). Surveillance has been used to monitor hand hygiene and the 
effect that increased hand hygiene compliance has on infections (L. Grayson, Russo, R., 
Cruickshank, M., Bear, J., Gee, C., Hughes, C., Johnson, P., McCann, R., McMillan,  A., 
Mitchell, B., Selvey, C., Smith, R., Wilkinson, I., 2011; M. L. Grayson et al., 2008; 




Another component of the physical approach to HAI prevention and the prevention of 
transmission of pathogen is the practice of isolating individuals with specific infections 
(Appendix C). Similar to hand hygiene, surveillance has been used to monitor compliance 
with isolation and the effect isolation practices have on reducing infections ( Gastmeier, 
Schwab, Geffers, & Rüden, 2004; Huang et al., 2006; Klein, Perloff, & Maki, 1989).  
 
A final example to demonstrate the role surveillance plays in the physical approach to HAI 
prevention is vaccination. Vaccination is an example of how infections can be prevented at 
the ‘source of infectious agent’ component in the chain of infection. Vaccination is a long 





Healthcare associated infections pose a serious threat to patient safety and are a common 
occurrence. They have a significant impact on morbidity and mortality for individual patients, 
in addition to increasing health service costs. This chapter explored a physical approach to 
infection prevention and control, namely the chain of infection. The chain of infection assists 
in explaining the ways that infections are transmitted and methods used to prevent and 
control infection.  
 
A second theoretical framework, a biopsychosocial approach, was also presented. This 
framework incorporates the physical approach to HAI prevention, with psychological and 
social aspects. From the literature described in this chapter, it can be argued that the physical 
approach in isolation (chain of infection) and a biopsychosocial approach have merit, in that 
they both help facilitate an understanding of infection prevention and control. Arguments put 
forward by Elliott (2009) suggesting why a physical approach to infection prevention has 
limitations were presented. As a result, it became clear that there is a need to consider a 





Importantly, however, frameworks are rarely incorporated in the infection control literature, 
as evidenced by the recent review conducted by Zimmerman et al. (2012), and no framework 
incorporating the role of surveillance, a key element of infection prevention activities, was 
identified. A biopsychosocial framework for HAI prevention relies on the use of HAI data, 
underpinned by surveillance. A revised biopsychosocial framework explicitly incorporating 
the role of surveillance has been presented (Figure 4). 
 
If HAI surveillance is a critical element of infection control strategies, it is imperative that 
surveillance is reliable and valid. Where this is not possible, limitations of the data should be 
clearly articulated. Returning to a point made in Chapter 1, the HICPAC believes that the 
reliability of HAI data may be compromised by the variability in the definitions used for 
HAIs, or in the methods and resources used to identify HAIs (McKibben et al., 2005). 
Through examining three studies in this thesis, I will demonstrate that the concerns of the 
HICPAC regarding reliability are valid. The first of the studies focuses on SAB and this is 




Chapter 3: Staphylococcus aureus bacteraemia 
 
3.1 Introduction to the chapter 
 
Some of the most serious HAIs are bloodstream infections, also known as bacteraemia. In the 
United States, bacteraemia is one of the leading causes of death (Wenzel, 2001). This chapter 
is concerned with the relatively uncommon, but serious bacteraemia, SAB. The chapter is 
divided into three main sections. The first section, background to SAB, describes pertinent 
clinical issues about S.aureus as an infectious agent and the development of SAB in 
particular. The second section is a literature review in which gaps in knowledge of the 
epidemiology of SAB at a population level are explored. Elements of population-based SAB 
surveillance programs, including detection, duplicates, classification, definitions of 
acquisition, focus of infection, validation, and reporting of data are examined. The third 
section of this chapter describes the first study of this thesis, the aim of which is to describe 
the epidemiology of SAB in Tasmania and influences on reliable and valid collection of SAB 
data.  
 
3.2 Background to Staphylococcus aureus and bacteraemia  
 
Staphylococcus aureus is a pathogen of significance, due to its ability to adhere, invade and 
develop antimicrobial resistance. Bacteraemia caused by S.aureus is one of the most common 
bloodstream infections and is associated with a high mortality. Worldwide, SAB is a serious 
cause of morbidity and mortality, regardless of whether the infection onset is in the 
community or in a hospital (P. Collignon, Wilkinson, I., Gilbert, G., Grayson, L.,Whitby, M, 
2006; Whitby, McLaws, & Berry, 2001). It is estimated that in Australia, there are around 
7000 episodes of SAB each year, equating to an annual rate of 35 per 100,000 population (P. 
Collignon, Nimmo, G., Gottlieb, T., Gosbell, I., Australian Group on Antimicrobial 
Resistance, 2005). Furthermore, it is estimated that a large proportion of SAB is directly 
related to healthcare interventions, with intravascular devices being the most common cause 




2007; P. Collignon, Nimmo, G., Gottlieb, T., Gosbell, I., Australian Group on Antimicrobial 
Resistance, 2005). 
 
Colonisation of S.aureus is an important element of S.aureus infection pathogenesis. 
Approximately 20% of the general population are persistent carriers of S.aureus and up to 
30% are intermittent carriers (Wertheim et al., 2005). A study undertaken by von Eiff (2001) 
found that a substantial proportion of cases of SAB appear to be of endogenous origin since 
they originate from colonies in the nasal mucosa. The results of this study support strategies 
to prevent S.aureus infections by eliminating nasal carriage of S.aureus.  
 
Additional risk factors for SAB include individual person specific factors which pose an 
increased risk of developing SAB including previous MRSA infection or colonisation, skin 
ulcers or cellulitis, presence of intravascular devices, urinary catheter insertions, surgical site 
infection, injecting drug use, presences of immunosuppressive conditions, and liver disease 
(Naber, 2009; Tacconelli, Venkataraman, De Girolami, & Dagata, 2004). Within a healthcare 
facility, other factors which influence the prevention and control of infections such as SAB 
include appropriate hand hygiene and correct insertion and management of intravascular 
devices. Underpinned by surveillance and quality improvement processes, improvements in 
hand hygiene compliance and management of intravascular devices have been demonstrated 
to reduce the occurrence of SAB in hospital settings (P. Collignon, Dreimanis, D., 
Beckingham, W., Roberts, J., Gardner, A, 2007; M. L. Grayson, et al., 2008). 
 
Bacteraemia caused by S.aureus often results in other infections such as infective 
endocarditis (Corey, 2009). In a study undertaken by Fowler (2003), 246 (34%) patients with 
SAB developed metastatic infections and the 12 week mortality rate was 22%. In patients 
with bacteraemia originating from an intravascular catheter, the incidence of metastatic 
infections was 14% (Fowler, 2003). Similar to the findings of Fowler (2003), a multi-centre 
study in Australia and New Zealand found an all-cause mortality of 20.6% in 1994 episodes 
of SAB (J. Turnidge, Kotsanas, D., Munckhof, W., Roberts, S., Bennett, C., Nimmo, G., 
Coombs, G., Murray, R., Howden, B., Johnson, P., Dowling, K., Australia New Zealand 




pathogen that is commonly involved in causing HAIs including bacteraemia. Factors that 
enable S.aureus to cause infection include its ability to adhere to and colonise the skin and 
nasal mucosa, to invade the bloodstream and cause host immunological response i.e. 
infection. The ability to disrupt the skin barrier by excreting exfoliative toxins and enzymes 
that destroy tissue, improve the ability of S.aureus to cause invasion. Invasion can also occur 
when the skin is compromised, for example following surgical procedures or when a break in 
infection control practices occurs (Naber, 2009). Given these characteristics, S.aureus is 
considered a highly successful and increasingly important Gram positive pathogen in humans 
(Naber, 2009).  
 
The development of resistance to antibiotics is another important element of the pathogenesis 
of S.aureus. Antibiotics to which strains of S.aureus have become resistant include penicillin, 
methicillin, cephalosporins, linezolid and vancomycin (Naber, 2009). Resistance to penicillin 
occurs by S.aureus producing β-lactamase, while MRSA strains have acquired the mec gene 
which encodes penicillin binding protein 2a and the fem gene which confers resistance to 
methicillin and cephalosporins (Jansen et al., 2006; Naber, 2009). Resistance to vancomycin 
is believed to rely on the acquisition of the vanA gene and linezolid resistance occurs by a 
mutation in S.aureus ribosomal RNA (Appelbaum, 2006; Naber, 2009; Peeters & Sarria, 
2005).  
 
Studies within hospitals have shown that the incidence of SAB can be reduced with 
improvements in hand hygiene compliance and intravascular device management (P. 
Collignon, Dreimanis, D., Beckingham, W., Roberts, J., Gardner, A, 2007; M. L. Grayson, et 
al., 2008). The seriousness of SAB coupled with the potential to reduce its occurrence, 
suggests that each case of SAB demands rigorous investigation.  
 
The following section of this thesis identifies gaps in knowledge of the epidemiology of SAB 
at a population level through a comprehensive review of the relevant literature, focussing on 





3.3 Literature Review 
 
3.3.1 Introduction to the literature review 
 
This literature review explores elements of an effective SAB surveillance program capable of 
identifying the incidence of SAB at population level and suitable for application in all 
settings. Key criteria used to judge the suitability of a surveillance program in all settings 
includes ensuring adequate detection of SAB, adequate and accurate data collection and 
strong validation. Therefore, the literature review will examine the methods of detection, 
accounting for duplicates and classification of S.aureus, discuss ways to define the place of 
acquisition for SAB, and explore the challenges faced by surveillance programs in ensuring 
that data are valid.  
 
 
3.3.2 Elements of a surveillance program 
 
Surveillance has an important role in healthcare as it can serve as an early warning 
mechanism, provide essential data for monitoring the effectiveness of interventions, detect 
trends and provide a framework for performance management (Clezy, 2008). According to 
Gregg (2002), the former editor of the Centre for Disease Control’s Morbidity and Mortality 
journal, surveillance programs should provide: an accurate assessment of the health status of 
a given population, an early warning system, measures to define specific priorities, 
information to design and plan future programs, and a measure to evaluate intervention or 
programs. The themes described by Gregg (2002) are similar to those by Nelson (2007) who 
describes sensitivity, timeliness, representativeness, positive predictive value, simplicity, 
acceptability and flexibility as key attributes of a surveillance system. These elements will 
frame the description of the components of a SAB surveillance program. 
 
 
3.3.3 Search strategy 
 
The literature was accessed from several sources. Database searches using Medline, Cinahl 




based on current practices at the time of the review. Other limits included publication in 
English and studies involving humans. Key search words included “Staphylococcus aureus 
bacteremia, Staphylococcus aureus bacteraemia, Staphylococcus aureus bloodstream 
infection AND Staphylococcus aureus bloodstream infection”. The key word “surveillance” 
was added to the search however this did not yield any new results. Once the literature was 
retrieved, articles that did not directly relate to surveillance of SAB were removed. Articles 
were excluded if the primary focus was not surveillance. For example, research studies that 
were undertaken to look for a specific outcome were excluded. The rationale for such limits 
was to ensure that the review concentrated on research that was relevant to continuous 
surveillance and therefore had the potential to be implemented and sustained. An individual 
review of each article was performed. 
 
Details of SAB surveillance programs undertaken at a jurisdictional or national level are 
often located in the grey literature. A further search of the English language grey literature 
was then undertaken, targeting government departments. This search involved identifying 
each Australian state and territory’s surveillance programs within Australia and targeting 
specific international surveillance programs from the United Kingdom, Europe (when 
published in English), Canada and the United States. This search yielded 14 additional 
documents.  
 
In addition to searching government departments, professional organisations that have 
recommendations relating to surveillance programs relevant to the literature review were 
targeted. International professional organisations were difficult to locate, therefore, the search 
was limited to Australian based professional associations. Two associations were identified as 
having either made recommendations for SAB surveillance or undertaken multi-centred 
studies for SAB. These two organisations were the Australian Infection Control Association 
(AICA) and the Australian Group on Antimicrobial Resistance (AGAR). A summary of 
literature used in the review as identified in the database searches and the grey literature is 
detailed in Appendix E. Figure 5 provides a summary of the search strategy process using the 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) as the 
basis for presentation (Moher, Liberati, Tetzlaff, Altman, & The, 2009). A total of 54 studies 
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Figure 5. Summary of search strategy for Staphylococcus aureus bacteraemia. 
 
As discussed earlier, the aim of this literature review is to describe the elements of a 
population-based SAB surveillance program that can be effectively applied in all settings. To 
address the aims described in the introduction, the topics of detection, duplicates, 
classification, definitions of acquisition, focus of infection, validation and reporting of data 
will be examined. In exploring each of these topics, the impact that varying practices have on 
the epidemiology of SAB will be discussed, where relevant. 
 




The majority of Australian state and territory  surveillance programs assume that a positive 
blood culture for S.aureus indicates SAB (Chang et al., 2003; de Oliveira Conterno, 2002; 
Health Protection Agency, 2009; Lyytikainen, Ruotsalainen, Jarvinen, Valtonen, & Ruutu, 




2004). There are very few false positive S.aureus isolates from blood cultures (P. Collignon, 
Dreimanis, D., Beckingham, W., Roberts, J., Gardner, A, 2007). The risk of this occurring 
remains low and in the context of developing a population-based surveillance program for 
SAB, it is not a significant issue. 
 
There are a number of advantages of using a positive S.aureus blood culture as the detection 
method for SAB. This method allows easy data extraction from laboratories, linkage of 
laboratory data to software programs and utilisation of existing ‘notification’ processes often 
used in public health. A well-established example of direct extraction of laboratory data to a 
national surveillance program occurs in Wales, United Kingdom (Welsh Healthcare 
Associated Infection Program, 2009). In Tasmania, SAB was made a notifiable disease in 
2009. The latter allows notification of SAB to occur direct from laboratories to public health 
officials and provides the trigger process for a SAB surveillance program (Mitchell, 




The determination of SAB using a positive blood culture is simple to implement, however, it 
does raise the issue of managing multiple positive samples and the subsequent duplication 
(Healthcare Associated Infection Unit, 2009). It would be clinically incorrect to classify each 
and every positive blood culture as a single case of bacteraemia. Contemporary practice in 
research and surveillance programs is to remove subsequent positive blood cultures for a 
given individual within a specified time frame. The specified time frame in the literature does 
vary, but is generally between 14 and 30 days. The majority of studies and continuous 
surveillance programs for SAB use 14 days as the timeframe for which any subsequent 
positive sample should be excluded (P. Collignon, Nimmo, G., Gottlieb, T., Gosbell, I., 
Australian Group on Antimicrobial Resistance, 2005; Dreimanis, 2005; Expert Working 
Group in surveillance of the Australian Infection Control Association, 2000; Health 
Protection Agency, 2009; Health Protection Scotland, 2009b; D. Jeyaratnam, Edgeworth, J., 








Staphylococcus aureus can be resistant to any number of antibiotics. More commonly, 
surveillance programs classify S.aureus into either methicillin-sensitive (MSSA) or MRSA, 
based on the antibiotic sensitivities (P. Collignon, Nimmo, G., Gottlieb, T., Gosbell, I., 
Australian Group on Antimicrobial Resistance, 2005; Health Protection Agency, 2009; Kuint 
et al., 2007; B. Mitchell, et al., 2009; van der Mee-Marquet, Domelier, Girard, Quentin, & 
Bloodstream Infection Study Group of the Relais d'Hygiene du, 2004). To effectively ensure 
that a surveillance program has the capacity to distinguish MRSA in addition to other 
emerging resistance patterns, it would be prudent for a surveillance program to capture a 
range of antibiotic sensitivities, but this does not happen consistently. Capturing this 
information in a population-based surveillance program would provide valuable information 
over time.  
 
Similar incidence of SAB have been reported from areas with high and low prevalence of 
MRSA (Huggan et al., 2010). In Tasmania, the setting for the SAB research detailed later in 
this chapter, there are regional variations in the prevalence of MRSA (B. Mitchell, 
McGregor, A., Coombs, G., 2009). Whether these regional differences in the prevalence of 
MRSA are translated into regional differences in MRSA bacteraemia is explored in the study 
presented later in this chapter.  
 
A number of studies have shown that MRSA bacteraemia is associated with poorer outcomes 
and increased mortality (Whitby et al., 2001). In contrast, a large, multi-centre study by 
Turnidge et al. (2009), indicates that MRSA bacteraemia is not an independent risk factor of 
mortality. The authors examine this finding in detail and suggest that sufficient patients 
infected with methicillin-susceptible strains were treated with vancomycin instead of a β–
lactam and it was the use of vancomycin that demonstrated a higher 30 day mortality, 
compared with flucloxacillin treatment. The authors suggest that it may be “better to consider 
MRSA as a major threat, mostly because the drug of choice for serious invasive infection are 
less effective than β-lactams are against methicillin-susceptible strains” (J. Turnidge, 




Howden, B., Johnson, P., Dowling, K., Australia New Zealand Cooperative on Outcomes in 
Staphylococcal Sepsis., 2009, p. 372). 
 
Acquisition definitions  
Overview 
 
To understand the epidemiology of SAB, it is important to establish the place of acquisition. 
There are varying terms used in the literature to define the place of acquisition. Definitions of 
acquisition found in the literature can however, be broken into three general groups: those 
infections associated with the community, those associated with healthcare including 
hospitals, for example, outpatient settings, and those acquired in hospital. The latter is a 
subset of the second. Acquisition should not be confused with the ‘strain’ of S.aureus. For 
example, ‘community acquired’ SAB may refer to a specific strain of S.aureus. Conversely, 
the term ‘community associated’, often refers to an infection originating in the community. It 
is therefore vital that researchers undertaking surveillance of infections relating to healthcare 




It appears from the literature that custom and practice has played a large part in defining what 
previously constituted ‘hospital acquired’ infections and definitions have evolved based on 
findings in the literature. Historically, hospital acquired infections were infections that 
occurred in patients in hospital for greater than 48 hours. This definition has a number of 
limitations, including neglecting patients who may have had recent hospital treatment with 
subsequent infection or patients who receive healthcare in the community. A study 
undertaken in Australia demonstrated this point and found that using the figure of 48 hours as 
the criterion for HAI substantially underestimates the number of episodes of bacteraemia that 
are healthcare associated (P. Collignon, Nimmo, G., Gottlieb, T., Gosbell, I., Australian 
Group on Antimicrobial Resistance, 2005). In this multi-centred study, 971 episodes of SAB 
were reviewed, with a total of 64-75% found to be healthcare associated, however only 46-
61% were acquired after the patient was in hospital more than 48 hours (P. Collignon, 




Healthcare systems are now providing more treatment in settings other than inpatient settings, 
so it is vital to capture these patients when undertaking surveillance.  
 
In 2002, Friedman suggested a new classification for bloodstream infections, using the 
terminology: hospital acquired, healthcare associated or community acquired. Lesens et al. 
(2005) undertook a multi-centred study to determine the usefulness of these definitions. The 
study supported the notion of having three different classifications, with particular emphasis 
on the point that some patients who acquire an infection in the community may do so as the 
result of healthcare exposure or treatment (recent or in the community). Therefore they could 
be incorrectly classified as community associated (Lesens et al., 2005). 
 
The definitions as outlined by Friedman (2002) and supported by Lesens et al. (2005) are not 
the only definitions used in current literature to determine acquisition of bloodstream 
infections. In a paper outlining a range of surveillance definitions, the Centre for Disease 
Control (CDC) and the National Healthcare Safety Network (NHSN) are less specific about 
the exact definitions of acquisition in respect to bloodstream infections (Horan, 2008). They 
define a HAI as a “localized or systemic condition resulting from an adverse reaction to the 
presence of an infectious agent(s) or its toxin(s). There must be no evidence that the infection 
was present or incubating at the time of admission to the acute care setting” (Horan, 2008, 
p.310). 
 
The definition as it stands by the CDC/NHSN requires a clinical review of the patient and is 
open to interpretation by less experienced staff undertaking surveillance. The CDC/NHSN 
definition is essentially the same as that defined by Friedman (2002) and Lesens et al. (2005) 
in that it is attempting to remove infections that are present or incubating on admission to a 
hospital from being classified as healthcare associated. Outlining specific criteria or 
timeframes is more suited for population-based SAB surveillance, as it will reduce the 
potential for variability in interpretation. 
 
From the initial examples described above, it is clear there has been a blurring in the 
differences between hospital, healthcare and community associated acquisition. Length of 




& Suh, 2008). To determine a definition for application of a state wide or national 
surveillance program suitable for all settings, it is important to review and critique the 




Worldwide, the majority of studies and surveillance programs define ‘hospital acquired’ SAB 
if a blood culture was taken greater than 48 hours after admission and/or there was no 
evidence of infection at presentation (Burke, Halpern, Baron, & Gutierrez, 2009; Chaves, 
GarcÃa-MartÃnez, de Miguel, Sanz, & Otero, 2005; Chua et al., 2008; Denniston & Riordan, 
2006; Dreimanis, 2005; Jeyaratnam, Edgeworth, & French, 2006; Nickerson et al., 2009; 
South Australian Infection Control Service, 2006; Wyllie, Crook, & Peto, 2006). In some 
studies however, a different definition of ‘hospital acquired’ is used, for example 72 hours 
(Guilarde, Turchi, Martelli, & Primo, 2006; Johnson, Bhan, Pawlak, Manzor, & Saravolatz, 
2003; Perovic et al., 2006). No rationale is given in either study for the basis of using 72 
hours as opposed to 48 hours and none was found in other literature examined. The greatest 
proportion of SAB surveillance programs described in the literature define an infection as 
hospital acquired if the blood culture was taken greater than 48 hours after admission and 
assuming there was no other recent positive blood culture.  
 
Hospital acquired SAB is only one classification of acquisition. The issue of community 
associated or healthcare associated SAB in patients with a blood culture less than 48 hours 




Patients who have a SAB identified in a community setting or in hospital but less than 48 
hours after admission can potentially have either community associated or healthcare 
associated SAB. Community associated SAB can also be referred to as ‘Community Onset’. 
Healthcare associated SAB could be caused by a recent hospitalisation or treatment received 
in a community or outpatient setting. It is therefore important to identify the different 






No specific continuous community associated SAB surveillance program was found in the 
literature. Surveillance or studies of community associated SAB are often undertaken for a 
limited period within a specific population group or occur as a result of undertaking 
surveillance within a specific population group, for example those who present or are 
admitted to hospital (Khairulddin, Bishop, Lamagni, Sharland, & Duckworth, 2004; Lin et 
al., 2009). The definitions used for determining community and healthcare associated SAB 
identified in the literature review vary considerably. 
 
In a retrospective study at a tertiary hospital, Chaves et al. (2005) defined community onset 
SAB as “evidence of infection at the time of presentation or blood specimen positive for 
S.aureus collected less than 48 hours after admission” (p. 151). Similarly, a retrospective 
study undertaken by Chia, Hsu, Chai and Tambyah (2008) investigating the epidemiology 
and onset of community-onset MRSA bacteraemia, defined community onset bacteraemia as 
“a positive blood culture drawn ≤48 hours after hospitalisation or if he/she remained 
symptomatic with no other cause of infection found in the event the blood cultures were 
positive >48 hours post hospitalisation” (p. 2). Chia et al. (2008) further classified this group 
into community acquired or healthcare associated cases based on the criteria proposed by 
Friedman (2002).  
 
Friedman (2002) defines community associated SAB as “a positive blood culture obtained at 
the time of hospital admission or within the 48 hours after hospital admission for patients 
who did not fit the criteria for a health care–associated infection” (p. 792). Variability in 
definitions of community SAB is found throughout the literature. A retrospective study by 
Chi, Wong, Fung, Yu, and Liu (2004) investigating the epidemiology of community acquired 
SAB in Taiwan, defines community associated as: 
A blood culture performed with the initial 48hours after hospital admission, the 
patient had not been hospitalized in an acute-care setting within one year before the 
isolation of MRSA; transfer from other hospitals occurred within 48 hours of 
admission; no history of renal dialysis, residence in a nursing home or surgery in the 
recent one year; no permanent indwelling catheter or percutaneous medical device 





The definition for community associated SAB is often made on the basis that the patient does 
not meet the criteria for hospital acquired or healthcare associated SAB. It is therefore 
important to finalise the definition of ‘healthcare associated’, in order for ‘community 





In 2002, Friedman defined a HAI as occurring in a person who has a positive blood culture 
obtained at the time of hospital admission (or within 48 hours of admission) and the patient 
fulfilled any of the following criteria: 
1. Received intravenous therapy at home; received wound care or specialized nursing 
care through a health care agency, family, or friends; or had self-administered 
intravenous medical therapy in the 30 days before the bloodstream infection. Patients 
whose only home therapy was oxygen use were excluded. 
2. Attended a hospital or haemodialysis clinic or received intravenous chemotherapy 
in the 30 days before the bloodstream infection. 
3. Was hospitalized in an acute care hospital for 2 or more days in the 90 days before 
the bloodstream infection. 
4. Resided in a nursing home or long-term care facility (Freidman, 2002, p. 792). 
 
The definitions described above were used in a study in Ireland (O'Connell, McMahon, 
Kelleher, & Rossney, 2007). Similar to the definitions used by Chia et al. (2008), O’Connell 
et al. (2007) and Friedman (2002), Chaves et al. (2005) used a different definition to classify 
HAIs. Chaves et al. (2005) defined ‘healthcare related infection’ if a patient had “documented 
evidence of hospitalization within the twelve months before collection of the current culture 
positive blood specimen, had undergone peritoneal dialysis or haemodialysis within the 
previous 12 months, or had used a vascular device at home immediately before hospital 
admission for the current infection” (p. 151). Those definitions unrelated to healthcare were 






In Australia, a number of states undertake surveillance of SAB. The definitions developed by 
the expert working group in surveillance of the Australian Infection Control Association are 
often used by the various jurisdictions or researchers within Australia (Centre for Healthcare 
Related Infection Surveillance and Prevention, 2009; Cordova et al., 2004; Expert Working 
Group in surveillance of the Australian Infection Control Association, 2000; Healthcare 
Associated Infection Unit, 2009; Mitchell et al., 2009; South Australian Infection Control 
Service, 2006). The definitions used by these groups can be summarised as: 
 
Health care associated criteria  
Acquired during hospitalisation and not present or incubating on admission (in 
inpatient neonates ≥48 hours after delivery), or is a complication of the presence of an 
indwelling medical device (e.g. IV line, CSF shunt, urinary catheter), or occurs within 
30 days of a surgical procedure, when related to a surgical site infection, or an 
invasive instrumentation or incision related to the bloodstream infection was 
performed within 48 hours (or longer if compelling evidence) before onset of the 
infection, or associated with neutropenia (<1000 neutrophils x 10
6 
/L) contributed to 
by cytotoxic therapy.  
 
Health care associated inpatient [IP]  
Episode occurs >48 hours after admission or within 48 hours of discharge.  
 
Health care associated non-inpatient [NIP]  
Patient is not an inpatient or episode occurs within 48 hours of admission.  
(Expert Working Group in surveillance of the Australian Infection Control 
Association, 2000)  
 
Although the definitions used in SAB surveillance may seem consistent, there are variations 
in how these data are analysed due to variations in reporting and validation processes. This 
will be discussed in more detail later. 
 
In the United Kingdom, continuous mandatory surveillance of SAB occurs within England, 
Wales and Scotland. Although similar, the methodologies and definitions used for 




Wales), each of these countries has included all positive SAB identified in a hospital, 
regardless of place of acquisition in the hospital’s (Trust) surveillance report. No delineation 
is made between hospital acquired, healthcare or community associated (Health Protection 
Agency, 2005; Health Protection Scotland, 2009b; Welsh Healthcare Associated Infection 
Program, 2009). Although very easy to implement, this reporting does not meet the objective 
of determining the most appropriate manner to undertake state wide surveillance as it only 
includes specimens taken in hospitals and fails to differentiate between the places of 
acquisition. Measures to reduce or eradicate infections cannot be implemented if the place of 
acquisition is not identified. More recently, in England, a voluntary enhanced surveillance 
program for SAB has been developed (Health Protection Agency, 2009). This program 
includes capturing admission date and therefore the ability to define hospital acquired for 
patients in hospital more than 48 hours after a blood culture is obtained. It still does not 
define or identify ‘healthcare associated’ infections. 
 
Canada does not appear to have a continuous surveillance program specifically for SAB, 
although methicillin resistant MRSA bacteraemia would be included within their surveillance 
program for MRSA infections (Canadian Nosocomial Infection Surveillance Program, 2008). 
Despite the variations in approaches used worldwide to define hospital, community and 
healthcare associated SAB it is possible to draw out common themes. 
 
The issue of defining healthcare associated bacteraemia appears to be dependent on the 
nature of the study and its intended aims (Lesse & Mylotte, 2006; Lin, Yeh, Peng, & Chang, 
2004). For the purpose of population-based surveillance, the definition of healthcare 
associated needs to be easily applied. The difficulty with the definitions described by 
Friedman (2002), is with their application. Identifying whether a patient has been in a nursing 
or residential home in the past year or had received wound care treatment in the past 30 days 
is made more complex by the range of public and private entities providing healthcare, often 
with limited or no access to obtaining such information in a timely fashion. A data linkage 
system may be of use in obtaining such information. Alternatively, a person investigating a 
case of SAB could rely on information the patient provides, however this may still cause 






Summary of acquisition definitions 
 
From the literature reviewed, it is clear that the definition of hospital acquired (also called 
healthcare associated inpatient) can be summarised as an infection in a person who has a 
blood culture positive for S.aureus taken 48 hours after admission (or within 48 hours of 
discharge). The position for defining the acquisition of infections occurring within 48 hours 
of admission but that might have resulted from healthcare, i.e. healthcare associated (also 
called healthcare associated non-inpatient) does vary. The common themes for defining 
healthcare associated includes recent related surgery (usually 30 days) or invasive surgical 
procedure, association with an indwelling or intravascular device, association with 
neutropenia or the person is receiving hemodialysis. There is some debate as to whether 
patients in long term care or residential facilities should also be defined as having a HAI 
(Friedman, 2002). Figure 6 summarises the position described above.  
 
 
Figure 6. Criteria used to determine acquisition of cases of Staphylococcus aureus 
bacteraemia.  
 
Is the positive blood culture 
taken 48 hours after admission 
or within 48 hours of 
discharge? 
No 












Figure 6 is consistent with recommendations made by the HAI Surveillance Committee, at 
the Australian Commission on Safety and Quality in Healthcare. These definitions have since 
been adopted at a national level (Australian Commission on Safety and Quality in Health 
Care, 2010). For the purposes of this review, the term healthcare associated refers to both 
healthcare associated inpatient and healthcare associated non-inpatient, unless otherwise 
stated. The acquisition of SAB is important but the questions used to determine the 
acquisition still do not provide definitive insight into the cause of the infection. 
 
Focus / Cause of infection 
 
To better understand and potentially prevent SAB, identifying the cause of infection is 
important. Causes of SAB are varied and it is not within the scope of this literature review to 
explore all causes. SAB can occur in any setting therefore data collection in a surveillance 
system may be sought from less experienced clinicians, or indeed, clinicians who rarely see 
SAB. In a paper describing SAB of unknown primary source, Saginur and Suh (2008) state 
that “there is no commonly held definition of bacteraemia of unknown source” (p. 21). This 
reinforces the need to consider ease of application when developing a system for identifying 
the cause of infection.  
 
There is a strong indication that intravascular devices are the most common cause of 
healthcare associated bloodstream infections in developed countries (Coello et al., 2003; 
Munckhof, 2005; N. P. O'Grady et al., 2002). Specific population groups, such as patients in 
intensive care or haemodialysis patients are particularly at risk, given the frequency of 
intravascular device use. It would be prudent for any surveillance program to identify 
whether persons with SAB have intravascular devices and whether they receive 
haemodialysis. It would not be practical to request information on whether the intravascular 
device was the cause of infection, as that would potentially require further microbiological 
testing. Identifying whether a person had an intravascular device at the time of blood culture 
collection is straight forward and is consistent with earlier recommendations of determining 




that the intravascular device was the cause of the infection unless the tip of catheter is 
cultured. If a person with SAB did have an intravascular device, it would be prudent to 
identify which device/s the person had. The practice of identifying the device is consistent 
with surveillance programs being undertaken in the Canberra Hospital and in South Australia 
(P. Collignon, Dreimanis, D., Beckingham, W., Roberts, J., Gardner, A, 2007; South 
Australian Infection Control Service, 2006). 
 
In addition to identifying whether a person has an intravascular device, other potential 
sources or causes of infection could be identified. Within Australia, surveillance programs 
that seek to identify the cause of infection group these into five areas: catheter/intravascular 
device-related, source unknown, neutropenia, procedure related, or organ site focus (Centre 
for Healthcare Related Infection Surveillance and Prevention, 2009; Healthcare Associated 
Infection Unit, 2009; South Australian Infection Control Service, 2006). Procedure related or 
organ site focus infections have not yet been discussed.  
 
When identifying whether the bacteraemia was procedure related, it is recommended that 
there must be compelling evidence that it was related to the bacteraemia, for example, 
identifying the same organism from the tip of a catheter through culture as identified in the 
blood culture. Similarly, organ site focus should only be identified when there is clinical or 
bacteriological evidence that the infection arose from the specific organ. The specific organ 
site is usually then identified (Centre for Healthcare Related Infection Surveillance and 
Prevention, 2009). Identifying whether a bacteraemia was procedure related or organ site 
focussed is made more difficult without the clinical support of infectious disease physicians 
or microbiologists (Jenkins, Price, Sabel, Mehler, & Burman, 2008). Therefore, in 
implementing a program suitable for all settings, identifying the cause of infections may 








Within Australia, South Australia, Western Australia, Queensland, and Tasmania conduct 
surveillance for SAB from hospitals participating on a voluntary basis within their respective 
states (P. Collignon, Dreimanis, D., Ferguson, J., van Gessel, H., Taylor, P., Wilkinson, I., 
Worth, L, 2008; M. Cruickshank, Ferguson, J., 2008; B. Mitchell, et al., 2009). The 
Australian Capital Territory has no territory wide surveillance unit as such, however at the 
Canberra Hospital, infection control staff use data from their laboratory department to 
commence the investigation of SAB cases (Dreimanis, 2005). This is a robust way of 
capturing all cases of SAB within their hospital. Each jurisdiction has variations in data 
collection, reporting and validation processes, for example, in South Australia, hospitals 
submit completed surveillance forms to the South Australian Infection Control Service, 
which collates and analyses the data. The voluntary surveillance data submitted to each 
jurisdiction’s surveillance unit is often reliant on hospital staff (infection control 
practitioners) completing and submitting a surveillance form. Therefore the catalyst for 
commencing the data collection process is often outside the control of the state wide 
surveillance units and this has the potential of leading to an incomplete or inaccurate dataset.  
 
One way of validating the number of surveillance forms received by the surveillance unit, is 
to have access to or receive a direct laboratory report from each of the hospitals outlining the 
number of S.aureus positive blood cultures identified in a given period. Although this may 
happen in practice, the process is not detailed in any of the jurisdictional surveillance 
programs protocols, other than Tasmania (Mitchell et al., 2009). It is also made more 
complicated by the use of a combination of private and public microbiology departments.  
 
At the beginning of 2009, all Australian states and territories agreed to participate in a 
national surveillance scheme for SAB. All acute hospitals within the jurisdictions are 
expected to contribute. At the time the literature review was undertaken, no evidence was 





In the United Kingdom a mandatory SAB surveillance exists, and in Wales, Scotland and 
England SAB data derived directly from microbiology laboratories are compiled. As 
discussed earlier, this has some limitations in respect to determining acquisition. From a 
validation perspective, however, this system does provide a way to capture all SAB cases 
(Health Protection Agency, 2005; Health Protection Scotland, 2009b; Welsh Healthcare 
Associated Infection Program, 2009). 
 
Reporting of rates 
 
The manner in which SAB rates are reported is subject to variation and often dependent on 
the purpose or aim of the surveillance program or research undertaken. This section examines 
how rates are reported at a hospital level and also at a state or national level. Before doing so 
however, it is important to define some of the terms commonly used in surveillance.  
 
The International Epidemiology Association defines the term ‘rate’ as the measure of the 
frequency of the occurrence of a phenomenon over a period of time and is an expression of 
the frequency with which an event occurs within a defined population, usually in a specified 
period (Porta, 2008, p. 207). Therefore, the rate equals the number of events in the specified 
period, divided by the average population size during the period. Not to be confused with the 
term rate, which the International Epidemiology Association also defines as ‘incidence’ and 
‘incidence rate’. Incidence is defined as the number of instances of illness commencing or of 
persons falling ill during a given period in a specific population. It may be measured as a 
frequency count, a rate or a proportion (Porta, 2008, p. 124). An incidence rate is the rate at 
which new events occur in a specific period divided by the time persons were exposed to risk 
during the period.  
 
The terms ‘rates’ and ‘incidence’ are often used in the literature when attempting to describe 
the disease burden of SAB (Chaves et al., 2005; Jeyaratnam et al., 2006; Turnidge et al., 




numerator and the denominator in the equation must be representing the same phenomenon 
and the time period must be specified.  
 
Describing rates of SAB within hospitals choice of denominators 
 
When reporting rates of SAB identified in hospitals, the choice of denominator varies not 
only within Australia, but also internationally making direct comparisons difficult. Examples 
of denominators used include ‘patients at risk’ days (Coello et al., 2003), occupied bed days 
(South Australian Infection Control Service, 2006) or separations (Grayson et al., 2008). 
Furthermore, each of these denominators requires a specific definition or clarification. For 
example, occupied days data may include or exclude day case patients in hospitals. It is 
therefore vital that the numerator used is relative to the denominator and is clearly defined. If 
a hospital is including healthcare associated SAB from their day case patients, then including 
patient bed days for this group in the description of the population at risk or denominator may 
be more suitable than separations for example. 
 
Despite the issues raised above about the choice of denominator, the major purpose of 
surveillance, particularly in a hospital setting, is to inform quality improvement processes. 
Studies have shown that despite the choice of denominator, for example comparing occupied 
bed days and separations, the overall trend of the incidence remains the same (P. Collignon, 
Dreimanis, D., Ferguson, J., van Gessel, H., Taylor, P., Wilkinson, I., Worth, L, 2008; A. 
McGregor & Mitchell, 2009). Therefore, a further consideration in choosing a denominator 
may be the audience of a report and how easily they can understand the meaning of occupied 
bed days, separations or admissions. In Australia, the national data dictionary has stated that 
patient care days should be used as the denominator. Patient care days are essentially the 
same as occupied bed days and are the only hospital activity data that is collected in a 
standardised manner by jurisdictions in Australia (Australian Commission on Safety and 






Describing the incidence of SAB within a region, state or national level 
 
Unless a surveillance program captures all SAB, in all settings, identifying the incidence of 
SAB accurately within a region, state or nationally is challenging (Laupland, Ross, & 
Gregson, 2008). One well recognised Australian study undertaken by the AGAR attempted to 
determine the incidence of SAB in Australia by extrapolating data from a number of 
hospitals.  
 
The AGAR undertook a review of SAB cases in 17 hospitals (public and private) in Australia 
(P. Collignon, Nimmo, G., Gottlieb, T., Gosbell, I., Australian Group on Antimicrobial 
Resistance, 2005) to quantify the number of cases, place of acquisition and the proportion 
caused by MRSA. Data were derived from microbiology departments that prospectively 
collected information on laboratory confirmed bacteraemia. Multiple or duplicate positive 
blood culture samples that occurred within the previous 14 days were considered a single 
episode. A case was classified as hospital onset if the positive blood culture was taken more 
than 48 hours after admission; all other cases were defined as community onset, including 
day only dialysis related cases. Published data relating to the number of hospital bed days and 
separations (referred to as admissions) were used to determine rates. In total, 3192 episodes 
of SAB were identified. The rates for both hospital and community onset SAB were 
determined for each hospital, using occupied bed days and admissions. The rates in different 
hospitals were extrapolated to estimate the incidence for Australia. Using the median 
bacteraemia rate of public and private hospitals surveyed, the AGAR estimated there are 
approximately 6900 episodes nationally each year or 35 per 100,000 population. The authors 
then used this figure to compare against data from Northern Ireland and the Unites States (P. 
Collignon, Nimmo, G., Gottlieb, T., Gosbell, I., Australian Group on Antimicrobial 
Resistance, 2005).  
 
The authors acknowledge the definitions of acquisition underestimate the rate of healthcare 
associated bacteraemia. Conversely, the authors may have overestimated the number of cases 
occurring in Australia because of the over inclusion of larger tertiary hospitals that have 




that better captured and reported on all bacteraemia episodes in well defined populations (e.g. 
all of Australia or a State) then this would give us a more accurate rate” (P. Collignon, 




3.3.5 Summary of literature review 
 
Throughout the review, elements of surveillance programs have been critiqued. These 
focussed on variations in the surveillance programs, particularly in reporting, validation and 
definitions of acquisition. Within Australia, each jurisdictional SAB surveillance scheme has 
focussed on assessing the number of cases within the context of a hospital environment and 
determining rates accordingly. These programs have a number of limitations that must be 
remembered when considering a program suitable for all settings. First, detection of SAB is 
primarily focussed on identifying those people who present or are associated with an acute 
hospital. This may include inpatients, those who present to emergency departments or those 
receiving healthcare directly from the hospital (e.g. haemodialysis patients). The population 
being sampled is therefore limited as it excludes people who may present to hospitals not 
participating in a coordinated surveillance program (public, private or less acute hospitals) or 
who receive healthcare in a community setting, for example a general practice or nursing 
home.  
 
Second, the definition of acquisition needs to be such that clinicians not familiar with causes 
of SAB, principles of surveillance and infection control terminology can understand and 
accurately complete a surveillance form. Third, to ensure the validity of a surveillance 
program, it must capture all bacteraemias and not be reliant on an individual’s submission of 
a surveillance form. To overcome the challenges of capturing all data, a recommendation 
suggested by Collignon et al. (2006) was to make SAB a notifiable disease. The notification 
process will ensure that all SAB are captured and pursuant to each state’s Public Health Act, 




used in Tasmania and allows all SAB to be captured, regardless of the patient’s healthcare 
provider (Mitchell et al., 2009). Similarly, the direct data extraction method from laboratories 
used in the United Kingdom would provide a comparable method of obtaining all SAB. 
However, the complex network of public and private healthcare providers may make the 
latter more difficult in Australia.  
 
The fourth consideration of a SAB surveillance program is the need to capture adequate 
information that is not only useful to acute hospitals, but also to understand the epidemiology 
of the infection within the wider population which includes the cause or focus of infection 
and antibiotic sensitivities.  
 
To truly understand the epidemiology of SAB at a population level, a surveillance program 
must capture data from all SAB cases in a given population and have the ability to accurately 
identify cases of HA SAB and the healthcare facility to which the infection is attributable. 
Ensuring the validity of SAB data at a population level is challenging and inherently linked to 
the data collection process. For example, internationally, England and Wales capture all cases 
of SAB by obtaining data direct from laboratories; however, they collect limited additional 
information to identify an accurate picture of the burden of HA SAB and acquisition in 
comparison to methods currently used by Australian states and territories. Conversely, 
Australian states and territories fail to capture and report on data from all cases of SAB in a 
given population. By having such data, an improved understanding of the true incidence of 
SAB and relevant epidemiological data is possible, which can be used to inform future 
planning. It is evident that if the incidence of SAB is to be calculated in a meaningful way at 
a population-based level, a surveillance system must capture all episodes of SAB. Through 
this process, the ability to quantify the occurrence of SAB occurring outside of acute public 
hospitals will be possible and provide some evidence on which to base a decision on whether 








3.4 Objectives and research questions 
 
The objectives for the first study of this thesis are to describe the epidemiology of SAB in 
Tasmania and to understand the methodological influences on reliable and valid collection of 
SAB data in that state. To address these objectives, the author devised the following research 
questions: 
1. In the general Tasmanian population for the calendar years 2009 and 2010: 
a. What is the incidence of SAB? 
b. What are the relative proportions of community associated and healthcare 
associated SAB? 
c. What are the relative proportions of methicillin-sensitive (MSSA) SAB and of 
methicillin resistant (MRSA) SAB? 
 
2. In the three geographical regions of Tasmania for the calendar years 2009 and 2010:  
a. What is the comparative incidence of SAB? 
b. What are the relative proportions of community associated and healthcare 
associated SAB? 
 
3. What is the potential for under reporting of SAB where: 
a. Data are only collected from public hospitals?  




3.5.1 Study design 
 
The author chose a descriptive, observational, population-based study which facilitates the 
examination of rare occurrences of disease, provides a mechanism for determination of risk, 
and ensures that data collected represent the entire population (Friis, 2009). A prospective 





3.5.2 Setting and timeframe 
 
The study captured all Tasmanian cases of SAB identified by microbiology services between 
the 1
st
 January 2009 and the 31
st
 December 2010 (as defined by the collection date of blood 
cultures). As of the 30
th
 June 2009, the estimated population of Tasmania, the smallest 
Australian state, was 503,292, representing the target population of the study (Australian 
Bureau of Statistics, 2011). More detail regarding the population of Tasmania is provided in 
Chapter 1. At the time of writing, there were three health services areas in Tasmania, namely 
the north, the north-west, and the south regions, which are recognised by the Australian 
Standard Geographical Classification. The northern area health service consists of one 
general hospital and nine rural hospitals with an estimated target population of 141,434. In 
Tasmania, the term ‘rural hospital’ refers to hospitals with a small number of inpatient beds, 
usually less than 20 and geographically located in towns with a small population. Rural 
hospitals in Tasmania may also provide a location for primary health services. The term 
‘general hospital’ refers to a hospital that has an accident and emergency capacity, high 
dependency or intensive care unit and resident general specialities. The north-west region has 
an estimated population of 112,383 with one regional hospital, a community hospital, and ten 
rural hospitals. The southern region has a tertiary referral hospital, five rural hospitals, and an 
estimated population of  249,475 (Australian Bureau of Statistics, 2011). The term ‘tertiary 
hospital’ refers to a hospital that provides services requiring highly specialised skills, 
technology and support. Typically a tertiary hospital may include centres of excellence, 
research and development and will provide a leadership role of integrated clinical services. 
Health services in Tasmania are provided in a similar fashion to other states and territories, 
with a mixture of public and private hospitals providing acute care. 
 
Different microbiology laboratories service each of the regions. A public hospital 
microbiology laboratory in each region services the public hospitals in the southern and 
northern regions, whilst in the north-west a private provider services the public hospital. 
There are four private microbiology laboratories in Tasmania, three of which are owned by 






3.5.3 Definition and selection of cases 
 
The definitions applied in this study were those developed by the ACSQHC, which have been 
accepted as national definitions in Australia (Australian Commission on Safety and Quality in 
Healthcare, 2009). The following operational definitions are provided for clarification. 
 
One or more blood cultures positive for the bacterium S.aureus defined a case of SAB. Only 
the first isolate per patient was counted, unless at least 14 days had passed without a positive 
blood culture, after which an additional episode was recorded. Using blood cultures to define 
a case of SAB runs the risk of including false positives in the data; however, it is believed 
that there are very few false positive S.aureus isolates from blood cultures (P. Collignon, 
Wilkinson, I., Gilbert, G., Grayson, L.,Whitby, M, 2006). Further, the use of blood cultures to 
define a case of SAB is standard practice in most research and surveillance programs as 
previously discussed in Chapter 3. 
 
A case of SAB defined as healthcare associated (HA) depended on the following criteria:  
 the first positive blood culture was collected more than 48 hours after hospital 
admission or less than 48 hours after discharge, or 
 the first positive blood culture was collected 48 hours or less after admission and one 
or more of the following key clinical criteria was met: 
1. The SAB was a complication of the presence of an indwelling medical device 
(e.g. intravascular line, haemodialysis vascular access, cerebrospinal fluid 
shunt (CSF), urinary catheter). 
2. The SAB occurred within 30 days of a surgical procedure where the SAB was 
related to the surgical site. 
3. An invasive instrumentation or incision related to the SAB was performed 
within 48 hours. 
4. The SAB was associated with neutropenia (<1 x 109) contributed to by 
cytotoxic therapy.  




If none of these criteria applied, then the episode of SAB was considered community 
associated (CA). 
 
3.5.4 Data collection 
 
This section on data collection is divided into two parts. The first part describes the data 
collection process, including validation, and the second part outlines the specific data 
collected.  
 
Data collection process 
 
Staphylococcus aureus bacteraemia is a notifiable disease in Tasmania and has been since the 
end of 2008. At the time of writing, Tasmania is the only state in Australia that has SAB 
listed as a notifiable disease. The data collection process utilised the existing notification 
system as the catalyst for commencement of data collection. Data collection involved two 
main steps. First, laboratories notified Public Health (Tasmanian Department of Health and 
Human Services) regarding all cases of SAB. Second, the TIPCU, a departmental unit within 
Public Health, investigated all notified cases and sought additional information. Figure 7 
illustrates the data collection process. 
 
Figure 7. Flow chart illustrating the data collection process. 
Case of SAB  identified by microbiology 
laboratory 
Public Health (TIPCU) notified of case by 
laboratory 
Additional information sought by TIPCU from relevant 
healthcare professionals 
Data collated by TIPCU 
Data forwarded to researcher by TIPCU 
Data validated 






To collect additional information on each case of SAB, the TIPCU used a data collection 
form
1
 which was developed through modifications of an existing instrument used in South 
Australia at the time. The data collection sheet was piloted for a period of six months during 
2008 and modifications were made following this pilot. Information obtained from 
microbiology laboratories and sent to the TIPCU was entered onto the data collection form 
and then into a database. In Tasmania’s larger public and private hospitals, the data collection 
form is forwarded to an infection control professional at the hospital where cases of SAB 
were identified. The TIPCU staff supported the completion of the required information by 
infection control professionals where required. A developed protocol was used as the 
foundation for education material and ongoing reference (Mitchell et al., 2009) and education 
to infection control professionals was provided at face-to-face meetings, video conferencing, 
and discussions on the telephone. Where there was no infection control professional, such as 
non-hospital settings, the form was sent to the responsible healthcare professional for each 
case. In these circumstances, TIPCU staff provided phone support to complete the form, 
which served to improve the reliability of the data collected. These processes ensured 
consistency of data quality given the range of experience of staff collecting and recording 
information. 
 
Once the data were received by the TIPCU, an initial interpretation of the data against 
available patient administration information was undertaken by the TIPCU staff. One staff 
member at the TIPCU classified the data as CA or HA SAB; where a case of SAB involved a 
hospital, the responsible infection control professionals discussed and reached agreement on 
the classification and attributable facility. The definition of attributable facility is discussed 
later in this chapter. In rare situations where agreement could not be reached, a senior TIPCU 
staff member referred to the national surveillance definition, and made a final decision. 
During the study period, this only occurred once. 
 
Upon completion of the process just described, data were entered into a Microsoft Excel 
spread sheet. To improve validation and ensure that all cases of SAB in Tasmania were 
captured, the TIPCU received a data file containing all positive S.aureus blood cultures, 
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directly from every laboratory in Tasmania (public and private) on a quarterly basis. This was 
used to cross check against notifications received, ensuring a complete Tasmanian dataset. 
 
Data items collected  
 
The data items collected as part of the two-step data collection process described in section 
3.5.4 are outlined in Table 2, including data sources. Further explanations for some of these 
data items are discussed below. 
 
Table 2  
Data items collected and the sources of these data 
Data item Source 
Name Laboratory  
Date of birth Laboratory 
Sex Laboratory 
Postcode of affected individual Laboratory 
Patient identification number (if applicable) Laboratory 
MSSA or MRSA Laboratory 
Admission date (where applicable) Laboratory 
Specimen collection location Laboratory 
Laboratory  Laboratory 
Antibiotic sensitivities for the antibiotics Flucloxacillin, 
Penicillin, Ciprofloxacin, Erythromycin, Fusidic acid, 
Gentamicin, Rifampicin, Tetracycline or Doxycycline, 
Trimethoprim or Trimethoprim  / Sulphamethoxazole. 
Laboratory 
Collection date TIPCU (via data collection form) 
> or ≤ 48 hours in hospital at the time of blood culture 
collection  
TIPCU (via data collection form) 
Key clinical criteria met TIPCU (via data collection form) 
Device type. In a case where the SAB was a complication 
of the presence of an indwelling medical device, the device 
type was recorded. 
TIPCU (via data collection form) 







For the purpose of data collection, any case of SAB that reported intermediate resistance to a 
particular antibiotic was reported as resistant. The data items listed in Table 2 include 
whether any key clinical criteria have been met. The key clinical criteria used to define a case 
of HA SAB were those agreed to nationally in Australia, as discussed previously:  
1. the SAB is a complication of the presence of an indwelling medical device 
(e.g. intravascular line, haemodialysis vascular access, CSF shunt, urinary 
catheter); 
2. the SAB occurs within 30 days of a surgical procedure where the SAB is 
related to the surgical site;   
3. an invasive instrumentation or incision related to the SAB was performed 
within 48 hours; 
4. the SAB is associated with neutropenia (<1 x 109) contributed to by cytotoxic 
therapy. 
(Australian Commission on Safety and Quality in Health Care, 2010) 
 
 
3.5.5 Ethical considerations  
 
The Tasmanian Human Research Ethics Committee (HREC) (H11130) and the Australian 
Catholic University (N20156) granted ethical approval for this research. Copies of ethics 
approvals are provided in Appendix N and Appendix O. The Tasmanian Director of Public 
Health granted access to data held by the TIPCU. The application for ethics approval 
included a request to have consent from participants waived. The justification for the waiving 
of consent submitted to the Tasmanian HREC is summarised in this section. As consent from 
participants was not obtained, compliance with the NHMRC research values and principles 
was paramount (National Health and Medical Research Council, 2007). More specifically, as 
consent was not obtained from participants, the privacy of participants’ data was critical.  
 
Section two of the NHMRC National Statement for Ethical Conduct in Human Research 




waiving of consent (National Health and Medical Research Council, 2007). The ethics 
application approved by the Tasmanian HREC contained details on the justification for the 
waiving of consent. The application demonstrated that criteria set out in section 2.3.6 of the 
National Statement for Ethical Conduct in Human Research were met (National Health and 
Medical Research Council, 2007). Of the criteria stated in section 2.3.6, four main points 
supported the request. First, the study undertaken was deemed low risk as there were no 
interventions and no harm or discomfort likely to be caused by the study. Second, it was 
argued that it was in the community's interest to ensure access to information about SAB as 
the mortality of SAB has been reported between 25% - 35%, an unacceptably high level. 
Further epidemiological studies have identified potentially modifiable risk factors to reduce 
the number of SAB cases (P. Collignon, Dreimanis, D., Beckingham, W., Roberts, J., 
Gardner, A, 2007; J. Turnidge, Nimmo, G., Pearson, J., Gottlieb, T., Collignon, P.,  
Australian Group on Antimicrobial Resistance, 2007). Third, the obtaining of consent was 
impractical as there was a high likelihood that up to one third of participants would have 
since died (J. Turnidge, Kotsanas, D., Munckhof, W., Roberts, S., Bennett, C., Nimmo, G., 
Coombs, G., Murray, R., Howden, B., Johnson, P., Dowling, K., Australia New Zealand 
Cooperative on Outcomes in Staphylococcal Sepsis., 2009). Finally, there were clear 
processes in place to ensure that the privacy of data was maintained. To ensure the privacy of 
data, a unique patient identifier was created for each person and all re-identifiable 
information removed (as described below) and the data collection spread sheet was password 
protected. 
 
To remove the need for re-identifiable information storage, a unique identifier was developed 
for each case of SAB and re-identifiable information was removed from the spread sheet. The 
list was securely locked and was subsequently destroyed following data analysis. In 
conducting the research, there was no known breach of privacy and no known harm occurred 
from the study. 
 
All other information related to this study will be kept for a period of five years at Australian 
Catholic University. This particular time frame was chosen to comply with the NHMRC 
Australian Code for the Responsible Conduct of Research, point 2.1.1 (National Health and 





3.5.6 Data management and analysis 
 
After the provision of an overview on data management, this section describes the analysis 
plan for each research question. 
 
Overview of data management 
 
In preparation for analysis, some data collected in the Microsoft Excel spread sheet were 
recoded into numerical values, ensuring that date formats were consistently applied. Checks 
were performed to ensure recoding was undertaken correctly. Data from the Microsoft Excel 
spread sheet were then imported into IBM SPSS Version 19.0 for data analysis (International 
Business Machines Corporation, 2011). Further recoding and data cleaning in SPSS occurred, 
including checking codes for errors, detecting implausible values, and identifying missing 
values through frequency and cross tabulation calculations. New variables were computed in 
SPSS based on the data collected.  














Table 3  
Operational definitions 
Variable Definition 
Age Age in years at the time of blood culture collection. 
Age group Age group (decade). The ages of cases were grouped into decades, 
consistent with descriptive epidemiology practices (Friis, 2009). 
Australian Bureau of Statistics 
(ABS) age group 
Age grouped according to available ABS population data for 
Tasmanian regions. Further discussed in section 3.6.3. 
Infection number Each infection occurring in the same patient was numbered in 
ascending order, with the first infection starting at ‘1’.  
Postcode region The geographical region of Tasmania based on the home address 
(postcode) of the participant.  
Location of blood culture 
collection 
The location where the positive blood culture was taken. 
Region where blood culture 
was collected  
The geographical region of Tasmania where the blood culture was 
collected. 
Attributable facility For HA cases of SAB, the attributable facility is the facility to which 
the infection was traced. 
Attributable facility region The geographical region of Tasmania where the attributable facility 
is located. 
Attributable facility type Defines the attributable facility type as a public hospital, private 
hospital, rural hospital, or other. 
Final classification of source 
of infection 
If a person had a blood culture taken more than 48 hours after 
admission to a hospital or any of the key clinical criteria described 
earlier were met (section 3.5.4), the case of SAB was defined as HA. 
All other cases were defined as community associated.  
 
Table 3 includes references to geographical regions of Tasmania. The three regions of 
Tasmania are the south, north, and north-west, as defined by the Australian Standard 
Geographical Classification (Australian Bureau of Statistics, 2007) . In relation to the 




postcode from a country other than Australia. These three cases were grouped and coded as 
‘non-Tasmania postcode’.  
 
Data analysis   
 
Data analysis addressed the three research questions posed. The statistical program SPPS was 
used to examine the frequency of SAB by gender, age group, SAB acquisition type (HA or 
CA), and the location where the SAB was attributed and identified. Occurrences of SAB in 
the same person were identified through exploring cases with the same date of birth and sex. 
Where this occurred, the unique patient identifier was used to identify whether these cases 
occurred in the same person. The incidence of SAB was determined by calculating the 
number of new cases of SAB during the two year study period and dividing that by the 
estimated at-risk population. For example, Tasmanian population data were used in 
calculating the incidence of SAB at a population level. Similarly, when the incidence of SAB 
was calculated at a regional level, population data for the relevant region was used. 
Population data for 2009, sourced from the Australian Bureau of Statistics, were used for data 
analysis, as data for 2010 were not available at the time. In the five years preceding 2009, the 
Tasmanian population increased by 1% or less each year. Age stratification for SAB was 
performed at both a population and regional level. Data from the Australian Bureau of 
Statistics contained population data only for the 0-14, 15-24, 25-39, 40-64, over 65, and over 
85 age groups for each of the regions. Using these data, it was possible to calculate the 
population for the 65-84 and the over 85 age groups for each region. Confidence intervals for 
incidence were calculated using Fisher’s Exact Test. As this is a cohort study, relative risks 
were calculated to compare risks between two groups, for example the risk of SAB in males 
compared with females.  
 
Data analysis was performed on cases of SAB that met the national SAB surveillance 
definition and therefore included repeat cases that occurred in the same person more than 14 
days apart. A number of factors influenced this decision. First, including cases of SAB 
occurring in the same person ensured that data could be compared to other published 




programs examining infection incidence at a population level, for example, Chlamydia 
(National Notifiable Diseases Surveillance System Annual Report Writing Group, 2010; 
Public Health Laboratory Network, 2009). Therefore, cases of SAB that occurred in the same 
person, but more than 14 days apart remained in the dataset for analysis.  
 
3.6 Results  
 
3.6.1 Overview of results 
 
Two hundred and fifteen cases of SAB were identified between the 1
st
 January 2009 and the 
31
st
 December 2010. The 215 cases occurred in 202 different individuals. Of the 202 
individuals identified with SAB, one hundred and twenty (59%) were male. The age of 
individuals varied from three weeks to 94 years (median 66.0 years). Of note was that 12 of 
the 18 cases (66%) of SAB occurring in individuals in the zero to nine age group occurred in 
persons aged less than one month. Figure 8 demonstrates the distribution of individuals with 
SAB by age group and sex.  
 






Of the 215 cases of SAB, one case of HA SAB was attributed to an interstate hospital. This 
case is not included in the following data analysis. Therefore, the total number of cases 
analysed was 214. As national surveillance definitions were applied, including the approach 
that a patient is included only once (unless at least 14 days had passed without a positive 
blood culture), it was assumed that each case of SAB was unrelated to a previous case. 
Therefore, cases of SAB occurring in the same person (but more than 14 days apart) were 
included. The data from persons who had more than one episode of SAB were examined. The 
results are detailed in Table 4. During the study period, 11 people had a second infection and 
one person had three infections (see Table 4). Most of the repeat infections occurred at least 
two months after the first episode. Such findings suggest that the likelihood of subsequent 























Stated region* Date of SAB 
HA SAB CA SAB 
MSSA MRSA MSSA MRSA 
1 1 - -  North-west April 2009 
2 - - North-west - November 2010 
2 1 North - - - June 2010 
2 North - - - July 2010 
3 1 - - North - November 2009 
2 - - North - November 2009 
3 South - - - January 2010 
4 1 - - North - November 2009 
2 - - North - December 2009 
5 1 North - - - June 2009 
2 North-west - - - July 2009 
6 1 South - - - March 2010 
2 South - - - April 2010 
7 1 North-west -  - March 2009 
2 - - North - May 2009 
8 1 South - -- - December 2009 
2 - - South - May 2010 
9 1 - - North-west - April 2010 
2 - - - North-west September 2010 
10 1 -  North - January 2009 
2 - South - - August 2009 
11 1 - - North-west - June 2009 
2 - - North-west - July 2009 
12 1 North-west - - - June 2009 
2 North - - - June 2010 











Two hundred and fourteen cases of SAB were identified between the 1
st
 January 2009 and the 
31
st
 December 2010. Of the 214 cases, 128 (60%) occurred in males. 194 cases (90.7%) of 
SAB were caused by MSSA.  
 
The annual incidence of SAB within Tasmania was 21.26 per 100,000 population, 95% CI 
[18.51, 24.31], Fisher’s Exact Test. The incidence was calculated on the assumption of a 
population of 503,282 per year during this period, indicating an at-risk population of 
1,006,584 over the two years studied. In 2009, there were 112 cases of SAB equating to an 
incidence of 22.25 per 100,000 population, 95% CI [18.32, 26.78]. In comparison, 102 cases 
of SAB occurred in 2010, equating to an incidence of 20.27 per 100,000 population, 95% CI 
[16.53, 24.60].  
 
The proportion of cases that were HA was 41.6%, with the remaining 58.4% being CA. The 
respective incidences of HA and CA SAB are detailed in Table 5. The majority of cases of 













Incidence of Staphylococcus aureus bacteraemia per year per 100,000 population within 
Tasmania.   
Characteristic Healthcare Associated Community Associated Total 
Incidence  
(n) 
95% CI Incidence  
(n) 


























































































































Note. Incidence = number of new cases of SAB per 100,000 population per year. n = number of cases. 
95% CI = 95% confidence interval. Confidence intervals are expressed using the lower and upper 




To explore the association between age and the risk of SAB, age specific incidence rates have 
been calculated and the results are shown in Table 6. Relative risks were calculated to 
compare the difference between groups. The relative risk of a male having an episode of SAB 
in comparison to a female was 1.52, 95% CI [1.15, 2.03]. Similarly, using the 60-69 age 
group as a reference category, the relative risk of SAB increases with age and represents a J 








Relative risk of Staphylococcus aureus bacteraemia by age group, Tasmania 2009-2010. 





































Note. N = 214. 95% CI = 95% confidence interval. Confidence intervals are expressed using 




Healthcare associated SAB and risk factors  
 
Of the 89 cases of HA SAB, 61 (68%) occurred in patients who were hospitalised for more 
than 48 hours whilst 29 (32%) occurred in persons who were in hospital less than 48 hours 
but met clinical criteria defining a case of HA SAB. Key clinical data for all cases of SAB 
were collected. Of note was the proportion of cases associated with indwelling devices. 
Forty-one cases (46%) of HA SAB were solely associated with an intravascular device. There 
were 12 (13%) cases of SAB associated with a surgical procedure, five (6%) cases associated 
with a neutropenia, one (1%) case associated with an invasive procedure, and 22 (25%) 
instances where one of the four clinical criteria was not met, but the patient was in hospital 
more than 48 hours. There were eight instances (9%) where persons had intravascular devices 
but one other key clinical criterion was not met. Of the 49 (55%) instances where an 




lines, 12 (25%) were a peripheral intravascular device, and ten (20%) were other devices that 
were not specified. 
 
More than half of HA SAB were associated with an intravascular device in both persons who 
had been hospitalised more than 48 hours (n = 34, 55%) and in persons hospitalised less than 
or equal to 48 hours (n = 15, 52%). 
 
3.6.3 Results by Tasmanian region 
 
A total of 103, 69, and 42 cases of SAB were attributed to healthcare facilities in the 
southern, northern, and north-west regions of Tasmania, respectively. As CA SAB cannot be 
directly attributed to any one cause, the geographic region in which the case of community 
SAB was identified was used for the purposes of data collection. Table 7 outlines the 
incidence of SAB by region and characteristic. The percentage of population by age group 





Annual incidence rate of Staphylococcus aureus bacteraemia per 100,000 population in each Tasmanian region  
Characteristic South 
(total population = 249,475) 
North 
(total population = 141,434) 
North-west 
(total population = 112,383) 
HA  
(n) [95% CI] 
CA 
(n) [95% CI]  
All  
(n) [95% CI] 
HA  
(n) [95% CI] 
CA 
(n) [95% CI]  
All  
(n) [95% CI] 
HA  
(n) [95% CI] 
CA 
(n) [95% CI]  
All  
(n) [95% CI] 














































































































































































































































































Note: SAB = Staphylococcus aureus bacteraemia. N = 214. HA = healthcare associated; CA = community associated. Incidence = number of new cases of SAB per 100,000 population per 
year. HA cases are listed against the attributable region; CA cases are listed as the region in which the case of SAB was identified. 95% CI = 95% confidence interval. Confidence intervals are 




From the results provided in Table 7, a number of results were of interest. First, there was a 
higher overall incidence of SAB in the northern region compared to the southern and north-
west regions, although not statistically significant. Second, there was a higher incidence of 
HA SAB in the southern region, compared to the other two regions. Consistent with data 
described in Table 7, it is also possible to see that the incidence of SAB generally increased 
with increasing age. Notably however, the incidence of SAB in the southern region was 
higher in the 0 to 14 age group, compared with the other two regions, before declining in the 
15-24 age group and increasing again.  
 
The incidence of SAB was homogenous among the three regions other than a large increase 
in CA SAB in the north and north-west regions in the 65-84 age group. The incidence of CA 
SAB in the north continued to increase in those aged 85 and over, whereas there was a 
decrease in the incidence of CA SAB in the north-west region for the same age group. 
However, there were small absolute numbers of cases and very wide confidence intervals in 
the highest age groups. 
 
Finally, differences between the location (region) where a blood culture was taken and the 
region to which it was attributed were analysed. Four cases (4.5%) of HA SAB were 
attributed to a different region from that where the blood culture was taken. Three of the four 
cases were situations in which the blood cultures were collected in the north-west region, but 
were attributable to the southern (2) and northern (1) regions. 
 
3.6.4 Results by hospital type   
 
This section examines cases of SAB according to where they were identified and 
distinguishes the attributed locations by hospital type. For the purposes of this section, 
‘identified’ refers to the locations where the positive blood cultures were collected. The 
reason for examining this, as opposed to only examining where a case of SAB was attributed 
to, is to answer the third research question for this study. Currently, the national surveillance 
program for SAB in Australia is concerned with cases of SAB associated with public 




question of what proportion of SAB cases would be missing from the national surveillance 
program, when only data from public hospitals were included. 
 
Table 8 shows the distribution of SAB cases found outside acute public hospitals. The 
majority of cases of SAB were identified in one of the four acute Tasmanian public hospitals. 
However, a small but potentially clinically significant proportion of SAB cases were 
identified in private hospitals.  
 
Table 8 
Identification of Staphylococcus aureus bacteraemia by healthcare facility type 
Characteristic Facility type where SAB was identified 
Acute Public Hospital Private Hospital Public Rural 
Hospital 
Total SAB 188 (88%) 24 (11%) 2 (1%) 
























Note: SAB = Staphylococcus aureus bacteraemia. 
 
A similar percentage of MRSA bacteraemia and MSSA bacteraemia were identified in public 
and private hospitals. The percentage of HA SAB was lower, however, in private hospitals, 
compared to public hospitals. The calculation of relative risk of SAB comparing public and 
private hospitals was not possible, as data on the number of persons exposed in private 
hospitals were not available.  
 
Table 8 demonstrates where cases of SAB were identified. Not all of the 89 cases of HA SAB 




attributed to different hospitals from those where the blood culture was taken and one case of 




Two hundred and fourteen cases of SAB were identified in this study. Of the 214 cases, 128 
cases (60%) occurred in males. Over 90% of cases (194, 90.7%) were caused by MSSA. The 
incidence of SAB within Tasmania was 21.26 per 100,000 population per year. The 
proportion of cases that were HA was 41.6%, with the remaining 58.4% being CA. 
 
Of the 89 cases of HA SAB, 61 (68%) occurred in patients who were hospitalised more than 
48 hours whilst 29 (32%) occurred in persons who were in hospital less than 48 hours but met 
clinical criteria defining a case of HA SAB. Of the 49 (55%) instances where an intravascular 
device was implicated in some way, 27 (55%) of these devices were central lines, 12 (25%) 
were a peripheral intravascular device and 10 (20%) were from all other devices.  
 
The incidence of SAB was relatively homogenous among the three regions at around two 
cases per 100,000 population per year; with 11% of SAB identified in private hospitals. Five 
cases (5.6%) of HA SAB were attributed to different hospitals from those where the blood 
culture was taken and one case of HA SAB was identified in a public hospital but attributed 








This study provides useful insights into the epidemiology of SAB. It is the first reported study 
in Australia to capture data from all cases of SAB in a discrete population. Tasmania is an 
island state in Australia with a relatively stable population. Results from the study were 
analysed at the population level, by region, and by hospital type. The discussion focuses on 
three main elements consistent with the research questions guiding the study: the overall 
incidence of SAB at a population level, regional variation of SAB, and the potential for under 
reporting SAB by only collecting data from public hospitals. In particular the overall 
incidence and its contributing proportions highlight many key points and therefore these are 
explored in more detail in the discussion. After exploring each of the three elements in more 
detail, the reliability and validity of the data and the limitations of the research are discussed. 
To conclude the discussion recommendations are identified regarding policy, practice, and 
further research. 
 
3.7.2 Incidence of SAB at a population level  
 
Three main results were of particular note when looking at the incidence of SAB at the 
population level. First, the study was unique, in that it collected data from all cases of SAB 
occurring in Tasmania. As such, I can confidently report the incidence of SAB as 21.26 per 
100,000 population, with approximately 40% of cases being HA. Second, my study suggests 
that the risk of SAB increases with age, with the exception of the first decade. Third, results 
suggest that males are more likely than females to suffer from SAB. Finally, my results 
suggest that there are a number of potentially modifiable risks for HA SAB. In this section, 
comparisons are drawn between the current findings and those published in the literature for 







Comparing the incidence of SAB 
 
Only a few reports describe the population-based incidence of SAB (Asgeirsson, 
Gudlaugsson, Kristinsson, Heiddal, & Kristjansson, 2011; P. Collignon, Nimmo, G., 
Gottlieb, T., Gosbell, I., Australian Group on Antimicrobial Resistance, 2005; Easton, 2010; 
Huggan, et al., 2010; Lamagni et al., 2011; Lessa et al., 2010; J. Turnidge, Nimmo, G., 
Pearson, J., Gottlieb, T., Collignon, P.,  Australian Group on Antimicrobial Resistance, 
2007). Of these reports, only one study captured all cases of SAB in a defined population 
(Asgeirsson et al., 2011). In the study undertaken in Iceland, the annual incidence of SAB 
was reported as 24.5 per 100,000 population between the years 1995 and 2008 (Asgeirsson et 
al., 2011). There are a number of similarities between the study undertaken by Asgeirsson et 
al. (2011) and the current study. Both had a clearly defined population and employed similar 
methodology in that they identified all cases of SAB in the population. Further, in the 
Icelandic study, 721 episodes of SAB were identified, with 4% of the episodes being re-
infection, a figure that compares to that of the present study (6%). Although the re-infection 
rates are similar between the studies, the Icelandic study was conducted over 13 years and 
therefore the potential for new infections in the same person is higher. Both studies had 
exclusion periods for duplicate cases of SAB. In my study, consideration was given to 
excluding all cases of SAB occurring in the same person, for the purposes of calculating a 
population incidence. In deciding whether to remove duplicate cases occurring in the same 
person but outside the 14 days exclusion period as described in 3.5.3, other population-based 
studies were reviewed. Following this process it was clear that like my study, other 
population-based infection surveillance programs do not remove second cases of infection 
occurring in the same patient in the same year. One example of this in Australia was the 
nationally notifiable disease Chlamydia (National Notifiable Diseases Surveillance System 
Annual Report Writing Group, 2010; Public Health Laboratory Network, 2009).  
 
The similarities between the current study and that conducted by Asgeirsson et al. (2011) 
continue. On initial review, it also appears that both studies have a similar proportion of HA 
SAB, with 46% and 42% of SAB being HA in the Icelandic study and this study, 
respectively. However, different case definitions for HA SAB were used. It is likely that the 




used patient administration data to define cases of nosocomial SAB and all cases of SAB 
occurring after 48 hours were classified as HA. In contrast to the current study, no clinical or 
other assessment criteria were used to determine cases of SAB that were HA, but were in 
hospital less than two days. In this study, 32% of persons defined as having HA SAB were in 
hospital less than 48 hours, a finding that is comparable to Dendle’s study performed over a 
27 month period in a single Australian hospital (Dendle et al., 2009). This study found that 
26.7% of HA SAB occurred in non-inpatients, using the same clinical criteria applied in my 
study (section 3.5.4). Assuming that by only including persons in hospital more than 48 hours 
in a HA definition misses other cases of HA SAB, then the true occurrence of HA SAB in 
Iceland is probably higher than in Tasmania. Such a finding is important, as many studies 
examining SAB, including those describing the incidence of SAB at a population level, use 
the simple criterion of a case of SAB occurring more than 48 hours after hospitalisation to 
define HA SAB (Easton, 2010; Huggan et al., 2010). These studies, therefore, underestimate 
the true occurrence of HA SAB. 
 
The advantages of using a timeframe such as 48 hours to define a case of HA SAB were 
explored in detail in Chapter 3. The use of well-defined terminology is important when 
describing study results to facilitate accurate comparisons. For example, the term ‘hospital 
onset’ SAB has been correctly used in several studies to describe instances of SAB occurring 
in patients hospitalised for more than 48 hours (Lessa, et al., 2010; J. Turnidge, Nimmo, G., 
Pearson, J., Gottlieb, T., Collignon, P.,  Australian Group on Antimicrobial Resistance, 
2007). The use of recognised terminology not only makes comparing results between studies 
easier to interpret, but also ensures that those without an in-depth understanding of these 
issues, including the wider public, do not misinterpret the data. Such issues become more 
critical when data on HA SAB are publicly reported or used as a performance measure.  
 
A similar incidence of SAB was found in a study undertaken by Huggan et al. (2010), which 
determined the population-based incidence of SAB in a region of New Zealand. Similar to 
the current study, population census data were used to calculate the incidence of SAB, which 
was found to be 21.5 per 100,000 population. One limitation of the New Zealand study was 
that data from community laboratories were not collected. Therefore, it is possible that it 




Zealand, not the entire New Zealand population. Challenges in accounting for a dynamic 
population and the potential crossover of persons receiving healthcare between regions would 
have been difficult to quantify, an issue also faced in my study.  
 
Compared to my study, a much higher incidence of SAB for Australia has been reported in a 
study undertaken by the AGAR which estimated the incidence of SAB at 35 per 100,000 
persons per year in Australia, with approximately 6900 cases of SAB occurring each year (P. 
Collignon, Nimmo, G., Gottlieb, T., Gosbell, I., Australian Group on Antimicrobial 
Resistance, 2005). Following this study, the figure of an estimated 7000 cases of SAB 
occurring in Australia each year has been widely used. This incidence was estimated using 
the median SAB rate from the 17 participating hospitals. The current data suggest that the 
SAB incidence suggested by the AGAR, and used in numerous publications since, is an 
overestimate. The authors acknowledge the limitations of their methodology and call for a 
program that captures all bacteraemia in a well-defined population (P. Collignon, Nimmo, G., 
Gottlieb, T., Gosbell, I., Australian Group on Antimicrobial Resistance, 2005). My study 
addresses this issue: extrapolating from an incidence of 21.26 per 100,000 population in 
Tasmania, there would be approximately 4800 cases of SAB in Australia each year, based on 
a population of 22.7 million.  
 
This discussion so far has compared the peer reviewed literature with the current study. 
However, government or professional organisations undertake many surveillance programs 
for SAB, as described in Chapter 3. These are reported through various websites and in other 
grey literature. A voluntary SAB surveillance program in England, Wales, and Northern 
Ireland attempted to report on the incidence of SAB at a population level and included 
stratification for age and sex (Health Protection Agency, 2011b, 2011c). Data from 185 
laboratories were used to collate the occurrence of SAB. One significant limitation of this 
three country program is that it is not clear what proportion of all laboratories contributed 
data. In 2010, 10,070 cases of SAB were reported in the three countries. The annual 
incidence of SAB was not reported in this study, but rather, it was reported in a bar graph 
comparing the total number of SAB cases by year, making a statement about an exact figure 
difficult (Health Protection Agency, 2011c). The authors stated that they used population data 




SAB in these three countries combined to be 17.9 per 100,000 population, with 15.5% of 
SAB reported as MRSA (2.77 per 100,000 population in 2010). These results suggest a lower 
incidence of SAB in the United Kingdom than in Tasmania but a higher proportional 
incidence of MRSA. However, a published study by Lessa et al. (2010) seems to cast doubt 
on the MRSA results published by the Health Protection Agency and this will now be 
examined in more detail.  
 
Lessa et al. (2010) compared the incidence of MRSA bacteraemia in the United States and 
England using population-based surveillance in these countries. Data from the United States 
used sources from eight metropolitan areas and one state, comprised of 162 hospitals under 
surveillance with an approximate population base of 16 million people. In England, the 
reporting of MRSA bacteraemia is mandatory and the information source was microbiology 
laboratories. The estimated population under surveillance in England was 56 million people. 
Hospital onset bacteraemia was defined as a positive blood culture three days after hospital 
admission. All other cases were defined as community onset. The total incidence of MRSA 
bacteraemia was 29.1 and 11.3 per 100,000 population for the United States and England, 
respectively. In the case of England, such a result was not consistent with the HPA results 
discussed earlier (Health Protection Agency, 2011b). The HPA data suggests the incidence of 
MRSA bacteraemia in the United Kingdom was only 2.77 per 100,000 population and 
therefore there is a significant discrepancy between this data and that reported by Lessa et al. 
(2010). One possible explanation is that England has a considerably higher incidence of 
MRSA bacteraemia compared with Wales and Northern Ireland, although some doubt is cast 
in this assertion as the percentage of SAB caused by MRSA is reported to be 28.8% in Wales 
(Welsh Healthcare Associated Infection Program, 2009). These points demonstrate the 
challenges in comparing data when definitions are inconsistent, catchment populations are 
not clearly defined, and a validation process is limited. I am confident that, in this study, data 
from all cases of laboratory confirmed SAB in Tasmania were collected using an open and 
consistent process with robust validation procedures. Issues relating to the validation of data 
are discussed later in this section. 
 
The study by Lessa et al. (2010) did highlight some points of interest. The incidence of 




compared to 3.5 in England (Lessa et al., 2010). These results suggest that the majority (75%) 
of MRSA bacteraemia in the United States is community onset. Comparisons of MRSA 
bacteraemia between my study and others should been undertaken with caution, given the 
relatively low prevalence of MRSA bacteraemia identified. For this reason, comparisons are 
not provided. 
 
I argue that by having a robust process for capturing data from laboratories on SAB, it is 
possible to improve the identification of cases of SAB in a defined population. This can be 
achieved by making SAB a notifiable disease, as is the case in Tasmania, or by having a 
robust data linkage system among all laboratories and a central agency. The latter must also 
be supported by a relevant structure that enables this to occur, for example a legislative or 
contractual requirement. Without this requirement, it would be possible for laboratories to 
refuse to be part of a co-ordinated data program. 
 
Healthcare associated SAB and risk factors 
 
The discussion in this section only refers to data pertaining to healthcare associated SAB. The 
collection of data on the potential causes of HA SAB identified important clinical problems. 
Forty-one cases (46%) of HA SAB were solely associated with an intravascular device and an 
intravascular device was implicated in some way in 55% of all HA SAB cases. 
 
Such a finding suggests that a considerable proportion of HA SAB can be prevented by 
improved processes relating to the insertion and maintenance of intravascular devices. 
Interventions proven to reduce the occurrence on intravascular device-associated bacteraemia 
include active surveillance and review of cases of SAB with feedback to clinical staff about 
potentially modifiable risk factors (P. Collignon, Dreimanis, D., Beckingham, W., Roberts, J., 
Gardner, A, 2007). An example of a process aimed at reducing the risk of infection such as 
SAB is the promotion of correct hand hygiene prior to any interventions, such as 
intravascular insertion. Improved hand hygiene compliance has been demonstrated to reduce 
the occurrence of HA methicillin resistant SAB (L. Grayson, Russo, R., Cruickshank, M., 




C., Smith, R., Wilkinson, I., 2011). A second example of an intervention aimed at reducing 
the risk of SAB is correct intravascular device insertion practices. Correct skin preparation 
with alcohol (70%) prior to intravascular device insertion has been shown to reduce the risk 
of bacteraemia and to lessen severe localised infections (Maki, Ringer, & Alvarado, 1991). 
Other measures to reduce the risk of intravascular device-related bacteraemia include the 
selection of the best entry point for the device, and the choice of device used. Each of these 
processes are themselves subject to considerable research and debate, which have led to 
guidelines from notable organisations such as the Centres for Disease Control and the 
NHMRC (National Health and Medical Research Council, 2010; N. O'Grady, Alexander, M., 
Burns, L., Dellinger, P., Garland, J., Heard, S., Lipsett, P., Masur, H., Mermel, L., Pearson, 
M., Raad, I., Randolph, A., Rupp, M., Saint, S., and the Healthcare Infection Control 
Practices Advisory Committee., 2011). The NHMRC are not alone in the issuing of 
guidelines aimed at reducing HAIs, such as HA SAB (L. Grayson, Russo, R., Ryan, K., 
Bellis, K., Havers, S., Heard, K., Simpson, P., 2010; Health Protection Scotland, 2011b; 
National Patient Safety Agency, 2010; World Health Organisation, 2011a).  
 
The findings from the current study demonstrate that HA SAB represents approximately 41% 
of all cases of SAB, meaning that CA SAB is more common that HA SAB. In comparison to 
the prevention of HA SAB, CA SAB appears to receive little attention and prevention 
strategies seem sparse. In light of this, more attention should be paid to understanding the risk 
factors for CA SAB, and where possible, to identifying strategies for prevention.  
 
Risk of SAB related to increasing age and male sex 
 
The research results presented in this chapter demonstrate that the risk of SAB increases with 
age. Similar results have been found in a number of studies (Asgeirsson, et al., 2011; 
Laupland, et al., 2008; Morin & Hadler, 2001; J. Turnidge, Nimmo, G., Pearson, J., Gottlieb, 
T., Collignon, P.,  Australian Group on Antimicrobial Resistance, 2007). My study also 
identified that the relative risk of SAB was higher in males, compared to females. The same 





3.7.3 Regional variation of SAB  
 
There were three key points of interest when reviewing the incidence of SAB among the 
three regional areas of Tasmania. The first was a higher incidence of SAB in the northern 
region and a higher incidence of HA SAB in the southern region in inter-regional 
comparisons, although these differences are not statistically significant. The second was a 
noticeable increase in the incidence of CA SAB in the three regions in the 65-84 age group 
from the 40-64 age group, but a decline in the north-west region for the 85 and over age 
group. Third, there were only minor differences when the study compared the numbers of 
cases of SAB by the region in which they were attributed to against the region in which they 
were identified. Each of these three issues is discussed in more detail. 
 
The higher incidence of CA SAB in the northern region of Tasmania is difficult to explain. 
The difference could be chance as the higher incidence is not statistically significant. 
Conversely, the higher incidence could be real but would require a longer study period to 
confirm. There are no published research papers in Australia examining or comparing the 
incidence of SAB at a regional level. Therefore, it is not possible to compare the current 
study with other published literature. Potential risk factors for CA SAB include intravenous 
drug use. In the case of my study, there is no known difference in the prevalence of 
intravenous drug use among the regions. Further, should intravenous drug use be a factor in 
the higher incidence of CA SAB, it would be more likely to appear in a younger age group 
than seen in my study. Other potential reasons that would require further research include 
whether health issues such as smoking, obesity, and diabetes play a role in CA SAB. Aged 
standardised mortality for diabetes is higher in the north compared to the other two regions; 
however, data are not available for the prevalence of smoking or for body mass indices for 
the regions (Population Health Epidemiology Unit, 2008).  
 
The increasing incidence of CA SAB with age is consistent among the regions, except for a 
decline in the 85 years and over age group in the north-west. Little weight should be attached 
to this result given the relatively low numbers of SAB occurring in this region. For example, 
if there were two more cases of SAB occurring in this age group and region, a continual 




and south. In the south, the incidence of HA SAB in the 0-14 age group is higher than in the 
other regions. Such a finding can be explained by this region containing a tertiary referral 
centre, with the state’s only neonatal intensive care and paediatric unit. 
  
The final point of interest in this section is the difference between where a case of SAB was 
identified compared to where it was attributed. Exploration of this point is important, as 
surveillance units and infection control professionals often spend considerable time debating 
whether a case of SAB should be attributed to their facility. This issue is also explored in 
more detail at a hospital level in the next section. Results from the study suggest that 
approximately 5% of HA SAB should be attributed to different regions from the origins of 
the blood cultures. Importantly however, this particularly affected the north-west region, 
where two cases of SAB were attributed to a hospital in the south and one to a hospital in the 
north. If these three cases had been included in the data analysis for the north-west region, it 
would have potentially overestimated the incidence of SAB in this region. Importantly 
however, given the small numbers of SAB occurring in the north-west, the addition of two 
extra cases of SAB can markedly change the incidence, in comparison to other regions with 
higher cases of SAB.  
 
The national SAB surveillance program in Australia seeks to attribute cases of HA SAB to a 
particular facility (H. Van Gessel, McCann, R., Peterson, A., Cope, C., Wilkinson, I., 
Mitchell, B., Wells, A., Kennedy, B., Hall, L., Gallard, J., Lee, R., Cooley, L., Cruickshank, 
M., Greig, S., Hanley, E., Willows, K., Board, N., 2011). Results from the current study 
suggest that approximately 5% of HA SAB cases identified in one facility were attributed to 
another. Furthermore, among this 5%, there were instances where a hospital may attribute a 
case of SAB to another facility, but have a case identified in a different facility attributed to 
them. Such findings would appear to influence further debate on whether the time spent on 
attributing HA cases of SAB to a particular facility is a suitable use of resources, since the 






3.7.4 Potential for under reporting  
 
This research study captured data on all cases of SAB. Therefore, for the first time in 
Australia, it was possible to accurately quantify the proportion of cases of SAB that occurred 
outside public hospitals. Since the commencement of this study, an Australian national 
surveillance program for SAB has been established for cases of SAB associated with public 
hospitals. The results detailed in section 3.6.4 provide quantitative data on the proportion of 
SAB cases that is potentially missed in the national surveillance program because of its 
limited focus on public hospital data. 
 
This study’s results indicate that approximately 11% of cases of SAB were identified in 
healthcare settings other than public hospitals. Such a finding is important, given the current 
national focus on public hospitals only and provides valuable insight into whether the 
national SAB surveillance program should be formally extended to private hospitals. Such 
findings open the door for further debate on whether the time spent capturing data from 
private hospitals is a valuable use of resources. Capturing data from private hospitals would 
enable a more accurate understanding of the epidemiology of SAB, including CA SAB. 
Conversely, as private hospitals differ significantly in structure and size, and use a variety of 
microbiology services, a one size fits all policy may not be suitable.  
 
The development of a surveillance definition and program for HA SAB in Australia was 
initially proposed as part of a safety and quality agenda. Therefore, HA SAB data could be 
used as part of a framework (Chapter 2) to drive interventions that can reduce its incidence. 
At the time of writing, HA SAB surveillance data were also being used in a performance 
management agenda. In using these data in such a way, the challenges of ensuring the data 
are valid, comparable, and reliable become more of an issue. This particular point is 
addressed further in Chapter 6. In Australia, HA SAB data at the hospital level were recently 
made public on the MyHospitals website (Australian Institute of Health and Welfare, 2011). 
This information is now available to media and members of the public. How these data are 
used and interpreted varies, as limitations are not fully necessary appreciated by the end 




thesis. Themes from the challenges faced in HAI surveillance and its use are described in 
more detail in Chapter 6.  
 
To improve the application of surveillance definitions, guidelines to interpret definitions 
should be developed. Such a process ensures all cases are treated and classified in the same 
manner. In the case of HA SAB, the Australian Commission on Safety and Quality in Health 
Care has developed guidelines for infection control professionals and clinicians for the 
interpretation of SAB surveillance definitions (H. Van Gessel, McCann, R., Peterson, A., 
Cope, C., Wilkinson, I., Mitchell, B., Wells, A., Kennedy, B., Hall, L., Gallard, J., Lee, R., 
Cooley, L., Cruickshank, M., Greig, S., Hanley, E., Willows, K., Board, N., 2011). 
Conversely, the use of strict and simplistic definitions potentially negates clinical 
interpretation and may result in disengagement by healthcare professionals. Such issues 
underscore the importance of using a psychosocial approach to infection control, as described 
in Chapter 2.  
 
As this study is concerned with SAB at the population level, individual hospital results are 
not presented. Further, bed occupancy data for individual private hospitals were not available, 
and therefore, such data analysis was not possible. In the case of Tasmanian public hospitals, 
although HCA SAB is reported by the TIPCU, bed occupancy data are not. Only summary 
rates are published (B. Mitchell, McGregor, A., Brown, S., Wells, A., 2011a). Therefore, 
comparisons between the incidence of SAB in public and private hospitals are not possible. 
 
 
3.7.5 Reliability of the data 
 
A number of steps were put in place to ensure the inter-relater reliability of data used in this 
study. First, mandatory reporting greatly increased the likelihood of all cases of laboratory 
diagnosed SAB being reported. As SAB is a notifiable disease in Tasmania, laboratories have 
a legal requirement to report all blood cultures that contained S.aureus. All but one laboratory 




culture was reported as growing S.aureus, a report was automatically generated by the 
computer and sent to the Public Health Department. This reduced the risk of human error 
associated with a manual reporting process. The one laboratory that did not have an 
electronic method of notification relied on laboratory staff faxing a copy of the result to the 
Public Health Department, which may reduce the reliability of all results being notified. To 
overcome this issue and to provide a secondary check, each laboratory was required to 
provide the Public Health Department with a monthly manual download of all blood cultures 
positive for S.aureus, as described in Figure 7. This download was then cross checked against 
previously submitted notifications, enhancing reliability by ensuring that all cases of SAB 
were reported.  
 
For the second important step, a number of processes were established at the commencement 
of data collection, to ensure that the data collected on each case of SAB were accurate and 
these processes were discussed in section 3.5.4. Some methods used in my study, such as 
monthly laboratory extracts to cross check against reported cases of SAB and the use of clear 
protocols and education are reproducible and are not labour intensive. However, one key 
element underscoring the processes of capturing all data was that SAB was a notifiable 
disease in Tasmania. The process for making SAB a notifiable disease in Tasmania was 
relatively straight forward and did not result in significant changes or workload for the Public 
Health Department. As each state and territory’s public health legislation differs in Australia, 
the key mechanism used in my study to ensure all cases of SAB were identified may not be 
possible elsewhere.  
  
3.7.6 Validity of the data 
 
The current study applied national surveillance definitions. Chapter 3 examines the issue of 
whether the surveillance definitions measure what they are supposed to measure. Since the 
development of the national SAB surveillance definitions, there has been a publication 
endorsing them (B. Mitchell, Gardner, A., Collignon, P., Stewart, L., Cruickshank, M. , 
2010). During this study, the national surveillance definition for SAB was found to be clear, 




explicit enough to enable easy application or where there was disagreement between a 
TIPCU classification of SAB and infection control professionals or clinicians. Where these 
situations occurred, in all circumstances, the issue was resolved by careful review of the 





The study does have limitations. First, the population of Tasmania is relatively small; thus, 
firm conclusions about the representativeness of the Tasmanian data at an Australian level 
require caution. Second, the calculation of incidence over the two year period was based on 
2009 population data, as data for 2010 were not available at the time of data analysis. The 
magnitude of any overestimation is unlikely to be significant, given that in the five years 
preceding 2009, the Tasmanian population increased by 1% or less each year (Australian 
Bureau of Statistics, 2011). Finally, the prevalence of MRSA in healthcare settings in 
Tasmania has already been established as generally low (B. Mitchell, McGregor, A., 
Coombs, G., 2009). Therefore, caution should be taken when comparing the incidence of 
MRSA SAB to other Australian settings where MRSA prevalence is higher. 
 
The incidence of SAB is based on laboratory confirmed cases of SAB. Cases where 
Staphylococcus aureus was not present at the time of blood culture or where a blood culture 
was not taken will be missed.  
 
3.8 Recommendations  
 
A number of recommendations can be made based on the finding of my study. Consistent 
with other research, my study found that half of HA SAB was associated with an 
intravascular device. This provides evidence of a need to have as system in place to monitor 




suggested that if timeframes are the sole criteria used to determine cases of HA SAB, 
approximately 30% of cases of HA SAB will be incorrectly identified as CA SAB. 
With these two points in mind, the following policy and research recommendations are made: 
1. Continued surveillance of HA SAB in Australia is required 
2. Surveillance of HA SAB should include the ability to collect data on its potential 
causes  
3. The definition of HA SAB should include clinical criteria  
 
The findings of this study also suggest that approximately 11% of cases of SAB were 
identified in healthcare settings other than public hospitals. In order to inform a debate about 
whether the national SAB surveillance program should be formally extended to private 
hospitals occurrences, I recommend:  
4. This population-based study be replicated in another Australian state, with the aim of 
comparing the incidence of SAB in private hospitals.  
 
While there is a strong policy focus in Australia on reducing HA infections including HA 
SAB, it is important to note that results from this study suggest that CA SAB is more 
common than HA SAB. An improved understanding of CA SAB in Australia is vital, in 
particular, improving our understanding of risk factors for CA SAB. Therefore, future 
research in the following areas is recommended: 




This chapter started by providing background to a common hospital pathogen, S.aureus and 
to a serious HAI, namely SAB. A literature review was undertaken to explore the 
epidemiology of SAB in current SAB surveillance programs. Through this review of the 




SAB cases in a given population and reported on these findings. Such a program would allow 
for an improved understanding of the epidemiology of SAB and to explore potential 
influences for under reporting of SAB.  
 
In response to the literature review, the first piece of research for this thesis was presented. 
This study examined the epidemiology of SAB at a population level using a descriptive, 
observational, population-based study design. All cases of SAB occurring in Tasmania 
between the 1
st
 January 2009 and 31
st
 December 2010 were explored. This is the first known 
Australian study to capture and analyse data from all cases of SAB at a population-based 
level and represent this as an incidence. In doing so, three main areas were explored, namely 
the incidence of SAB at a population level, the incidence of SAB at a regional level and the 
potential for under reporting for SAB where data is collected from public hospitals only and 
where different case definitions are applied. 
 
The findings from this study can be summarised into four themes. First, the incidence of SAB 
at a population level has been accurately determined for the first time in Australia. The 
annual incidence of SAB was found to be 21.26 per 100,000 population. Using the incidence 
of SAB in Tasmania, it was estimated that there are approximately 6800 cases of SAB 
occurring each year in Australia. Both the incidence of SAB and the estimate of the total 
number of cases of SAB in Australia are lower than that reported in other Australian studies. 
Second, a large proportion of HA SAB was associated with intravascular device 
management. Third, case definitions for HA SAB will influence its detection. If only 
timeframe from admission to hospital and infection onset are used to determine cases of HA 
SAB, approximately 30% of HA SAB will be incorrectly classified as CA SAB. Fourth, 11% 
of SAB were identified in private hospitals and these fall outside the scope of almost all SAB 
surveillance programs in Australia. Such a finding enables an informed debate on whether 




Chapter 4: Clostridium difficile infection and mortality  
 
4.1 Introduction to the chapter 
 
In the first section of this chapter, issues relating to CDI are explored through a critical 
review of the literature. Initially, background on CDI will be provided, with a particular 
emphasis on CDI pathogenesis, detection and issues commonly faced when undertaking 
research or surveillance of CDI, namely, how to define cases and the location of CDI 
acquisition. An exploration of the risk factors associated with CDI is also provided in this 
section. A literature review related to mortality and CDI will then be presented. Through an 
exploration of the literature, current gaps in the understanding of CDI and mortality in the 
southern hemisphere are identified. The findings from this review indicate that CDI has a 
significant adverse effect on hospitalised patients. Further, no published study was identified 
examining CDI and mortality in the southern hemisphere. Studies investigating the mortality 
of CDI in settings outside of Europe and North America are needed so that the epidemiology 
of CDI in these regions can be understood and appropriate decisions regarding infection 
prevention strategies made. The second study of this thesis addresses this deficit by 
examining CDI and associated mortality in an Australian setting, more specifically, the Royal 
Hobart Hospital, Hobart, Tasmania. Following the literature review, this study is presented. 
To conclude this chapter, recommendations are made.  
 
4.2 Background to Clostridium difficile infection and surveillance 
 
All members of the genus Clostridium are anaerobic bacteria and all have the ability to form 
endospores, one of the most highly resistant life forms on earth (Cartman, Heap, Kuehne, 
Cockayne, & Minton, 2010). There are over 100 identified Clostridium species, however 
90% of clinical disease is caused by just 12 (Cartman et al., 2010). Clostridium difficile is a 
bacterium that is commonly the cause of diarrhoea in hospitalised patients. The spectrum of 
disease caused by C.difficile ranges from uncomplicated diarrhoea through to pseudo 
membranous colitis and toxic megacolon and is often termed “Clostridium difficile-associated 
diarrhoea” or “Clostridium difficile infection” (Heinlen & Ballard, 2010; L. Clifford 
McDonald et al., 2007; Stuart & Marshall, 2011; H. Van Gessel, Riley, T., McGregor, A, 





Clostridium difficile can be cultured from the faeces of 3% of healthy adults, 16-35% of 
hospitalised inpatients and up to 80% of healthy newborns and infants (Aslam, Hamill, & 
Musher, 2005; Bartlett, 1992). There is however, a widely held belief that C.difficile is not 
pathogenic in neonates (Kuijper, Coignard, & Tull, 2006). It is on the basis of this 
assumption, that the majority of CDI research and surveillance excludes people of less than 
two years of age (Australian Commission on Safety and Quality in Health Care, 2010). 
 
Around the world, the incidence of CDI has been increasing since 2002. Explanations for this 
increase may in part be explained by a change in circulating strains of C.difficile, in particular 
the emergence of a strain known as polymerase chain reaction (PCR) ribotype 027 (Bauer, 
van Dissel, & Kuijper, 2009). This strain has been implicated in hospital outbreaks of CDI in 
the northern hemisphere (Goorhuis et al., 2007; Loo et al., 2005).  
 
This section of the chapter explores the pathogenesis, detection and diagnosis of CDI and 
related issues encountered when undertaking research or surveillance of CDI, namely, how to 
manage relapses of CDI in surveillance and how to determine the location of CDI acquisition. 
This section concludes by exploring the risk factors for CDI. 
 
4.2.1 Pathogenesis and treatment diagnosis 
 
Individuals colonised with C.difficile may remain asymptomatic carriers or they may exhibit 
symptoms. In healthy adults, colonisation with C.difficile does not usually result in infection 
due to the protective effects of colonic flora (Cartman et al., 2010). Disruption of the normal 
flora can occur following exposure to antibiotics, leading to a loss of colonisation resistance 
and an enabling of C.difficile to proliferate and cause symptoms (Cartman et al., 2010). 
Colonisation resistance is the term used to describe the process where the indigenous 
anaerobic flora limit the concentration of potentially pathogenic (mostly aerobic) flora in the 
digestive tract (Vollaard, 1994). The ability of antibiotics to alter bowel flora depends on the 




properties and rates of elimination. The risk of CDI due to antimicrobial exposure is explored 
in more detail later in this chapter. Chemotherapy, antiperistaltic drugs and 
gastroenterological surgery are other factors that have the potential to influence colonic flora 
(Cartman et al., 2010; Kuijper et al., 2006).  
 
In CDI, inflammation of the bowel is caused from the production of two protein toxins; toxin 
A and toxin B. Isolates of C.difficile that do not produce either of these toxins are non-
pathogenic (M. Bauer, van Dissel, J., Kuijper, E, 2009). Whether differences between toxin A 
and toxin B are associated with variation in disease severity remains unknown (M. Bauer, van 
Dissel, J., Kuijper, E, 2009; Warny et al., 2005). Toxins A and B are endocytosed by 
enterocytes and as a result, damage the intestinal mucosa. The damage to enterocytes causes 
an inflammatory response in the bowel mucosa and clinical symptoms ranging from mild 
diarrhoea to toxic megacolon can result (M. Bauer, van Dissel, J., Kuijper, E, 2009; Kelly & 
LaMont, 2008). In addition to toxins A and B production, a small number of isolates produce 
a binary toxin; however the role of this third toxin remains unknown. 
 
Treatment of symptomatic CDI usually involves the prescribing of either vancomycin or 
metronidazole. There is ongoing debate as to which of these two antibiotics is the most 
efficacious. It is not within the scope of this chapter to explore this particular issue. The 
immune response plays an important role in CDI and in particular its recurrence, so 
immunotherapy has also played a role in the treatment of recurrent CDI. As normal pooled 
immunoglobulin can neutralise toxins A and B, intravenous immunoglobulin has been used 
to treat recurrent infection (Kelly & LaMont, 2008). Although no randomised control trials 
have been undertaken, immunoglobulins appear to be effective (Kelly & LaMont, 2008). 
Probiotics such as lactobacillus species and Saccharomyces boulardii have also been used to 
treat CDI. They have shown efficacy in reducing antibiotic associated diarrhoea but 
prevention of CDI has been inconsistent. Probiotics have not been shown to be effective as a 
solo treatment option for CDI (Kelly & LaMont, 2008). 
 
A person who has recovered from CDI may suffer a relapse. Whether the relapse is due to 
endogenous re-infection or re-infection from the environment remains unclear (Bauer et al., 
2009; O'Neill, Beaman, & Riley, 1991; Rupnik, Wilcox, & Gerding, 2009). Regardless, a 




Relapse of CDI is associated with older age, co-morbidity and duration of previous episodes 
of CDI (McFarland, Elmer, & Surawicz, 2002; Pepin, Routhier, Gagnon, & Brazeau, 2006). 
The specific issue of managing relapses (potential duplicate cases) of CDI in the same 
individual is explored in section 4.2.3.  
 
4.2.2 Diagnosing and defining CDI 
 
This section provides detail on CDI diagnosis. The issues related to CDI diagnosis are 
important to understand, as they have implications for case definitions and ascertainment 
bias. Consensus criteria for CDI diagnosis are being developed, with the majority of 
researchers and clinicians utilising diagnostic definitions proposed by McDonald et al. 
(2007). More specifically, laboratory detection of C.difficile is the most common method 
used to define a case of CDI (Australian Commission on Safety and Quality in Health Care, 
2010; Boyd, 2007; A. McGregor, Riley, T., Van Gessel, H, 2008).  
 
The diagnosis of CDI occurs through testing of faecal samples at a microbiology laboratory. 
Laboratory diagnosis of CDI is made through detection of C.difficile by culture and/or by 
detection of its toxins. The sensitivity of culture is high, however this method lacks 
specificity. Similarly, culture does not produce any information about the toxigenicity of 
isolates (toxin A or B) and time to a result can be delayed due to the need to perform a further 
test to determine the presence of a toxin (DuPont, Garey, Caeiro, & Jiang, 2008; Kufelnicka, 
2011). 
 
The detection of C.difficile toxin A or B (CDT) in faeces is a common method used by 
laboratories. Compared to culture, the identification of CDT and hence CDI, is faster due to 
the availability of commercial CDT assays. Laboratories generally test for CDT using an 
enzyme immunoassay (EIA) that detects both CDT A and B, or by a neutralised cell 
cytotoxicity assay (Planche et al., 2008). More recently, other detection methods for 
C.difficile such as PCR, which ensures a rapid sensitive result, or the detection of the 
presence of glutamate dehydrogenase (GDH), are being used (DuPont et al., 2008; Reyes et 




identifies the presence of C.difficile and it provides a rapid result. Conversely, the specificity 
of the GHD assay is poor (Sharp et al., 2010).  
 
In a systematic review examining diagnosis of CDI by toxin detection kits, the authors 
reported that the positive predictive value of a range of assays was unacceptably low when 
the prevalence of CDT A and B was less than 10% in the population at large (Planche et al., 
2008). This is not unique to CDI testing, but is a feature of screening in populations with a 
low prevalence of the disease (Grimes & Schulz, 2002). The low positive predictive value has 
a direct impact on clinical management and the reliability of data. The authors suggest that to 
improve diagnosis, a two-stage testing strategy for CDT occur by using a highly sensitive 
rapid screening test initially, with a confirmation by reference method for positive samples 
(such as culture) (Planche et al., 2008).  
 
One issue faced when using a laboratory based method for the detection of CDI relates to 
choosing which faecal samples should be tested for C.difficile. A positive test in an 
asymptomatic patient proves colonisation, not necessarily infection. It has been suggested 
that any diarrhoeal sample in a hospitalised patient should be tested for C.difficile (A. 
McGregor, Riley, T., Van Gessel, H, 2008). Surveillance definitions proposed by McDonald 
et al. (2007) recommend that a case of CDI is defined as diarrhoea (i.e. unformed stool that 
conforms to the shape of a specimen collection container) or toxic megacolon (i.e. abnormal 
dilation of the large intestine documented radiologically) without other known aetiology that 
meets one or more of the following criteria: 
(1) the stool sample yields a positive result for a laboratory assay for C. difficile toxin A 
and/or B, or a toxin-producing C. difficile organism is detected in the stool sample by 
culture or other means or;  
(2) pseudomembranous colitis is seen during endoscopic examination or surgery or;  
(3) pseudomembranous colitis is seen during histopathological examination 
 (McDonald et al., 2007) 
 
Within Australia, the surveillance definition used to define CDI is similar to that proposed by 
McDonald et al. (2007). As summarised in Table 9, a CDI case is defined as a case of 





(1) the stool sample yields a positive result in a laboratory assay for C. difficile toxin A 
and/or B, or  
(2) a toxin-producing C. difficile organism is detected in the stool sample by culture or 
other means. 
(Australian Commission on Safety and Quality in Health Care, 2010) 
 
The advantage of using the definition proposed and adopted by all states and territories in 
Australia is the ability to obtain data from laboratories, rather than rely on a combination of 
laboratory and clinical evaluation and subsequent reporting as per criteria two and three 
proposed by McDonald et al. (2007).  
 
Internationally, laboratory based CDI programs are used in a number of countries including 
England, Scotland, Wales, and Belgium. In England, a case of CDI is defined as a toxin 
positive result for CDI detected by the Health Care Trust whose laboratory processes the 
specimen (Health Protection Agency, 2011a). In Wales, the detection of C.difficile toxins in 
diarrhoeal stool samples is used to define a case of CDI. Surveillance in Wales is restricted to 
C.difficile occurring in inpatients with diarrhoea, however laboratories are unable to ascertain 
information on faecal consistency (Welsh Healthcare Associated Infection Programme, 
2010). The Scottish CDI surveillance program defines a case of CDI as: 
Someone in whose stool C.difficile toxin has been identified at the same time as they 
have experienced diarrhoea not attributable to any other cause, or from cases of whose 
stool C.difficile has been cultured at the same time as they have been diagnosed with 
PMC (pseudomembranous colitis).  
(Health Protection Scotland, 2009a, p. 4).  
 
Essentially, the programs in the United Kingdom are the same as those in Australia. 
 
In France, a patient based voluntary surveillance program is used, which is reliant on 
hospitals and nursing homes notifying severe cases of CDI. Similarly, the Netherlands use a 
patient based surveillance program for severe or cluster cases of CDI, in addition to periodic 
laboratory based studies. In the United States, there is no nationally co-ordinated surveillance 
program (A. McGregor, Riley, T., Van Gessel, H, 2008). Belgium commenced CDI 




Prevention and Control (ECDC) (Kuijper et al., 2006; Lambert, Mertens, Ramboer, Delmee, 
& Suetens, 2009). Canada undertakes laboratory based CDI surveillance which is mandatory 
for all hospitals participating in the Canadian Nosocomial Infection Surveillance Program 
(CNISP). In Canada, a case of CDI is defined as:  
1. diarrhoea
 
or fever, abdominal pain and/or ileus AND laboratory confirmation of a 
positive toxin assay for C.difficile; OR  
2. diagnosis of pseudomembranes on sigmoidoscopy or colonoscopy, or 
histological/pathological diagnosis of CDAD.  
(Boyd, 2007) 
 
Although there are differences in the criteria used to define a case of CDI, there is broad 
agreement that a person who is displaying symptoms of infection, such as diarrhoea, and 
whom has C.difficile toxin detected from faeces, has CDI. As we have seen, some literature 
suggests that a diagnosis of pseudomembranous colitis could also be used to define CDI, 
however this requires additional diagnostic techniques and it is difficult to obtain accurate 
and consistent information on all cases of CDI.  
 
On a practical level, the use of laboratory diagnosed CDI is relatively easy, noting that 
different laboratory testing methodologies and definitions for diarrhoea pose some 
inconsistencies when attempting to compare data. In addition, multiple samples of faeces 
from the same patient can be sent for testing and this raises the specific issue of how to 
exclude such patients when using laboratory diagnosed CDI for research or surveillance. This 
issue will now be discussed further.  
 
 
4.2.3 Managing duplicate samples with laboratory diagnosed CDI 
 
Recurrent positive laboratory tests for C.difficile toxin pose a challenge for interpretation. For 
the purposes of research and surveillance, duplicate episodes for a given individual within a 
defined period are often excluded (Health Protection Agency, 2011a; Welsh Healthcare 
Associated Infection Programme, 2010). In Australia, cases are excluded where a known 




included once in an eight week period) (Australian Commission on Safety and Quality in 
Health Care, 2010).  
 
Table 9 provides a summary of the CDI surveillance definitions used in Australia. The 
approach taken in Australia is consistent with CDI surveillance definitions proposed by 
McDonald et al. (2007) and by ECDC (Kuijper et al., 2006). In some countries that undertake 
CDI surveillance, duplicates at four weeks are discarded (Health Protection Scotland, 2009a). 
Research that uses laboratory diagnosed data to determine cases of CDI, generally applies the 
surveillance definitions described by the ECDC and McDonald et al. (Chung et al., 2010; 
Goorhuis et al., 2007). In some instances however, no mention of the management of 
duplicate samples is discussed (Dubberke et al., 2008; Gasperino, Garala, Cohen, Kvetan, & 
Currie, 2010). 
 
As C.difficile is assumed not to be pathogenic in neonates and the risk of CDI increases with 
age, CDI surveillance programs often make age specific exclusions. The ECDC does not 
make any specific age related exclusions, however it does comment that depending on the 
population and the reasons for surveillance and reporting, some restrictions may be warranted 
(Kuijper et al., 2006). Similarly to the ECDC, definitions proposed by McDonald et al. 
(2007) do not define any age restrictions. Despite these recommendations, Australia, England 
and Wales exclude persons under two years old identified with C.difficile in their surveillance 
programs (Australian Commission on Safety and Quality in Health Care, 2010; Health 
Protection Agency, 2011a; Welsh Healthcare Associated Infection Programme, 2010). In 
Scotland, only persons aged 15 years or older are included and in Canada, only persons aged 
less than one month old are excluded (Boyd, 2007; Health Protection Scotland, 2009a).  
 
In summary, there is a variation in criteria used to exclude cases of CDI in surveillance and 
research. There is however, a broad acknowledgement that duplicate cases within a given 
period need to be excluded. A timeframe of between four and eight weeks is most commonly 
used to exclude duplicate samples in laboratory based CDI research and surveillance, with 
authors of notable publications calling for a consistent approach of eight weeks (Kuijper et 




practices vary. Despite both the ECDC and McDonald et al. (2007) not stating an age for 
which cases should be excluded, practices across the world do apply some form of age limit. 
Most commonly, persons aged less than two years old are excluded from laboratory based 
CDI surveillance and research.  
 
Table 9 provides a summary of the CDI surveillance definitions used in Australia. The use of 
laboratory based CDI surveillance and research does have limitations, particularly when 
trying to differentiate between healthcare associated and community associated cases of CDI. 
Further information is required to determine such differences and this will be explored in 
more detail in the next section.  
 
Table 9  
Australian Clostridium difficile infection surveillance definition  
A CDI case is defined as a case of diarrhoea (that is, an unformed stool that takes the shape of the 
container) that meets the following criteria: 
 the stool sample yields a positive result in a laboratory assay for C.difficile toxin A and/or B, 
or  
 a toxin-producing C.difficile organism is detected in the stool sample by culture or other 
means. 
A hospital identified CDI case is: 
 a case diagnosed in a patient attending an acute care facility (that is, it includes positive 
specimens obtained from admitted patients and those attending the emergency department, 
and outpatient departments).  
Exclusions: 
 cases where a known previous positive test has been obtained within the last eight 
weeks (that is, only include cases once in an eight week period).  
 patients less than two years old. 
Note: Adapted from “Data Dictionary and Collection Guidelines for the Surveillance of 
Healthcare Associated Infections: Staphylococcus aureus bacteraemia & Clostridium 





4.2.4 Defining the location of CDI acquisition  
 
Surveillance for CDI primarily focuses on the hospital environment, yet not all cases of CDI 
occur in hospitals nor are necessarily attributable to the hospital in which CDI has been 
identified. To overcome this issue, a range of definitions to determine the place of acquisition 
of CDI has been proposed. These can broadly be summarised as healthcare associated 
healthcare facility onset; healthcare associated community onset; community associated; 
indeterminate; and unknown (Australian Commission on Safety and Quality in Health Care, 
2010; Kuijper et al., 2006; McDonald et al., 2007). 
 
Hospital identified CDI, is an Australian term used to define cases of CDI that are identified 
in persons who are admitted patients or those attending the emergency department and 
outpatients departments at the time a specimen is collected (Australian Commission on Safety 
and Quality in Health Care, 2010). Hospital identified CDI is the same classification as the 
term ‘healthcare facility onset’, proposed by McDonald (2007). The term hospital identified 
CDI, reflects a practical approach to CDI surveillance by acknowledging the limitations of 
information systems which are unable to merge patient admission data with laboratory data. It 
also removes the need for individual case review, and for allocating CDI cases to other 
hospitals. Such an approach is used in Wales and England (Health Protection Agency, 2011a; 
Welsh Healthcare Associated Infection Programme, 2010). A limitation of using this 
definition is the inability to distinguish between cases of CDI identified at a hospital, but 
occurring as a result of healthcare outside of that hospital or those that are community 
associated. 
 
Healthcare associated healthcare facility onset (HCA HFO) CDI is defined when the onset of 
symptoms occurs at least 48 hours following admission. A person is classified as having 
healthcare associated community onset (HCA CO) CDI when symptom onset (or date and 
time of stool specimen collection if a laboratory system is used) occurs in the community or 
within 48 hours of admission to a healthcare facility, provided that symptom onset was less 
than four weeks after the last discharge from a healthcare facility. A person is classified as 
having community associated (CA) CDI when symptom onset (or date and time of stool 




hours of admission to a healthcare facility, provided that symptom onset was more than 12 
weeks after the last discharge from a healthcare facility. Indeterminate onset refers to a 
person that does not fit any of the other criteria for exposure setting, for example onset in the 
community but within four and 12 weeks of discharge from a healthcare facility. The 
unknown classification is used when the exposure setting cannot be determined because of a 
lack of data (Kuijper et al., 2006; McDonald et al., 2007). Figure 9 provides a summary of the 




Figure 9. Timeline for Clostridium difficile infection acquisition definitions. *refers to a 
window period. Cases of CDI during this period could be classified as HCA community 
onset, CA CDI or intermediate disease. Adapted from “Recommendations for surveillance of 
Clostridium difficile-associated disease,” by L. McDonald, B. Coignard, E. Dubberke, X. 
Song, T. Horan, P. Kutty, and et al., 2007, Infection Control & Hospital Epidemiology, 28(2), 
p.141. Copyright 2008 by The University of Chicago Press. 
 
 
4.2.5 Risk factors for Clostridium difficile infection  
 
This section will broadly discuss the risk factors for CDI, before explaining two risk factors 
in more detail, namely the roles of antimicrobials and the healthcare environment. The risk 
factors for CDI can be broken into two categories, host and non-host factors summarised in 
Table 10. Non host factors include the presence of spores and associated transmission to 




H2 receptor drugs. Host risk factors affecting the risk of CDI include advancing age and the 
presence of co-morbidity (DuPont et al., 2008).  
 
There is some debate about the role of proton pump inhibitors (PPI) and CDI. Use of proton 
pump inhibitors may be a risk factor for CDI because survival of spores is facilitated by 
elevated gastric pH levels. In addition, PPI may have an effect on the immune function or 
toxin production of the organism (Vaishnavi, 2009). Studies have shown contradictory results 
when trying to determine the influence that PPI has on CDI. A case control study 
demonstrated an increased risk of CDI in hospitalised patients who had received PPI 
compared to those who did not (Cunningham, Dale, Undy, & Gaunt, 2003). Conversely, a 
study by Pepin (2005) reported an elevated risk of CDI with PPI occurring in univariate 
analysis but not after adjustment for co-morbidities on multivariate analysis. These two 
studies are examples of the conflicting evidence on the role that PPI may have in CDI. There 




Potential risk factors for Clostridium difficile infection 
Host Non host 
Advancing age (DuPont et al., 2008) Hospitalisation (Bignardi, 1998; McDonald, Owings, & 
Jernigan, 2006) 
Co-morbidity (Vaishnavi, 2009) Exposure to antimicrobials (J. Pépin, Saheb, N., 
Coulombe, M., Alary, M., Corriveau, M., Authier, S., 
Leblanc, M., Rivard, G., Bettez, M., Primeau, V., 
Nguyen, M.,  Jacob, C., Lanthier, L, 2005; Polgreen et 
al., 2007; Thomas, Stevenson, & Riley, 2003) 
 Healthcare Environment (Best, Fawley, Parnell, & 
Wilcox, 2010; Dubberke et al., 2007; Dumford, 
Nerandzic, Eckstein, & Donskey, 2009) 
 Proton Pump / H2 receptor drugs (Cunningham et al., 







Antimicrobials and Clostridium difficile infection 
 
Antibiotics are thought to be an important risk factor for CDI because they reduce the 
colonisation resistance of the bowel (Bignardi, 1998). There are a large number of studies 
reporting an association between antibiotic use and CDI (J. Pépin, Saheb, N., Coulombe, M., 
Alary, M., Corriveau, M., Authier, S., Leblanc, M., Rivard, G., Bettez, M., Primeau, V., 
Nguyen, M.,  Jacob, C., Lanthier, L, 2005; Polgreen, et al., 2007; Thomas, et al., 2003). It has 
been suggested however, that despite this large number of studies there is a lack of well-
designed epidemiological research (Thomas et al., 2003). In a systematic review examining 
the role of antibiotics in the acquisition of hospital acquired CDI, Thomas et al. (2003) 
suggests that methods used in the majority of studies demonstrating a link between antibiotics 
and CDI estimated the risk of CDI in hospitalised patients when exposed to a number of 
factors, rather than to antibiotic therapy alone. Similarly, a lack of a priori sample size 
calculation, incorrect control groups, inadequate control of confounders and diagnostic bias 
were particular threats to validity of the data (Thomas et al., 2003). The conclusion of the 
systematic review was that only two studies in the review McFarland, Surawicz and Stamm 
(1990) and Chang and Nelson (2000) were considered valid in providing evidence of the role 
of antibiotics in development of hospital acquired CDI (Thomas et al., 2003).  
 
The cohort study undertaken by McFarland et al. (1990) found an increased risk of CDI after 
exposure to cephalosporins for 1 - 7 days (RR 2.82) and exposure to penicillin (RR 3.52) for 
8-14 days, after adjusting for age and severity of illness (McFarland et al., 1990). The study 
by Chang and Nelson (2000) examined the risk antibiotics pose in causing CDI by using a 
retrospective cohort study design. After multivariate analysis, exposure to the antibiotic 
clindamycin (RR 4.22) and the number of antibiotics taken (RR 1.49) were found to be 
significant risk factors for CDI (Chang & Nelson, 2000). In the majority of studies, regardless 
of their methodological imperfections, clindamycin, fluroroquinlones, third-generation 
cephalosporins, and penicillins have been considered to pose the greatest risk for CDI, 
however nearly all classes of antimicrobials have been implicated (Owens, Donskey, Gaynes, 
Loo, & Muto, 2008; Thomas et al., 2003). The final risk factor for CDI explored in this 





The healthcare environment and transmission of Clostridium difficile  
 
The primary mode of transmission of C.difficile is person to person via the faecal-oral route 
(National Health and Medical Research Council, 2010). Clostridium difficile can exist in a 
vegetative or spore form, with spores acting as a reservoir through persistence in the 
environment for several months. In turn, this places patients at risk through contamination of 
healthcare workers’ (HCWs) hands and of regularly touched items or fomites (Dumford et 
al., 2009; Mayfield, Leet, Miller, & Mundy, 2000; Stuart et al., 2011).  
 
Individuals with symptomatic CDI shed C.difficile spores into the environment. In heavily 
contaminated environments spores may be aerosolised by movement of HCWs and patients, 
allowing widespread dissemination (Best et al., 2010). Environmental contamination may in 
turn play a role in CDI transmission through colonisation pressure. Similar theories have been 
used to explain transmission of organisms such as MRSA and vancomycin-resistant 
enterococcus (VRE) (Bonten et al., 1998; Eveillard et al., 2005; Merrer et al., 2000; Puzniak, 
Mayfield, Leet, Kollef, & Mundy, 2001). Clostridium difficile is transmitted in a similar 
fashion to VRE and hence it is thought that colonisation pressure and the environment play 
an important role in CDI transmission.  
 
 
To prove that colonisation pressure is a risk factor in CDI transmission, a cohort and nested 
case control study of 36,000 admissions was undertaken. Following multivariate logistic 
regression, the authors suggest that the greater the number of patients with CDI there are on a 
hospital ward, the more likely it is that other patients will acquire the organism (Dubberke et 
al., 2007). Environmental contamination with spores is now well accepted as a risk factor for 
the acquisition of C.difficile. It is thought that as the level of environmental contamination 
increases, so too does the amount of C.difficile on the hands of healthcare workers and 
frequently touched items, posing a risk of transmission (Dancer, 2009). Contamination of the 
environment can act as a reservoir, leading to potential transmission and subsequent ingestion 
of spores by susceptible persons. In turn, C.difficile spores can germinate and cause 
asymptomatic carriage. Events that subsequently alter the bowel flora, such as antimicrobial 
exposure, can trigger alteration in bowel flora and CDI. Therefore, the role of environmental 




its potential role in breaking the cycle of CDI transmission. The cycle of CDI is summarised 
in Figure 10. 
 
 
Figure 10. The cycle of Clostridium difficile infection. Shaded boxes denote the stages where 




Having explored the background to CDI in section 4.2 and the risk factors for CDI in this 
section, it is evident that there are opportunities for prevention of CDI as seen in Figure 10. 
Improved antimicrobial usage and control, often termed ‘antibiotic stewardship’ is one 
strategy in CDI prevention. The use of contact precautions, such as isolating symptomatic 
individuals and the use of gloves and gowns, also has the potential to minimise contamination 
of C.difficile bacteria and spores. Two further strategies to prevent CDI include the 
prevention of spore transmission among patients by healthcare workers, through processes 
such as hand hygiene and cleaning the environment, to minimise colonisation pressure and 
the risk of subsequent transmission. In Chapter 2, the impact that HAIs have on individuals 
and the health services was briefly discussed (section 2.3). To explore this further, the next 






4.3 Literature review  
 
4.3.1 Introduction to the literature review 
 
As already stated, the incidence and severity of CDI appears to be increasing, particularly in 
the northern hemisphere (Khanna & Pardi, 2010). In the United Kingdom, the number of 
death certificates in England and Wales citing C.difficile rose from 1416 in 2002 to 6480 in 
2006 (Office for National Statistics, 2008). The increase in incidence appears to be driven by 
a number of factors, including large outbreaks of CDI in hospitals, a change in circulating 
strains of C.difficile, such as C.difficile ribotype 027 and 006 and other host and 
environmental factors as described in section 4.2.5 (Cartman et al., 2010; Healthcare 
Commission, 2006, 2007; Healthcare Inspectorate Wales, 2009; Kelly & LaMont, 2008).  
 
This section presents a review of studies that have investigated mortality and CDI in 
hospitalised patients. The purpose of this section is to describe current gaps in the literature 
and the various methods used to examine mortality in this population.  
 
4.3.2 Search strategy 
 
The literature was accessed through searches on Medline and Pubmed limited to the period 
from 1
st
 January 2005 to 30
th
 April 2011. The review was limited to these years to reflect the 
recently changing epidemiology of C.difficile. Other limits included only searching literature 
published in English and studies involving humans. Key search words used were 
“Clostridium difficile AND mortality” and “Clostridium difficile AND death”. These searches 
were combined with duplicate studies removed. The initial search yielded 362 articles. A first 
review of these articles was undertaken. Only case control, cohort designs or reviews were 
included. Additionally, articles were only included if they examined mortality of all 
hospitalised patients and were not limited to a CDI in a specific patient group (for example a 
person with cancer) and did not use CDI as a comparison group, for example mild versus 
severe CDI and related mortality. The rationale for excluding such articles was to ascertain a 
better understanding of CDI in the general hospitalised population, not restricted to those 




59 articles remained. In a second review of these 59 remaining articles, studies which did not 
examine CDI mortality at fixed intervals, for example 30 or 90 days, were excluded. The 
inclusion of studies that documented mortality at fixed intervals was chosen in an attempt to 
assist in the pooling of data during data analysis. A total of 26 articles remained after the 
second review. Figure 11 provides a summary of the search strategy process using the 
PRISMA as the basis for presentation (Moher et al., 2009). Table 11 provides a list of the 
included articles. 
 





Full-text articles assessed 
for  eligibility
(n = 59)









Figure 11. Summary of the search strategy used in the review examining mortality and 
Clostridium difficile infection. 
1 
Articles were excluded if they were not case control, cohort 
or reviews or did not examine mortality in hospitalised patients. 
2
Articles were excluded if 
they did not examine mortality at fixed intervals. 
 
A review of mortality due to CDI was recently published, however this only included studies 
from 2000 to March 2010 that contained data on attributable mortality or circumstances 
where attributable mortality could be calculated from the data included (Karas, Enoch, & 
Aliyu, 2010). All articles identified in the review published by Karas et al. (2010) and 
published since 2005 were identified through the search strategy described above and were 





4.3.3 Findings from the literature review 
 
The section commences by providing an overview of the characteristics of the included 
studies, before discussing the reported mortality. To appreciate the reported mortality and to 
inform future research examining mortality and CDI, strengths and weaknesses of the study 
design, data analyses, case definitions and the data items collected from the included studies 
are also discussed. These particular topics are important considerations for future research on 
mortality when attempting to control for bias in primary research, and for future systematic 




Of the 24 articles included, one was a review. Eighteen studies reported mortality at 30 days 
or less, with 11 studies reporting mortality at further end points, predominantly 90 or 180 
days. One study which reported 30 days mortality, used 30 days post-discharge as the 
definition (Outi Lyytikainen et al., 2009). The choice of 30 days post-discharge as the method 
to examine mortality was made due to limitations in available data and should be noted when 
considering results from this study. Four studies examined in-hospital mortality, in addition 
to 30-day mortality. The reported mortality in each of these studies is detailed in Table 11 
and is explored in more detail later in this section.  
 
The majority of studies were undertaken in the United States (9), United Kingdom (7) or 
Canada (3). No studies were included from an Australian setting. As there are different 
circulating strains of CDI in different countries, this is an important issue because mortality 
from persons with CDI in Australia may differ from these countries. A higher incidence of 
CDI compared to other countries with data on CDI incidence including Australia, coupled 
with an increased focus on CDI due to high profile hospital outbreaks, may provide insight 
into explaining the number of included articles from these countries. These studies did not 
meet my inclusion criteria and were excluded as the participants were from a selected clinical 
group. For example, they had a specific strain of CDI or had severe CDI. Conversely, my 




reason for this discrepancy is the inclusion of more recent publications, with 11 of these 14 
published in the past two years. Also, the review by Karas et al. (2010), was limited to studies 





Summary of included articles in the review examining mortality and Clostridium difficile infection 
Author Study type Country 30 day all-cause mortality  
(population to which mortality refers) 
Mortality at any other endpoint 
(population to which mortality refers) 
Arvand, Hauri, Zaiss, Witte, & Bettge-
Weller, 2009 
Case series Germany 25% (persons who had CDI) - 
Bhangu, Bhangu, Nightingale, & Michael, 
2010  
Case series1 UK 38% (persons who had CDI) - 
Bishara, Peled, Pitlik, & Samra, 2008 Cohort Israel 15% (persons who had CDI)  
11.5% (persons who didn’t have CDI) 
- 
Cadena et al., 2010 Cohort US 16% (persons who had CDI) 45% at 90 days (persons with relapsing CDI) 
23% at 90 days (persons with non-relapsing CDI) 
Chung et al., 2010; Cohort Taiwan 23.5% (had CDI and mild diarrhoea) 
25.8% (had CDI and prolonged diarrhoea) 
23.3% (all persons who had CDI) 
37.2% IHM (all persons who had CDI) 
Cloud, Noddin, Pressman, Hu, & Kelly, 
2009 
Cohort US - 12.1% IHM (all persons who had CDI) 
13.6% IHM (persons who had CDI and NAP-1 strain) 
12.4% IHM (persons who had CDI and non-NAP-1 strain) 
 
 
Dubberke et al., 2008 Cohort US - 38% at 180 days (persons who had CDI) 
12% at 180 days (persons who didn’t have CDI) 
Fenner et al., 2008 Case series Switzerland 9% (persons who had CDI) - 
Gasperino et al., 2010 Cohort US 16% (persons who had CDI) 
5% (persons who didn’t have CDI) 
20% (persons who had CDI) 
8% (persons who didn’t have CDI)  
Gravel et al., 2009 Case series  Canada 16.3% (persons who had CDI) 
5.7% attributable mortality+ 
- 
Gulihar, Nixon, Jenkins, & Taylor, 2009 Cohort 
 
UK 19% (persons who had CDI) 
12%(persons who didn’t have CDI) 
67% at 180 days (persons who had CDI),   
27% at 180 days (persons who didn’t have CDI) 
 
Karas, Enoch, & Aliyu, 2010 Review UK Review Review 
Kenneally et al., 2007 Cohort US 36.7% (persons who had CDI)  
30.6% (persons who didn’t have CDI) 
6.1% attributable* 
- 
Labbe et al., 2008 Cohort Canada 16% (persons who had CDI with a non 027 ribotype) 





23.9% (all persons who had CDI) 
Loo et al., 2005 Cohort Canada 24.8% (persons who had CDI) 
Not stated for controls (persons without CDI) 
6.9% attributable** 
- 
Lyytikainen et al., 2009 Case series Finland -- 14% at 30 days post-discharge 
Marra, Edmond, Wenzel, & Bearman, 2007 Case series1 US  17.2% at 14 days 
27.6% IHM 
McGowan et al., 2011 Cohort UK 3.4% (persons who had CDI, aged <40 years) 
11.9% (persons who had CDI, aged 40-49) 
10.1% (persons who had CDI, aged 50-59) 
28.8% (persons who had CDI, aged 60-69) 
27.6% (persons who had CDI, aged 70-79) 
36.2% (persons who had CDI, aged 80-89) 
41.2% (persons who had CDI, aged <90) 
 
 
Musher et al., 2005  Case series US - 27% at 90 days 
Pant et al., 2010 Case series US 13.6% (persons who had CDI) - 
Shears, Prtak, & Duckworth, 2010 Case series UK 24.7% (persons who had CDI) 30.0% at 90 days (persons who had CDI) 
Sundram et al., 2009 Cohort UK 14.4% (persons who had CD) at 28 days ***   
Wilson et al., 2010 Cohort UK 35.1% (persons who had CDI with a non 027 ribotype) 
38.2% (persons who had CDI with a 027 ribotype) 
- 
Zilberberg, Shorr, Micek, Doherty, & Kollef, 
2009# 
Cohort  US 26.9% (persons who had CDI aged < 65 years 
45.2% (persons who had CDI aged ≤ 65 years 
- 
Note: IHM = in hospital mortality.US = United States. UK = United Kingdom.1 The authors state their study was a cohort study. Listed as a case series in this table as only persons with CDI 
were included in the study population. *Attributable mortality was defined by the authors as crude mortality in persons who had CDI minus crude mortality in persons who had CDI. ** Attributable 
mortality was determined by two physicians who judged independently whether CDI was an attributable cause. *** Attributable mortality was determined by an assessment by a hospital 
epidemiologist or a physician to determine whether the death was attributable to CDI. ~ This figure was calculated from data presented. Data for controls was not reported and could not be 




Mortality at fixed intervals 
 
Despite limiting inclusion criteria to studies with fixed endpoints, as previously described, 
there was considerable variability in the study designs, exclusion criteria and data collected. 
This made the pooling of data for analysis impossible and limited the interpretation. All-
cause mortality at 30 days varied considerably among the included articles, with reported 
mortality ranging from 9% to 38% as shown in Table 11. Three studies reported all-cause 
mortality at 90 days with a range of 27% to 30% (Cadena et al., 2010; Musher et al., 2005; 
Shears, Prtak, & Duckworth, 2010). Similarly, three studies reported attributable mortality at 
30 days, varying from 5.7% to 6.9% (Gravel et al., 2009; Kenneally et al., 2007; Loo et al., 
2005). In-hospital mortality was reported in four studies and ranged from 8% to 37.2% 
(Chung et al., 2010; Cloud, Noddin, Pressman, Hu, & Kelly, 2009; Gasperino et al., 2010; 
Marra, Edmond, Wenzel, & Bearman, 2007).  
 
Eighteen studies documented all-cause mortality at 30 days, or 28 days in the case of the 
study undertaken by Sundram et al. (2009). The study undertaken by Sundram et al. (2009) 
examined two strains of C.difficile (027 and 106) and their respective associated mortality. 
The total cohort size was larger than these two groups combined and therefore it was unclear 
whether participants with other strains of CDI died. Acknowledging the limitations of 
different study designs and excluding the study undertaken by Sundram et al. (2009), a total 
of 2041 out of 7774 persons (26.3%) died within 30 days of CDI diagnosis. These figures 
include those persons identified with CDI in these studies who died within 30 days (all-cause 
mortality) (Arvand, Hauri, Zaiss, Witte, & Bettge-Weller, 2009; Bhangu, Bhangu, 
Nightingale, & Michael, 2010; Bishara, Peled, Pitlik, & Samra, 2008; Cadena et al., 2010; 
Chung et al., 2010; Fenner et al., 2008; Gasperino et al., 2010;  Gravel et al., 2009; Gulihar, 
Nixon, Jenkins, & Taylor, 2009; Kenneally et al., 2007; Labbe et al., 2008; Loo et al., 2005; 
McGowan et al., 2011; Pant et al., 2010; Shears et al., 2010; Wilson et al., 2010; Zilberberg, 






Data analysis and presentation of results 
 
The manner in which mortality was analysed and presented in the studies differed, however 
there were some similarities. In two cohort studies, participants were divided into those with 
CDI and those without (Gasperino et al., 2010; Loo et al., 2005). Other cohort studies divided 
participants into two groups: survivors and non-survivors (Bhangu et al., 2010; Kenneally et 
al., 2007; Wilson et al., 2010). Regardless of the methods used, similar data analyses 
occurred and involved using 30 day mortality as the primary outcome and using logistic 
regression for the controlling of potential confounders. Commonly, the use of Chi squared or 
Fisher’s Exact Test were used for categorical data analysis and Student t test for continuous 
variables (Cadena et al., 2010; Chung et al., 2010). Kaplan-Meier survival analysis was used 
in a study undertaken by Bishara et al. (2008). Several studies used adjusted odds ratios to 
make comparisons between groups, following multivariate analysis (Fenner et al., 2008; 
Kenneally et al., 2007; Labbe et al., 2008; Marra et al., 2007; Wilson et al., 2010). Not all 
studies undertook adjustment for variables when determining mortality rates. Despite 
collecting basic demographic data on cases, Charlson co-morbidity data and exposure to 
recent medication such as antimicrobials, the study undertaken by Chung (Chung et al., 2010) 
did not adjust for any variables in the calculation of hospital mortality and all-cause 
mortality. 
 
In addition to studies comparing survivors with non-survivors or those with and without CDI, 
some studies enhanced comparisons by stratifying analyses by age group (Zilberberg et al., 
2009). In a retrospective cohort study, McGowan et al. (2011) examined the difference in 
mortality by age groups divided into decades, with all aged less than 40 years old grouped 
together. A significant difference in 30 day mortality was found for the age groups (decades) 
above 60 years old, using the <60 years old as the reference group (X
2
 = 65.82; df: 2; P< 
0.05). However, the study did not examine the effect of co-morbidity on outcomes and the 
authors made a recommendation for inclusion of this in future research (McGowan et al., 
2011). Similar to McGowan et al. (2011), a prospective multi-centred study of 1430 
participants demonstrated that age specific mortality attributed to CDI increased sharply after 
60 years of age (Gravel et al., 2009). These two studies demonstrate the importance of 





Some studies presented data comparing groups based on the causative strain of the CDI 
(Labbe et al., 2008; McGowan et al., 2011; Sundram et al., 2009). The retrospective cohort 
study undertaken by Labbe et al. (2008) found that patients affected by C.difficile ribotype 
027 were twice as likely to die within 30 days of diagnosis than patients affected with other 
ribotypes. Similar results were demonstrated in a study comparing persons with CDI caused 
by ribotype 027, 106 and all other ribotypes (Sundram et al., 2009). Importantly not all 
studies comparing the effect of different C.difficile strains have found an effect on mortality 
(Cloud et al., 2009). It is therefore important for any studies examining mortality and CDI to 
include data on the relevant strains of C.difficile wherever possible.  
 
Regardless of how participants were grouped, some commonalities were found in the way in 
which data were analysed. The majority of studies used a statistical model involving 
univariate analysis, followed by the development of a multivariable or regression model. 




The majority of studies used the identification of toxin A or B via EIA or ELISA as the case 
definition of CDI. There were variations in the approach taken as to which faecal samples 
were tested for C.difficile, however the majority only tested patients suffering diarrhoea 
(Bishara et al., 2008; Chung et al., 2010; Dubberke et al., 2008; Gasperino et al., 2010; 
Gravel et al., 2009; Marra et al., 2007; McGowan et al., 2011; Sundram et al., 2009; Wilson 
et al., 2010). The CDI case definitions varied and the impact such variation has on reported 
mortality remains unknown. It would, however, be logical to assume that a less sensitive 
laboratory detection approach may identify fewer cases in a given population and this has the 
potential to underestimate the incidence of CDI and thus the total number of persons who 





Similar to variation in CDI definitions, the data collected in each of the studies varied 
considerably. Data collected include gender, age, co-morbidities, length of stay in hospital 
prior to CDI, exposure to drugs including antimicrobials, clinical symptoms and whether the 
person was a resident of a nursing home. In the vast majority of studies, gender and age of 




A co-morbidity score such as the Charlson co-morbidity index, was calculated in a limited 
number of studies (Chung et al., 2010; Cloud et al., 2009; Dubberke et al., 2008; Kenneally et 
al., 2007; Labbe et al., 2008; Loo et al., 2005; Marra et al., 2007; Wilson et al., 2010). A 
number of studies used another tool such as the American Society of Anaesthesiologists 
(ASA) grade, or Acute Physiology and Chronic Health Evaluation (APACHE) II, and a 
number of studies collected data on co-morbidities but did not specify how or why they 
choose these co-morbidities  (Bishara et al., 2008; Cadena et al., 2010; Fenner et al., 2008; 
Goorhuis et al., 2007; Gravel et al., 2009; Sundram et al., 2009; Zilberberg et al., 2009). The 
admitting diagnosis was collected for two studies (Loo et al., 2005; Marra et al., 2007). This 
variation in the use of co-morbidity data makes comparison between studies challenging and 
potentially limits the validity of results. Co-morbidities were shown to influence mortality in 
patients with CDI (Bishara et al., 2008; Kenneally et al., 2007). In one instance where co-
morbidity data were not collected, the researchers recognise this limitation and suggest this is 
an area to be included in future research (McGowan et al., 2011). Conversely, one study used 
electronic data to attempt to collect ASA grades, but acknowledged that information was 
found to be incomplete (Gulihar et al., 2009). Patients with incomplete data were censored, 
therefore this may have introduced an element of bias as only persons with an ASA grade, 
that is, had anaesthesia, were included.  
 
The length of stay in hospital prior to CDI was collected in a number of studies (Fenner et al., 
2008; Goorhuis et al., 2007; Gravel et al., 2009; Kenneally et al., 2007; Labbe et al., 2008; 
Zilberberg et al., 2009). In one study there was a trend of increasing mortality with increasing 




(Bishara et al., 2008; Cadena et al., 2010; Chung et al., 2010; Fenner et al., 2008; Labbe et 
al., 2008; Loo et al., 2005; Musher et al., 2005; Sundram et al., 2009; Zilberberg et al., 2009). 
Some of these studies reported an association between antibiotics exposure and increased risk 
of CDI (Cadena et al., 2010; Chung et al., 2010; Loo et al., 2005). Exposure to other drugs 
such as proton pump inhibitors or steroids and information on interventions such as surgery 
or the use of a nasogastric tube were reported in some studies (Bishara, et al., 2008; Cadena, 
et al., 2010; Chung, et al., 2010; Fenner, et al., 2008; Goorhuis, et al., 2007; Loo, et al., 2005; 
Sundram, et al., 2009; Zilberberg, Shorr, et al., 2009). The manner in which data were 
collected on drug therapy, surgery and nasogastric tube exposure was not reported 
consistently, with different time periods and a range of procedures used. Further, in these 
studies, mortality was one outcome being examined alongside other variables, such as risk 
factors for CDI. If a study was to examine mortality following CDI as the single outcome, 
then the efficacy of including data on some of the data described above could be limited, 
particularly as there is no standardised method or definition used.  
 
Three studies collected data on whether participants were nursing home residents (Bishara et 
al., 2008; Gasperino et al., 2010; Wilson et al., 2010). If a study was to only examine 
healthcare associated/healthcare facility onset CDI, the usefulness of collecting these data 
becomes questionable. Clinical symptoms such as temperature, white cell count or severity of 
disease were collected in a number of studies in various ways (Bhangu et al., 2010; Fenner et 
al., 2008; Gasperino et al., 2010; Kenneally et al., 2007; Labbe et al., 2008; Marra et al., 
2007; Musher et al., 2005; Wilson et al., 2010). The purpose of some of these studies was to 
examine mortality according to clinical risk factors such as albumin level and urea, 
explaining why such data was collected (Bhangu et al., 2010). 
 
4.3.4 Summary of literature review 
 
There was considerable heterogeneity among the studies included in this review. Differences 
were found in study design, patient groups and data collected from participants. Some studies 
lack demographic and co-morbidity data, a similar finding to the review undertaken by Karas 




a mortality of 15% or greater. Several studies demonstrated that age was a risk factor for 
mortality indicating the need to adjust for such data in future studies.  
 
There were no articles from an Australian setting or a setting from the southern hemisphere 
included in this review. Even accepting all-cause mortality at the low end of the included 
studies in this review, CDI clearly has a significant impact on hospitalised patients. Studies 
investigating the mortality of CDI in an Australian setting are needed so that a picture of this 
disease in this region can be understood. Future studies examining the mortality of CDI 
should include basic demographic data, reporting of mortality at seven days, 30 days and 90 
days after the first diagnosis of CDI, the use of exclusion criteria and acquisition definitions 
as recommended in the international literature, and the studies should use a co-morbidity 
index score such as the Charlson co-morbidity index. In doing so, pooling of data becomes 
possible and comparisons between studies will be easier. Similarly, the addition of data on 
antibiotic exposure will assist future meta-analysis on the role of antibiotics and CDI. The 
second study of this thesis, examining mortality and CDI in an Australian setting, will now be 
presented.  
 
4.4 Objectives and research questions 
 
The objectives for the second study are to describe the risk of mortality associated with CDI 
and to explore potential limitations in estimating mortality associated with CDI when current 
international surveillance definitions for CDI are applied. To address these objectives, the 
following research questions were devised: 
1. During the calendar years 2007 to 2010, for patients hospitalised in a Tasmanian 
acute public hospital for more than 48 hours and aged two years or older:    
a. What percentage of people who had an episode of CDI died within 30, 60, 90 
and 180 days of admission to hospital?  
b. What is the risk of a person diagnosed with CDI during their hospital stay 




2. What are the potential limitations of using CDI surveillance definitions when 
examining the risk of death in people who had an episode of CDI? 
 
4.5 Methods  
 
4.5.1 Study design 
 
To address the research question, a non-concurrent cohort study design was used.  
 
4.5.2 Setting and timeframe 
 
The RHH in Hobart, Australia, was the setting for this study. The RHH is the only tertiary 
hospital in Tasmania and consists of approximately 500 inpatient beds. An overview of 
Tasmania and the health services available was detailed in Chapter 1. The RHH is a publicly 
funded hospital and is serviced by one microbiology department. The timeframe for the study 
was the calendar years 2007 to 2010.  
  
4.5.3 Definition and selection of cohort 
 
The source population for the study cohort included all persons hospitalised for 48 hours or 
greater and aged two years or older between 1
st
 January 2007 and 30
th
 December 2010. The 
exposed group included all patients in the source population who had CDI during their 
hospitalisation between 1
st
 January 2007 and 30
th
 December 2010. A comparison group was 
sampled on a two to one basis from among those members of the source population without 
CDI at any time during their stay, matching on sex, age group (decade of life) and date of 
hospital admission of patients in the exposed group.  
 






Selection of the exposed (persons with CDI)  
 
As discussed in the previous chapter, there are several ways to define an episode of CDI. In 
Australia, a national surveillance definition for CDI was developed by ACSQHC (Australian 
Commission on Safety and Quality in Health Care, 2010). Clostridium difficile infection is 
defined as an infection in a hospitalised patient who has a positive stool sample result for 
C.difficile, using either a laboratory assay (Enzyme immunoassay or polymerase chain 
reaction) detecting toxin A and or toxin B, or culture, resulting in the isolation of C.difficile 
that is subsequently shown to produce toxin A and/or toxin B. 
 
During the full study period, the RHH microbiology department tested all diarrhoeal samples 
from hospitalised patients, regardless of reason for hospitalisation for C.difficile. Diarrhoea 
was defined as an unformed stool that took the shape of the container.  
 
Until 30 August 2007, the RHH microbiological department cultured all faecal samples. 
Faeces samples that grew C.difficile were tested for toxin B using a cell culture cytotoxin 
assay (CCNA). From September 2008, samples that were culture positive, but CCNA 
negative then had a further CCNA performed on the organism, that is to say that the same test 
was performed specifically on the organism (McGregor, 2011).  
 
In September 2010, the RHH microbiology department implemented a further change to the 
testing methodology for C.difficile. While all diarrhoeal samples from hospitalised patients at 
the RHH were still tested for C.difficile and all were still cultured, from 1
st
 September, faecal 
samples were tested for glutamate dehydrogenase (GDH) antigen assay using Quik Check 
(Techlab). Those samples that were GDH positive and toxin positive were considered to be 
diagnostic of CDI. Samples that were GDH positive but toxin negative were subsequently 
tested using PCR. Samples that were PCR positive were reported as having pathogenic CDI, 
whilst those that were negative were considered to have the organism, but not the toxin, and 
therefore were considered as having non-pathogenic C.difficile. Samples that were GDH 
negative, toxin negative but culture positive were tested using PCR, whilst samples that were 




that were PCR positive were considered to have CDI (Cooley, 2011; McEwan, 2011). Figure 




Figure 12. Algorithm for Clostridium difficile testing at the Royal Hobart Hospital. Adapted 
from McEwan (2011). Comment 1 = Clostridium difficile detected and toxin producing. 
Comment 2 = Clostridium difficile detected but has not been shown to be toxin producing. 
Comment 3 = preliminary report, initial screening tests for Clostridium difficile are negative. 
Comment 4 = indeterminate result and a repeat test is requested. GDH = glutamate 
dehydrogenase. PCR = polymerase chain reaction. CMB = cooked meat broth. Dotted ovals 
indicate situations where the test indicates Clostridium difficile infection. *Diarrhoeal stool 
sample refers to faeces that take the same shape as its container.  
 
Despite the changes in testing methodology, there are two important points for noting. First, 
all the methods employed by the RHH microbiology during this study period are highly 
sensitive, particularly as all diarrhoeal faecal samples are cultured for C.difficile. Second, in 
all situations, the laboratory was testing for C.difficile toxin using an assay, either CCNA or 
PCR. Issues relating to the detection of CDI were described in more detail in section 4.2.2. 
Therefore, the change in methodology is not likely to have increased or decreased sensitivity 





For the purposes of this study, the exposed group were all persons hospitalised at the RHH 
for more than 48 hours between 1
st
 January 2007 and 30
th
 December 2010 inclusive, and who 
were diagnosed as having CDI using the national definition for CDI described earlier. The 
laboratory processes for identifying persons with CDI at the RHH enabled a direct translation 
of a laboratory result into defining an exposed individual. As discussed in section 4.2.2, 
episodes of CDI that occur more than 48 hours after admission are often referred to as 
healthcare associated, healthcare facility onset (HCA HFO) episodes of CDI (L. Clifford 
McDonald, et al., 2007; H. Van Gessel, McCann, R., Peterson, A., Cope, C., Wilkinson, I., 
Mitchell, B., Wells, A., Kennedy, B., Hall, L., Gallard, J., Lee, R., Cooley, L., Cruickshank, 
M., Greig, S., Hanley, E., Willows, K., Board, N., 2011). Any positive stool sample for 
C.difficile occurring in patients less than two years old or occurring within eight weeks of the 
last positive test was excluded (Australian Commission on Safety and Quality in Health Care, 
2010). All infectious episodes included in this study are HCA HFO episodes. 
 
In this study, the term ‘persons who had CDI’ may be used to describe the exposed, in 
situations when the use of this term would make the sentence unclear.  
 
 
Selection of the non-exposed (persons who did not have CDI) 
 
From the study cohort a subset of non-exposed persons was selected to assess the relationship 
between CDI and increased mortality above that which would be expected among 
hospitalised individuals of the same age and sex. For each person exposed to CDI, two 
persons from the source population who did not have CDI at any time during their stay were 
chosen, matching on sex, age group (decade in which a person was born) and period of 
hospital admission of patients who had CDI. If the matching process resulted in more than 
two persons without CDI being identified from the source population, then a random 
selection process was used to limit the selection to two individuals. The choice of matching 
criteria was decided following substantial consideration of the relevant issues. As discussed 
in the background to this chapter, age is a risk factor for CDI, therefore it was considered that 




potential changes which may affect the risk of CDI and mortality needed to be considered. 
Such changes include variation in staffing, differing infection control policies and priorities, 
and variations in processes that may affect CDI such as hand hygiene and antimicrobial 
prescribing. Therefore, if the admission date for the non-exposed were to be substantially 
different to the exposed, controlling for a range of additional variables would be required. 
This would be inherently difficult to undertake, given the inability to obtain accurate and 
consistent data on additional variables. The relative importance of each of these variables is 
difficult to quantify. With these issues in mind, matching by admission period occurred, with 
each admission period being one quarter and representing a season, as there is strong seasonal 
weather variation in Tasmania. The final matching criterion used was sex as this has been 
reported as a potential risk factor for CDI (Dial, 2005). More details regarding the matching 
process are detailed in section 4.5.4.  
 
4.5.4 Data collection 
 
This section on data collection is divided into two parts. The first part describes the data 
collection process and the second section outlines the specific data items collected during 




Data were retrieved from four different sources. These sources comprised data from:  
1. the TIPCU 
2. the Clinical Coding department of the RHH   
3. a review of the patient administration system 
4. a review of medical records of each participant by the researcher.  
 
 
Figure 13 provides a summary of the data collection process and sources of data. Each of the 




Remaining  data sent to supervisor
Exposed identified by the TIPCU and forwarded 
to researcher
(Source 1)
Selection of non exposed 
(matching) occurs by supervisor
Non exposed sent to researcher
All persons hospitalised > 48 hours and ≥ 2 
years old identified by Clinical Coding (RHH) 
(Source 2)
Exposed removed by researcher
Researcher reviews data held on the PAS 
(Source 3)
Researcher reviews medical records  
(Source 4)
 
Figure 13. Flow chart illustrating the data collection process and sources of data. PAS = 
patient administration system. CDI = Clostridium difficile infection. RHH = Royal Hobart 
Hospital. 
 
The TIPCU is a unit of the Tasmanian Health and Human Services department and is a data 
repository for all episodes of CDI occurring at the RHH. Data on episodes of CDI were 
provided to the TIPCU direct from the RHH microbiology department using definitions 
described in section 4.5.3. The TIPCU provided me with data on all persons who had CDI 
identified at the RHH between the 1
st
 January 2007 and the 30
th
 December 2010. Only 
infections occurring in persons who had been hospitalised greater than 48 hours and aged two 
years or older were provided by the TIPCU.  
 
To select the non-exposed, all persons admitted to the RHH for more than 48 hours during 
the study period, were identified by the Clinical Coding department at the RHH at my 
request. Data were provided in an Excel spread sheet and comprised all patient admissions, 
including the exposed. The exposed were identified and removed. I then copied the data from 




matching was then undertaken independently by my supervisor to ensure no potential bias 
was introduced.  
 
The matching process involved the removal of a number of entries because their recorded 
admission period was in January or February 2007, when there were no episodes of CDI. 
Further entries were excluded because their gender was intersex or unknown. Cross 
tabulation for both the exposed and non-exposed databases was performed, enabling the 
identification of the number of exposed in each sub group that were being matched (i.e. 
admission period, age group and sex). Three potential non-exposed persons were then 
randomly selected, using a computerised random selection process, to match each exposed 
person. Two potential non-exposed were sent to myself from my supervisor, and the third 
retained as a backup, if required. The third was used in situations where the medical records 
of either of the first two persons could not be located or where the same person had been 
readmitted (to prevent the same control being used more than once). 
 
Once I had obtained the list of the exposed from the TIPCU and the non-exposed from my 
supervisor, a review was performed of the records held on the RHH patient information 
system for both the exposed and non-exposed. Similarly, I undertook a review of the medical 
records relating to the admission period at the RHH for the study group. Therefore, I was 
aware of whether the medical record belonged to an exposed or non-exposed person i.e. this 
process was not blinded. The review of the medical records for admission period data was a 
quality assurance check against the data provided by the TIPCU and Clinical Coding 
department (Table 12). The data items collected during this process and the rationale for 




This section will contain information on the specific data items collected from each of the 
various sources of data, as previously described. The rationale for the manner in which some 
data items were collected will also be explained in this section. More specifically, the manner 




exposure to antibiotics will be discussed in more detail. Table 12 provides a summary of the 
items collected during the data collection process, the manner in which they were defined and 





Data collected and source 
Data field Definition 
 
Source of data 
Exposed Non-exposed 
Date of birth Date of birth  TIPCU** RHH Clinical Coding* 
Sex Defined as male, female or intersex TIPCU** RHH Clinical Coding* 
Age  Age in years at time of specimen collection TIPCU** RHH Clinical Coding* 
Admission date Date of admission to the RHH TIPCU** RHH Clinical Coding* 
Discharge date  Date of discharge from RHH or date of death (whichever is first) Researcher- review of medical 
records & PAS 
Researcher- review of medical 
records & PAS 
Date of death 
(if applicable) 
Date of death up to 180 days post-admission date^ Researcher- review of medical 
records & PAS 
Researcher- review of medical 
records & PAS 
CCI score Charlson co-morbidity index score. Described in section 4.5.4 Researcher- review of PAS Researcher- review of PAS 
Diagnosis Related Group Methods used to categorise and characterise episodes of care 
received by patients admitted to hospitals.*** 
Researcher- review of PAS Researcher- review of PAS 
Date infection commenced Date of specimen collection TIPCU N/A 
Strain of C.difficile Ribotype of C.difficile TIPCU N/A 
Exposure to antibiotics Received oral or intravenous antibiotics during admission period, up to 
date of infection commencement for cases. 
Researcher- review of medical 
records 
Researcher- review of medical 
records 
Note: PAS = Patient administration system. *Sourced from the patient admission system by Clinical Coding. **Originally sourced from the PAS by the TIPCU and cross checked by the 
researcher. ***Adapted from “Australian Refined Diagnosis Related Groups Version 6.0 Definitions Manual Volume One,” by Australian Government. Copyright 2008 by the Commonwealth of 




Charlson co-morbidity index (CCI) 
 
The CCI is often used by health researchers to measure co-morbid disease. The CCI was 
originally developed through a review of hospital medical records and used to assess the 
relevance of a number of diseases in the prediction of one year mortality (Charlson, Pompei, 
Ales, & MacKenzie, 1987). A weighted score was assigned to each of the 17 co-morbidities. 
The score was based on the relative risk of one year mortality. The total CCI therefore is an 
indicator of disease burden and provides a strong estimate of mortality risk. Since the initial 
development of the CCI many studies have validated its use and demonstrated it as a valid 
prognostic indicator (Gabriel, Crowson, & O'Fallon, 1999; Zhang, Iwashyna, & Christakis, 
1999). Further, algorithms using the International Classification of Disease (ICD) coding data 
have been developed to match the Charlson Index variables (Deyo, Cherkin, & Ciol, 1992).  
 
My study used ICD-10 coding data to calculate a CCI score using a validated algorithm 
developed by Sundararajan et al. (2004). The decision to use ICD-10 coding data as opposed 
to ascertaining a CCI score from a review of medical notes was undertaken following a pilot 
study. The pilot study involved the researcher reviewing the notes of ten persons included in 
the study to calculate a CCI score (Charlson et al., 1987). The score was then compared 
against a score derived using ICD-10 codes and the algorithm published by Sundararajan et 
al. (2004). The algorithm proved more accurate as the review of the medical notes by the 
researcher failed to identify all co-morbid disease identified by clinical coders. In situations 
where the researcher failed to identify co-morbid disease, a further review of the notes was 
conducted to check the accuracy of the coding. Following this process, it was clear that the 
clinical coding was superior at identifying co-morbid disease when compared to the 
researcher. Therefore, the algorithm published by Sundararajan et al. (2004) to match the 
coding to the CCI was subsequently used for this study. There was no missing ICD-10 coding 
data, therefore CCI could be calculated for each exposed and non-exposed person.  
 
The Clinical Coding department at the RHH codes patients’ data using ICD-10-AM codes. 
The algorithm developed by Sundararajan et al. (2004) and used in my study, matched ICD-







The final data collection element to be explored in more detail in this section is antibiotic 
exposure. As discussed in Chapter 5, antibiotic exposure is a risk factor for CDI. It is unclear 
as to whether antibiotic exposure plays any prognostic element in mortality and length of stay 
in hospital. Therefore, a decision to collect data on antibiotic exposure was made. Antibiotic 
exposure was defined as receipt of one or more doses of oral or intravenous antibiotics during 
an admission period. If the medication prescription chart was signed by a health professional 
as having administered the antibiotic, a person was considered to have received the antibiotic 
and subsequently, the variable was coded as “yes” to antibiotic exposure. Further, when these 
data were collected, the class of antibiotic that a person received was also recorded.  
 
For the exposed, data collection on antibiotic exposure ceased on the date of CDI infection 
commencement estimated as the date of faeces collection. Antibiotic data from the non-
exposed continued until the end of their hospitalisation. Topical antibiotics were not included 
in data collection as they are not a risk factor for CDI. The approach taken in collecting data 
on antibiotic exposure in my study was consistent with the approach taken in other studies 
examining CDI mortality (Fenner et al., 2008; Zilberberg et al., 2009).  
 
4.4.5 Ethical considerations  
 
Ethical approval for this research was granted by the Tasmanian HREC (H0011484) and by 
Australian Catholic University (N201150). Copies of ethics approvals are provided in 
Appendix P and Appendix Q. The application for ethics approval included a request to have 
consent from participants waived. The justification for consent being waived was as 
previously described in Chapter 3 and the principles remained the same for this research. One 
major difference between the first study (Chapter 3) and this study is the higher level of 
access to personal information. This study involved the review of medical notes and patient 
information system. At all times confidentiality was maintained and the only data reviewed 




the patient administration system using a secure Department of Health and Human Services 
computer and under the supervision of staff from the TIPCU.  
 
This research also involved the sending of data to the researcher’s supervisor for the purposes 
of the selection of controls, as described in section 4.5.3. All records were permanently 
deleted by the supervisor once matching had occurred. There were no adverse events related 
to this study because no persons were contacted and no breaches of confidentiality occurred.  
 
4.5.6 Data analysis 
 
After providing an overview of data management, this section will conclude by describing the 
analysis plan for each research question. 
 
Overview of data management 
 
Datasets of the exposed and non-exposed were merged once the collection of data concluded. 
The data collected in Microsoft Excel was coded from text into numerical values; ensuring 
date formats were consistently applied. Data from the Microsoft Excel spread sheet was then 
imported into IBM SPSS Version 20.0 for data analysis. Further data cleaning in SPSS 
occurred. New variables were computed in SPSS based on the data collected. The variables 
(data fields) used in this study are detailed in Table 13, with an explanation of how these 






Operational definitions  
Variable title Categories 
(where applicable) 
Detail 
Patient identifier N/A The number applied to each individual person.  
Episode number N/A A number applied in ascending order for every infection occurring in the same patient. 
Group Exposed or non-exposed Exposed is a person who had CDI during their hospital stay. 
Non-exposed is a person who did not have CDI during their hospital stay. 
 See section 4.5.3 for full details.  
Age group  2-9 yo, 10-19 yo, 20-29 yo, 30-39 yo, 40-
49 yo, 50-59 yo, 60-69 yo, 70-79 yo, 80-89 
yo, ≥ 90 yo 
The decade in which a person’s age falls. The categories applied were grouped in a 
manner consistent with descriptive epidemiology practices (Friis, 2009). The first decade 
was for the 2-9 year age group given no participants less than 2 years old were included. 
Admission period Pre-Jan 2007, Jan 2007-Feb 2007, Mar 
2007-May 2007, Jun 2007-Aug 2007, Sep 
2007-Nov 2007, Dec 2007-Feb 2008, and 
continuing until the last category of Dec 
2010 
An admission period is the period in which a person was admitted to hospital. The 
admission periods correspond to the four seasons of each year of data collection. A total 
of 18 categories applied to this variable.  
Admission season Summer, Autumn, Winter or Spring The season in which a person was admitted i.e. summer, autumn, winter or spring. 
Length of stay N/A The difference in days between the admission date and discharge date. 
Length of stay group Length of stay <7 days 
Length of stay ≥7 days 
A length of stay < 7days or ≥7 days. 
Date of study exit N/A Defined as the date of death or 30th June 2011, whichever is first. 




Discharge outcome Alive 
Dead 
Defined as whether the person was discharged dead or alive. A person was coded dead 
if the admission date was the same as the date of death.  
Kaplan survival Alive or Dead Defined as whether the person was dead or alive as at the 30th June 2011, coded by the 
researcher 
DRG category – Nervous Yes / No The person had an AR DRG category defined in the “Nervous system” category 
(Australian Government, 2008). 
DRG category – Respiratory Yes / No The person had an AR DRG category defined in the “Respiratory system” category 
(Australian Government, 2008). 
DRG category – Circulatory Yes / No The person had an AR DRG category defined in the “Circulatory system” category 
(Australian Government, 2008). 
DRG category – Musculoskeletal Yes / No The person had an AR DRG category defined in the “Musculoskeletal system” category 
(Australian Government, 2008). 
CCI score group Charlson score = 0, Charlson score >0 A total CCI score = 0 or > 0. 
Any antibiotics use Yes / No Defined as whether a patient had any antibiotic exposure or not. 








This section provides the statistical methods used for data analysis. Data analysis for this 
study involved two steps. Data were initially analysed using descriptive statistics before 
survival analysis was used. These two elements of data analysis will now be explored in more 
detail. All data analysis was performed in IBM SPSS Version 20.0 (International Business 




Univariate analysis comparing the characteristics of the exposed and non-exposed was 
performed. To test for normal distribution, data were analysed using Q-Q plots and the 
Kolmogorov-Smirnov test. As this was a matched cohort study, Mantel-Haenszel methods 
were used to estimate the differences between the exposed and non-exposed (Kirkwood, 
2003). Continuous variables were compared using the Mann Whitney U test, as all 
continuous variables were non-normally distributed. The median Charlson score for exposed 
and non-exposed was zero. Similarly, the median Charlson score for exposed and non-
exposed combined was zero. For these reasons, the Charlson co-morbidity index was 
recorded into two categorical variables for data analysis, those with a score equal to and those 
with a score greater than zero. Length of stay was grouped into length of stay greater or equal 
to seven days or less than seven days. Seven days was chosen as the dividing point as the 
median length of stay for the two groups combined was seven days. 
 
Survival analysis  
 
Following univariate analysis, survival analysis using the Kaplan-Meier method was 
performed to examine mortality at 30, 60, 90 and 180 days. A log rank Mantell-Cox test was 
used to compare survival between exposed and non-exposed. The time from admission date 
was used for both exposed and non-exposed when examining mortality at fixed periods. 




controlling for categorical variables found to be significant at the 0.1 level in univariate 
analysis. Kendall’s tau rank correlation was used to determine the correlation between 
individual antibiotics found to be significant in univariate analysis and the variable ‘any 
antibiotic use’. Similarly, correlation between individual co-morbidities and the ‘CCI group’ 
was undertaken. A correlation was found in all instances. Therefore, survival, controlling for 
the individual categorical variables of length of stay group, CCI group and any antibiotic 
exposure were undertaken using Kaplan-Meier.  
 
Risk of death comparing exposed and non-exposed 
 
A conditional logistic regression model was used to estimate the risk of a person with and 
without CDI dying at 30, 60, 90 or 180 days, while controlling for confounders. The 
conditional logistic regression analysis was performed using Cox Proportional Hazard data 
analysis in IBM SPSS (International Business Machines Corporation, 2011). The same three 
variables found to be significant in univariate analysis, namely: any antibiotic exposure, 
length of stay longer than seven days, and CCI score greater than zero, were entered into the 
model.  
 
Exploratory analysis was also undertaken on non-survivors up to 180 days post-admission to 
investigate potential association with strains of C.difficile. This analysis breaks the matching; 
therefore analysis included comparison of age and admission period.  
 
4.5.7 Summary of methods section   
 
In the methods section provided above, details on the study design, data collection, ethical 
considerations and data analysis of my study examining the relationship between patients 
who had CDI (exposed) and a subset of the non-exposed population were provided. The next 







4.6.1 Overview of results 
 
A total of 484 persons were included in this study. In section 4.5.3 the methods used to select 
cases and controls were discussed. Figure 14 summarises how the cohort for this study was 
derived.  
316 non-exposed 
(((persons did not  have CDI)
158 exposed
(persons who had CDI)
Exposed (n = 158) removed from dataset by
researcher
Data on 58,799 admissions sent to supervisor
Removal of 2225 entries by supervisor. 
2215 of these entries removed as admission period was 
January or February 2007, 10* were removed because 
gender was intersex or unknown.
Matching against exposed performed by supervisor
Data on 316 non-exposed sent to researcher
Researcher receives data on the 
exposed (n = 158) from the TIPCU. 
158 exposed included in study
484 persons included in study
Study cohort
Data on 58,957 admissions identified by clinical 
coding department and sent to researcher
 
Figure 14. Summary of selection of cohort. *Three of these ten entries were admitted during 
January or February 2007. 
 
At total of 158 episodes of CDI occurred between the 1
st
 January 2007 and the 30
th
 December 
2010. Of the 158 cases, 79 (50%) were male. The median age of cases was 67 years, with a 
range between two and 102 years. As discussed earlier, non-exposed for the study were 
matched two to one, by age group, sex and admission period. Figure 15 demonstrates the age 
distribution of the study group, whilst Figure 16 illustrates the season and year in which the 





Figure 15. Age distribution of the exposed, 1
st
 January 2007 to 30
th
 December 2010. The exposed 
were persons who had Clostridium difficile infection identified ≥48 hours after hospital admission and 





Figure 16. Distribution of admission to hospital for the exposed, 1
st
 January 2007 to 30
th
 December 
2010. The exposed were persons who had Clostridium difficile infection identified ≥48 hours after 





Despite removing duplicate samples occurring within eight weeks of the previous positive 
sample, as outlined in Chapter 4, there were five instances of a second infection occurring in 
the same person during the four year study period. Further analysis of these five individuals 
suggests that second cases were unrelated to the first episode. There was at least four months 
between the first and second infection, with one person having a second episode of CDI three 
years after the first. These results are summarised in Appendix H. With this in mind and 
given that the study has used international and national definitions for exclusion of duplicate 
cases, data from these five episodes were included in this study. The non-exposed were 
matched on each individual episode. Therefore it was possible that an individual with 
multiple hospitalisations may have been a control on multiple occasions, however this did not 
occur. 
 
4.6.2 Clinical characteristics of exposed and non-exposed  
 
Table 14 summarises and compares the characteristics of the exposed and non-exposed. 
There was a statistically significant difference between exposed and non-exposed in relation 
to the CCI group, with the exposed having a CCI group score of greater than zero, with the 
non-exposed having a CCI group score of zero. There was also a difference in the length of 
stay between the two groups. Using the Kolmogorov-Smirnov test, length of stay was found 
not to be normally distributed for both exposed and non-exposed (0.20, df = 158, p< 0.01 and 
0.28, df = 316, p< 0.01) respectively. The range of the length of stay was three to 214 days 
for cases and two to 109 days for controls. The median length of stay for exposed and non-
exposed combined was seven days. For the exposed, the median time to infection after 
admission was eight days, with a range of two to104 days. The range is important to note, as 





Table 14  
Univariate analysis of exposed and non-exposed characteristics (N = 474) 
Characteristic 
Exposed  
(n = 158) 
Non-exposed 
(n = 316) 
OR 95% CI p value 
Charlson category  
  
    
 
Cancer (yes) 26 29 1.95 1.10-3.44 0.029 
Cerebral accident (yes) 19 11 3.79 1.76-8.18 0.001 
Chronic pulmonary disease(yes) 7 13 0.65 0.28-1.56 0.449 
Congestive heart failure (yes) 10 13 1.58 0.68-3.68 0.406 
Connective tissue (yes) 3 1 6.10 0.63-59.10 0.214 
Dementia (yes) 4 8 1.00 0.30-3.38 1 
Diabetes (yes) 3 1 6.10 0.63-59.10 0.214 
Diabetes complications (yes) 11 8 2.88 1.14-7.31 0.039 
HIV (yes) 1 0 - - - 
Liver disease (yes) 0 3 - - - 
Metastatic cancer (yes) 11 14 1.61 0.72-3.65 0.345 
Myocardial infarct (yes) 4 12 0.66 0.21-2.07 0.653 
Paraplegia (yes) 6 11 1.09 0.40-3.02 0.93 
Peptic ulcer (yes) 2 1 4.04 0.36-44.88 0.539 
Peripheral vascular disease (yes) 1 1 2.00 0.13-32.29 0.802 
Renal disease (yes) 11 16 1.40 0.64-3.10 0.529 
Severe liver disease (yes) 2 0 - - - 
CCI group (score >0) 98 120 2.67 1.80-3.95 <0.001 
Length of stay  
     
Median 17 4 N/A N/A <0.001*  
Length of stay group (> 7 days) 137 90 16.38 9.74-27.56 <0.001 
Persons who received antibiotic  
     
Any other AB (yes) 56 48 3.07 1.96-4.80 <0.001 
Any penicillin (yes) 69 77 2.41 1.60-3.61 <0.001 
Any cephalosporin (yes) 64 76 2.16 1.43-3.24 <0.001 
Any floroquinolone (yes) 14 11 2.70 1.19-6.09 0.024 
Any aminoglycoside (yes) 20 23 1.85 0.98-3.48 0.08 
Any macrolide (yes) 11 16 1.40 0.64-3.10 0.529 
Any antibiotic (yes) 121 158 3.27 2.13-5.02 <0.001 
Note: The exposed were persons who had Clostridium difficile infection identified ≥48 hours after hospital admission and aged ≥2 years 
old. Non-exposed were matched by age group, sex and admission period. OR = odds ratio. OR calculated using conditional logistic 





Exposure to antibiotics for exposed and non-exposed were compared by antibiotic class and 
whether they had received any antibiotic. When comparing antibiotic exposure between the 
groups, there are two points to note. First, there was a significant difference between the 
exposed and non-exposed in their exposure to all of the individual classes of antibiotics, other 
than the macrolide and aminoglycoside groups. Second, there was a significant difference in 
‘any antibiotics’ use. 
   
4.6.3 In-hospital mortality  
 
In section 4.3, the literature surrounding mortality and CDI was explored. Many authors 
calculated in-hospital mortality, despite the risk period for in-hospital mortality varying due 
to different lengths of stay. Thus, so comparisons between the current and the literature can 
be undertaken in-hospital mortality was calculated. Among persons with CDI, five (3.2%) 
died whilst in hospital, compared to ten (3.2%) among controls.  
 
4.6.4 Clostridium difficile infection and mortality using Kaplan-Meier   
 
Table 15 demonstrates the numbers of exposed and non-exposed who were dead at 30, 60, 90 
and 180 days following admission to hospital, using Kaplan-Meier survival analysis. A 
significant difference in mortality between the exposed and non-exposed at 60, 90 and 180 









Table 15  
Kaplan-Meier death rates with and without Clostridium difficile infection 
Timeframe Exposed  
(n = 158) 
Non-exposed 
(n = 316) 
Chi-square p value 
Mortality up to 30 days (%) 11 (7.0%) 13 (4.1%) 1.70  0.191 
Mortality up to 60 days (%) 20 (12.6%) 20 (6.3%) 5.32  0.021 
Mortality up to 90 days (%) 23 (14.6%) 23 (7.3%) 6.37  0.012 
Mortality up to 180 days (%) 37 (23.4%) 29 (9.2%) 17.72  <0.001 
Note: The exposed were persons who had Clostridium difficile infection identified ≥48 hours 
after hospital admission and aged ≥2 years old. Non-exposed were matched by age group, sex 





Figure 17. Survival up to 180 days following hospital admission. Non-exposed = unbroken 
line. Exposed = dashed line. The exposed were persons who had Clostridium difficile 
infection identified ≥48 hours after hospital admission and aged ≥2 years old. Non-exposed 





To control for differences between the exposed and non-exposed, three categorical variables 
found to be significant in univariate analysis were individually added to the Kaplan-Meier 
analysis. These three variables were any antibiotic exposure, length of stay group and CCI 
group. As described in section 4.5.6, the CCI group indicated those participants with a CCI 
score greater than zero, whilst the length of stay group represented those with a length of stay 
greater than seven days in hospital. 
 
Table 14 demonstrates a significant difference between the exposed and non-exposed for the 
individual CCI variables of cerebral accident, cancer and diabetes. These variables were not 
included in future models as a significant correlation was found using Kendall’s tau rank 
correlation, between the CCI group and the following variables: cerebral accident (τ= 0.28, 
p<0.001); cancer (τ= 0.39, p<0.001); and diabetes complications (τ= 0.22, p<0.001). 
Similarly, for antibiotics, the variables of penicillin (τ=0.56, p<0.001), cephalosporin (τ=0.54, 
p<0.001), other antibiotics (τ=0.44, p<0.001), floroquinolone (τ=0.20, p<0.001), and 
aminoglycoside (τ=.0.26, p<0.001) were all found to be significantly correlated to the 
variable any antibiotic use.  
 
Table 16 outlines the results of Kaplan-Meier analysis, controlling for the three variables of 
any antibiotic use, length of stay and CCI group. A significant difference in mortality 
between exposed and non-exposed remained at 180 days, after controlling for any one of the 
three variables. Mortality at 60 and 90 days only remained significantly different after 
controlling for any antibiotic use (x
2
 5.95, p=0.02 and x
2







Adjusted Kaplan-Meier death rates with and without Clostridium difficile infection 
Timeframe Covariate Exposed 
(n = 158) 
Non-exposed  




Mortality up to 
30 days  
 
 
Any AB use         No 






LOS                      ≤ 7days 






CCI Score            0 






Mortality up to 
60 days 
 
Any AB use        No 






LOS                     ≤ 7 days 






CCI Score            0 






Mortality up to 
90 days 
 
Any AB  use       No 






LOS                     ≤ 7 days 













Mortality up to 
180 days 
Any AB use         No 






LOS                   ≤ 7 days 













Note: The exposed were persons who had Clostridium difficile infection identified ≥48 hours after 
hospital admission and aged ≥2 years old. Non-exposed were matched by age group, sex and 
admission period. Log rank test (Mantel-Cox); df1. AB = antibiotic. LOS = length of stay.  
 
To further explore the association between CDI and mortality, a Cox regression model was 
developed. 
 
4.6.5 Clostridium difficile infection and mortality using logistic regression 
 
A conditional logistic regression model was developed in SPSS to estimate the hazard of 




or non-exposed entered as a forced step. Consistent with the results in section 4.6.4, a 
significant difference in mortality was found between the exposed and non-exposed at each 
timeframe, when no additional variables were added to the equation. For each of these four 
timeframes, three variables—antibiotic use, length of stay longer than seven days and CCI 
score lower than zero—were then included in the model using a forward stepwise conditional 
(likelihood ratio) process. The results are displayed in Table 17. There are two important 
points to note from this table. First, no model that included any of the three variables was 
found to be significant at the 30, 60 and 90 day endpoints. Second, the most parsimonious 
model was at 180 days, which included the variable of a CCI score higher than zero and 
demonstrated a significant difference between exposed and non-exposed, controlling for CCI.  
 
Table 17  
Conditional logistic regression models for mortality at four timeframes post hospital 








95% CI p 
value 
Variables not in the 
equation (p value) 












Any AB use (0.224) 
LOS > 7 days (0.472) 












Any AB use (0.433) 
LOS > 7 days (0.852) 












Any AB use (0.473) 
LOS > 7 days (0.957) 












Any AB use (0.254) 
LOS > 7 days (0.384) 
Note: OR = odds ratio. The exposed were persons who had Clostridium difficile infection identified 
≥48 hours after hospital admission and aged ≥2 years old. Non-exposed were matched by age group, 
sex and admission period. AB = antibiotic. LOS = length of stay. CCI = Charlson co-morbidity 
index.
1 
The non-exposed were the reference category. 
2 







4.6.6 Characteristics of non-survivors  
 
Exploratory analysis was undertaken on non-survivors up to 180 days post-admission. A total 
of 66 persons (37 exposed, 29 non-exposed) died within 180 days post-admission. Univariate 
analysis was performed comparing characteristics of non-survivors, as detailed in Table 18. 
 
Table 18 
Characteristics of non-survivors 180 days post-admission 
Characteristic Exposed  
(n = 37) 
Non-exposed  
(n = 29) 
Total 





















Median age (range) 67 (2-102) 76 (48-97) 74 (2-102) 2.13^ 0.145 
CCI group (score >0) (%) 30 (81.1%) 21 (72.4%) 51 (77.3%) 0.70^ 0.404 
Median length of stay (range) 14 (5-77) 6 (2-60) 11(2-77) 5.27** 0.022 
Length of stay group (LOS > 7 
days)  
31 (83.8%) 14(48.3%) 45 (68.2%) 9.45^ 0.002 
Any antibiotic exposure (yes) 24 (64.9%) 15 (51.7%) 39 (59.1%) 1.16^ 0.281 












































Note: ^Chi-square. *Fisher’s Exact Test. **Mann Whitney U test. N/A = Not applicable. LOS = 
length of stay. The exposed were persons who had Clostridium difficile infection identified ≥48 hours 






In Table 18 of particular note is the year of admission. For the exposed group, there was an 
increase in the number of deaths each year (between 2007 and 2010). During 2010, there was 
a large, but not statistically significant, difference in the number of people who died when 
comparing the exposed and non-exposed.  
 
The results in section 4.6.4 indicated a statistically significant difference in mortality between 
the exposed and non-exposed from 60 days after admission. Exploratory analysis was 
performed on those who died up to 30 days after admission to identify any possible 
explanation for this. No significant differences were found between the two groups when 
comparing their length of stay, age or CCI group (>0).  
 
4.6.7 Strains of Clostridium difficile  
 
Data on the strain of C.difficile affecting the exposed was available in ten persons, and these 
data are presented in Table 19. Strain data were not available for all cases of CDI as typing 
was only undertaken on isolates that had been kept in frozen storage. Storage of isolates was 
not undertaken routinely by the RHH laboratory.  
 
Table 19 
Strains of Clostridium difficile affecting exposed 
 
Status at 180 days 
Strain of Clostridium difficile 
Ribotype 014 Ribotype 078 Not available 
Dead 2 0 35 
Alive 7 1 113 
Note: Typing of strains was undertaken by a reference laboratory, namely PathWest 






4.6.8 Summary of results 
 
The study cohort consisted of 474 persons, 158 exposed to CDI and 316 non-exposed. In-
hospital mortality was reported as 3.4% for both the exposed and non-exposed. There was a 
statistically significant difference between the exposed and non-exposed in mortality from 60 
days and beyond using Kaplan-Meier analysis. Using conditional logical regression, at 180 
days, a significant difference in mortality between the exposed and non-exposed remained 






As the first known study to examine CDI mortality in Australia in over a decade, this 
research provides interesting insights into the mortality associated with CDI in hospitalised 
patients in Australia, as well as the opportunity for robust comparison with studies in other 
countries. This study also provides results indicating that persons who had CDI have a higher 
all-cause mortality compared to persons without CDI. Further, one key finding from my 
study is that mortality is significantly higher from 60 days after admission and beyond. These 
two points are explored in the first two sections of this discussion. The next section of the 
discussion reviews the characteristics of the exposed and non-exposed further, with a focus 
on potential confounders. This point is explored in the context of reflecting on the data 
collected in my study and informing future research approaches examining mortality and 




The first research question for this study had two parts. The first was to determine the 
percentage of persons who died within 30, 60, 90 and 180 days following admission and who 
had an episode of CDI during the incident admission. The second was to examine the risk of 




CDI. Mortality was reported in a number of different ways in the results section of this 
chapter, in order to answer these two research questions. There were significant differences in 
mortality between the cases and controls at various endpoints, even after adjusting for other 
factors. The risk of dying at 180 days was twice as high in cases, compared to controls, OR 
2.04, 95% CI [1.24, 3.36]. In this section I will discuss mortality and CDI in relation to the 
research questions and explore why mortality is higher at a relatively late stage following 
admission to hospital.  
 
Mortality at fixed timeframes 
 
Mortality increased steadily in cases and was reported as 7.0%, 12.6%, 14.6% and 23.4% at 
30, 60, 90 and 180 days following admission to hospital. There were statistically significant 
differences in mortality between the exposed and non-exposed at 60, 90 and 180 days post-
admission using Kaplan-Meier analysis. It is important to remember that, as a result of being 
a matched cohort study, these data are inherently adjusted for the matching variables of age 
group, sex and admission period. After additional adjustment for antibiotic exposure at 60, 90 
and 180 days, these differences in mortality remained. Similarly, at 180 days, adjusting for 
any one variable—antibiotic exposure, length of stay and CCI—using Kaplan-Meier analysis, 
significant differences remained. 
 
Using a conditional logistic regression model, the risk of dying by 180 days following 
admission to hospital was twice as high in cases compared to controls. In this final model, the 
only variable that was retained was a CCI score of greater than zero. Indeed, a CCI of greater 
than zero was associated with mortality at all endpoints examined. This reinforces the need 
for studies to collect and analyse the effect of co-morbidities, thereby enabling a more 
accurate statement about the association between CDI and mortality (Karas et al., 2010).  
 
There are a number of ways that mortality associated with CDI is reported in the literature. In 
some published case control studies, statistically significant differences in all-cause 30 day 




respectively (Gasperino et al., 2010; Gulihar et al., 2009). Thirty day mortality adjusted for 
age and sex remained significantly different in the study conducted by Gasperino et al. 
(2010). In the study undertaken by Gulihar et al. (2009) controls were matched to cases by 
age, sex, residential status and ASA score where known. This study design was similar to that 
used in my study. At six months, a significant difference in mortality remained between the 
exposed and non-exposed (67% vs. 29%, p<0.001) (Gulihar et al., 2009). 
 
It is also interesting to note the reported percentage of persons with CDI who died at various 
endpoints. As previously stated, mortality at 30 days has been reported as being 16% and 
19% at 30 days, and as high as 67% at 180 days (Gasperino et al., 2010; Gulihar et al., 2009). 
A number of cohort studies have reported all-cause mortality in persons with CDI. In these 
studies, all-cause mortality ranged from 9% to 38% at 30 days (Bhangu et al., 2010; Fenner et 
al., 2008) and between 27% and 30% at 90 days (Musher et al., 2005; Shears et al., 2010). 
The reported mortality as a percentage is higher than that reported in the present study (7% 
and 23.4% at 30 and 180 days, respectively). The numbers of cases used in the studies 
performed by Gulihar et al. (2009) and Gasperino et al. (2010) were 170 and 108, 
respectively with similar numbers of controls. In the study undertaken by Fenner et al. (2008) 
there were 78 persons with CDI. 
  
Similar to my study, one study reported a non-statistically significant difference between 
persons who had CDI (exposed) and persons who did not (non-exposed) in examining all-
cause mortality at one month (15% vs. 11.5%) (Bishara et al., 2008). The sample size of this 
study was limited to 52 persons who had CDI and 165 without CDI; only persons with CDI 
who had been exposed to antibiotics in the previous 40 days were included in the study. In a 
matched case control study, significant differences in mortality between those with and 
without CDI were reported at 90 and 180 days (Dubberke et al., 2008). By 180 days after 
hospital admission, 127 (36%) persons who had CDI had died, compared with 107 controls 
(30%). Similar to the present study, persons who had CDI were no more likely to die than 
those without, at 60 days after hospital admission, but a divergence became apparent more 
than 60 days after hospital admission (Dubberke et al., 2008). The hazard ratio for death was 





The findings of my study, which indicate a divergence in survival between the exposed and 
non-exposed at 60 days, support previous findings. As discussed earlier, the study undertaken 
by Dubberke et al. (2008) demonstrated a delayed impact on death. My previous suggestion 
that studies examining CDI and mortality may be influenced by the methodologies used (and, 
in particular, exclusion criteria) is supported by Dubberke et al. (2008), who comments that 
delayed death caused by CDI may not be easily recognised as related to the initial CDI 
episode and CDI may contribute to a decline in patient function and overall illness over time, 
ultimately leading to death in many patients. This particular point is explored in more detail 
later in this section. Analysis is also included examining the characteristics in persons who 
died (non-survivors) and more specifically, any differences between the exposed and non-
exposed. In my study, in those persons who died, the only significant difference between the 
exposed and non-exposed found after applying univariate analysis was length of stay.  
 
Of interest from this analysis was the comparison of death by exposed and non-exposed and 
the year of admission. For the exposed, there was an increase in the number of deaths each 
year (between 2007 and 2010). During 2010, there was a large, but not statistically 
significant, difference in the number of people who died when comparing exposed and non-
exposed (p = 0.086). This increase in the number of deaths in cases may result from a 
changing epidemiology of C.difficile, such as a change in the circulating strain. My study was 
only able to obtain limited data on the strain of C.difficile affecting the exposed. Nonetheless, 
these data are important as they can be used to pool with data from other studies. In doing so, 
conclusions about whether specific strains of C.difficile result in different levels of mortality 
may be possible. Due to the limited data available from my study, no conclusions can be 
drawn with respect to the influence that different strains of C.difficile may have on death. 
Further, there are no published data on the circulating strains of C.difficile across Australia at 









An in-hospital mortality of 3.2% was found for both the exposed and non-exposed. This 
proportion is lower than reported mortality from a number of studies, which has ranged 
between 8% and 37% (Chung et al., 2010; Cloud et al., 2009; Gasperino et al., 2010; Marra et 
al., 2007). Comparisons between my study and those reported elsewhere however should be 
undertaken with caution. There are a number of issues inherent in comparing in-hospital 
mortality data amongst studies for CDI. The circulating strains (and therefore virulence) of 
C.difficile vary not only among institutions, but also among countries (McDonald et al., 2005; 
Warny et al., 2005). In-hospital mortality for CDI reported in the literature does not adjust for 
this difference. A further challenge when comparing in-hospital mortality, which is not 
limited to CDI, is the case-mix of the participants in the study (Ansari, Ackland, Jolley, 
Carson, & McDonald, 1999; Iezzoni, Ash, Shwartz, & Mackiernan, 1997). As demonstrated 
by the results in the present study and others, co-morbid disease plays a role in CDI, yet in-
hospital mortality data may not account for this (Vaishnavi, 2009). The size of the hospital 
can also play a part in the calculation of in-hospital mortality which can become less precise 
in smaller hospitals, with fewer deaths as a function of fewer admissions (Scott, Brand, 
Phelps, Barker, & Cameron, 2011). Given the issues with reporting in-hospital mortality, I 
suggest comparisons using this method are not made in examining mortality associated with 
CDI.  
 
4.7.3 A limitation of surveillance definitions  
 
The second research question for this study was to examine the potential influences of using 
CDI surveillance definitions when examining the risk of death in people who has an episode 
of CDI. One question the findings from my study poses is why CDI is associated with 
mortality at a relatively late stage following admission to hospital. Earlier, in section 4.6.2, 
data on the time from hospital admission to infection was discussed. Eight persons had an 
episode of CDI commence more than 30 days after admission; but none of these persons died. 
Therefore, the timing of infection commencement during a hospital stay may not fully 
explain the higher occurrence of mortality at 60 days and beyond. One potential reason for 





In clinical practice, a person may suffer several relapses of CDI before recovering or dying, 
and relapses often occur within a few weeks of initial recovery (Pépin et al., 2005). For 
example, it has been suggested that CDI will recur in 33-65% of persons who have had more 
than two relapses (Barbut et al., 2000; Gerding, Muto, & Owens, 2008). In situations where a 
person has a relapse within eight weeks of the previous episode of CDI, data relating to this 
relapse were not captured in my study. Any episodes of CDI occurring within eight weeks of 
the previous episode were excluded, in accordance with national surveillance definitions. 
This would include persons who have been discharged from hospital. Figure 18 seeks to 
illustrate this point graphically. 
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Figure 18. Scenario of a person who had Clostridium difficile infection dying 43 days 
following initial admission to hospital. The second episode of CDI would not be included in 
data as it occurred within eight weeks of the previous episode. If the second episode of CDI 
was included, the person would have died seven days following the second episode of CDI.  
 
Any study that uses exclusion criteria to remove duplicate cases may run into the same issue. 
In section 4.2.3, the literature surrounding the management of duplicate samples of CDI was 
explored. In my study, episodes of CDI occurring within eight weeks of the previous, as 
defined by a laboratory diagnosis, were excluded, consistent with national and international 
surveillance definitions. My study is not alone in encountering this issue (Sundram et al., 






Findings from previous research on CDI suggest that the more relapses a person has, the 
poorer the outcome for the person (Musher et al., 2005). This scenario may go some way in 
explaining a higher mortality at 60 days post-admission and beyond. If this is the case, it 
demonstrates a potential weakness in using exclusion definitions for CDI surveillance 
programs as this goes to the heart of what constitutes a case of CDI. Whether episodes of CDI 
occurring within eight weeks of the previous case are relapses or new infections is an 
important point to consider, not only when considering mortality as described in the section 
above, but also when determining the incidence of CDI. In the case of the latter point, failure 
to account for these could result in under reporting of CDI. Further work is required on 
refining how duplicate episodes of CDI occurring in the same person in a defined period are 
managed and classified for the purposes of data analysis.  
 
4.7.4 Exploration of length of stay, co-morbidities and antibiotic exposure  
 
In univariate analysis, a number of differences in length of stay in hospital, co-morbidities 
and exposure to antibiotics in hospital between the exposed and non-exposed were identified. 
In this section these differences are discussed. There also appeared to be more exposed in the 
last year of this study, and more people with CDI in older age groups. These points are 
explored in more detail in Chapter 5 using a different study design and so are not explored 
further here. 
 
The length of stay differed significantly between the exposed and non-exposed. It was not the 
purpose of the present study to attribute length of stay to CDI as this is the focus of the next 
study of this thesis. Rather, the exploration of length of stay in the exposed and non-exposed 
is interesting in the context of interpreting survival at different endpoints which is discussed 
later in this section. The median length of stay was 17 days for the exposed and four days for 
the non-exposed. This is consistent with other studies examining mortality and HAIs that 
have also demonstrated a significant difference in the length of stay between those with and 
without infection (Askarian & Gooran, 2003; Laupland, Lee, Gregson, & Manns, 2006; 
Leleu, Aegerter, & Guidet, 2002; Piednoir et al., 2003). Mortality was measured according to 
the number of days after admission to allow comparisons to other studies that used the same 




hospital stay and dies on day 40, they will be recorded as having died within 60 days or 
admission, not 30 days. In my study, the median time to infection after admission was eight 
days, with a range of 2-104. Further analysis of the study group showed that for the exposed 
who died up to 180 days following admission, the median time to infection from admission 
was five days (range 2-27 days). Therefore it appears that time of infection did not play a 
significant role in explaining why mortality was higher at 60 days and beyond.  
 
There were also significant differences in co-morbidities between the exposed and non-
exposed. Given the differences found in my study and evidence that the CCI is a valid 
prognostic indicator for mortality, the inclusion of these data are a particular strength of this 
study (Gabriel et al., 1999; Zhang et al., 1999). This is further supported by a review in which 
the authors call for future studies to include co-morbidities when examining mortality and 
CDI (Karas et al., 2010). Findings from my study suggest that more people who had CDI had 
had a cerebral accident, cancer or diabetes complications compared to those who did not have 
CDI. Dubberke et al. (2008) found a difference in the number of people with diabetes 
complications (p = 0.06), cancer (p<0.001), congestive heart failure (p<0.001), chronic 
pulmonary disease (p<0.001), and leukaemia (p<0.001) when comparing the exposed and 
non-exposed. Conversely, a study by Gasperino et al. (2010) did not identify any difference 
in co-morbidities between persons who had CDI and persons without CDI. 
 
There were also notable differences in exposure to antibiotics between the exposed and non-
exposed in my study. As discussed in section 4.2.5, exposure to antibiotics is thought to be an 
important risk factor for CDI (Bignardi, 1998). There are a large number of studies 
supporting the association of antibiotic exposure and CDI (J. Pépin, Saheb, N., Coulombe, 
M., Alary, M., Corriveau, M., Authier, S., Leblanc, M., Rivard, G., Bettez, M., Primeau, V., 
Nguyen, M.,  Jacob, C., Lanthier, L, 2005; Polgreen, et al., 2007; Thomas, et al., 2003). 
Results from this study were consistent with the literature in suggesting that a larger 
proportion of people who had CDI were exposed to antibiotics, compared to those who did 
not have CDI. When exposure to antibiotics was divided into antibiotic class, there were 
significant differences in exposure to all classes other than macrolides (p = 0.50) and 
aminoglycoside (p = 0.08). It was not the primary purpose of the present study to examine the 




results suggest that antibiotic exposure played little role in mortality as adjusting for this 
variable made no difference to survival under the Kaplan-Meier survival analysis. Further, 
antibiotic exposure was excluded in the final conditional logistic regression models for the 
four timeframes examined in this study (Table 17).  
 
Given the reported mortality associated with CDI in the present study, the importance of 
infection prevention activities, such as antibiotic stewardship, were underlined. Antibiotic 
stewardship is the term used to describe an effective approach to improving antimicrobial use 
in hospitals (Duguid & Cruickshank, 2011). The RHH has had an active antibiotic 
stewardship program since late 2010. The hospital also monitors the use of antimicrobials 
through the National Antibiotic Utilisation Surveillance Program. At a national level in 
Australia, there has been a growing push for hospitals to have an antibiotic stewardship 
program in place (Duguid & Cruickshank, 2011). With CDI being associated with increased 
mortality, the need is increased for CDI prevention strategies, such as antibiotic stewardship 
programs and surveillance programs to monitor their effectiveness.  
 
Antibiotic exposure was only one of several potential confounders that were considered in 
this study. Consideration of other potential confounders was attempted either through the data 
analysis or through the study design (i.e. matching). Further detail regarding the rationale for 
the collection of specific data items and the criteria used for matching are described in detail 
in section 4.5.4. Nevertheless, when discussing and interpreting the results below, the 
relationship that variables have with both CDI and subsequent mortality needs to be 
understood, particularly when reviewing results from the regression model. The relationship 
between variables considered in the design and interpretation of the present study is displayed 















Figure 19. Relationship between variables and Clostridium difficile infection and mortality. 
Note: Broken line indicates an uncertain relationship. “External factors” represents those 
factors that were attempted to be controlled for through matching by admission period. These 
are described in the methods section. 
 
In my study, the final conditional logistic regression model explaining mortality at 180 days 
only included co-morbidities. As age and sex were used as part of the matching process for 
controls, this study is unable to draw conclusions on their role in CDI and mortality. In the 




There are some limitations to this study. Caution should be applied when comparing this 
research to other published studies: based on conditions in the northern hemisphere the 
circulating strains of C.difficile and their effect on mortality may be different (Loo et al., 
2005; Miller et al., 2010). Also, as with all retrospective studies, the number of variables are 
limited by the existing range of data collected. For this study, this limited the number of 
potential explanatory variables that could be introduced in the regression modelling and 





4.8 Recommendations  
 
From the findings, a number of recommendations can be made. First, in my study, data were 
not captured on the time between CDI diagnosis and treatment. This variable may be 
important in understanding the effect that CDI has on mortality. Second, my study also 
demonstrated the importance of considering co-morbidities when examining mortality. As 
identified in the literature review not all studies examining the influence of CDI on mortality 
capture data on co-morbidities. Unlike co-morbidity data, data on the strains of C.difficile 
affecting all cases was not available, thus the role that different strains play should be 
considered for future studies. Often such data are limited, therefore it becomes even more 
important that studies include strain data where possible, to allow for future meta-analysis. 
With these points in mind, the following recommendation is made for future research:  
1. Future research examining the association between CDI and mortality should include 
collection of data on: 
a. co-morbidities of individuals in the cohort 
b. strains of C.difficile.  
 
Findings from my study suggest that CDI is associated with increased mortality but only a 
considerable time after initial infection commencement. Efforts to better understand the 
epidemiology of CDI in Australia are required and infection prevention and control strategies 
for CDI need to be enhanced given that these findings suggest mortality in persons who had 
CDI is higher compared to persons who did not have CDI. With this in mind, the following 
recommendations are made: 
2. Surveillance programs for CDI are enhanced to include collection of: 
a. The date of death up to 180 days following infection (where relevant) 
b. Examination of strains of C.difficile where possible  
3. The use of exclusion criteria for duplicate cases of CDI, in both surveillance data and 
in research, needs further refinement to consider how new infections within an eight 







This chapter presented an overview of CDI, including risk factors and the association 
between CDI and mortality. No published study examining CDI and mortality in the southern 
hemisphere was identified. This finding informed the second study for this thesis, presented 
in this chapter which examined mortality following CDI at the Royal Hobart Hospital, 
Tasmania. Results from this study indicated that CDI was associated with increased 
mortality, compared to persons who did not have CDI. More specifically, mortality following 
CDI was significant at 180 days post-admission to hospital and a considerable time after 
initial infection commencement. One potential reason for the result seen could be the use of 
exclusion criteria applied to the study population. This is an important finding in itself, as this 
study not only highlights the impact the CDI has on individuals, but also the potential 
influence that case definitions may have on valid and reliable results.  
  
This study has the potential to influence local, state and national policy in CDI prevention by 
demonstrating the late impact that CDI may have on hospitalised individuals, compared to 
persons without CDI. Based on the findings of this research, specific recommendations have 
been made that are relevant to policy makers, infection control professionals and researchers. 
The next chapter discusses the third study contained within this thesis which examines the 









Chapter 5: Examining length of stay and Clostridium difficile infection  
 
5.1 Introduction to the chapter 
 
In the previous two chapters, the epidemiology of SAB and CDI in an Australian setting was 
discussed by presenting the first two studies of this thesis. In doing so, methodological 
influences on reliable and valid data have been highlighted. The third and final study of this 
thesis, presented in this chapter, continues this theme. In this chapter, the epidemiology of 
CDI is explored further in addition to estimating the prolongation of hospitalisation due to 
CDI.  
  
In this chapter, the prolongation of length of stay in hospital is initially explored through a 
critical review of the literature which informed data analysis methods used for the third study 
of this thesis, examining the incidence of CDI and prolongation of length of stay due to CDI 
at the RHH in Hobart, Tasmania. The findings and recommendations from this study extend 
beyond CDI and have wider ramifications for examining other HAIs and their impact on 
length of stay.  
 
In Chapter 4, background on C.difficile and CDI was presented. Reference can be made to 
Chapter 4, section 4.2 for details on pathogenesis, diagnosis, management of duplicate 
episodes of CDI, CDI acquisition and risk factors for the infection. The next section of this 
chapter details the literature surrounding CDI and prolongation of length of stay in hospital. 
 
5.2 Literature review 
5.2.1 Introduction to the literature review 
 
Through exploration of epidemiology and mortality in the second study (Chapter 4), a picture 
emerges of the impact that CDI has on health services and patients. One important element in 
understanding the burden that CDI has on a health service is the additional economic cost of 




HAI, it is possible to inform basic economic analysis of the costs associated with a particular 
infection.  
 
Determining the additional length of stay due to a HAI, including CDI, is challenging due to 
the need to manage time-dependent bias, that is, the longer a person stays in hospital, the 
greater the risk of acquiring an infection. Therefore, managing issues such as time-dependent 
bias and sampling bias are important. Through a review of the literature, this section will 
examine what is known about the impact CDI has on extending the length of stay in hospital, 
what gaps there are in our knowledge, and the different study designs used to determine this 
issue. 
 
5.2.2 Search strategy 
 
To evaluate the methodologies used to determine the excess length of stay caused by CDI in 
hospitalised patients, the literature was accessed through searches on Medline and Pubmed, 
limited to the years 2000 to 30
th
 April 2011. Other limits included only searching literature 
published in English and studies involving humans. Key search words used in the search 
were “Clostridium difficile AND economic”, “Clostridium difficile AND length of stay”, 
“Clostridium difficile AND cost” and “Clostridium difficile AND burden”. These searches 
were combined, with duplicate studies removed. The initial search yielded 330 articles. After 
a subsequent review of these articles, case control, cohort or reviews were included if they 
examined the length of stay from hospitalised patients with CDI. Following this step, 
interventional studies, for example the effect of immunoglobulin treatment on length of stay 
were excluded.  
 
Figure 20 summarises the search strategy used in this review and uses the PRISMA as the 
basis for presentation (Moher et al., 2009). A total of 16 articles remained and were included 
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Figure 20. Summary of the search strategy used in the review examining length of stay and 
Clostridium difficile infection. 
1
Articles were excluded if they were not case controlled, 
cohort or reviews or if they did not examine length of stay in hospitalised patients. 
2
Interventional studies were excluded. 
 




The majority (n = 12) of the 16 studies identified through the search strategy were 
retrospective in design. Two reviews were identified in addition to two prospective studies. 
The manner in which participants were identified differed, with several studies using ICD 
codes to identify episodes of CDI (Ananthakrishnan, McGinley, & Binion, 2008; Nguyen, 
Kaplan, Harris, & Brant, 2008; O'Brien, Lahue, Caro, & Davidson, 2007; Zerey et al., 2007; 
Zilberberg et al., 2009), whilst others used laboratory diagnosis. The use of ICD codes to 
identify participants has the potential to reduce the sensitivity and specificity of identifying 
cases of CDI. In addition, coding practices can vary among hospitals and therefore multi-
centred studies have a greater potential for variation in sample selection. Further, the timing 





The search strategy used to identify articles for this review did not identify the exact articles 
as those included in the latest review published by Ghantoji et al. (2010). Two articles 
included in the review by Ghantoji et al. (2010) were not included in my review, whilst my 
review identified and included eight studies not used by Ghantoji et al. (2010). The primary 
reason for these discrepancies is that my review examined the prolongation of length of stay, 
whereas the focus by Ghantoji et al. (2010) was economic cost. Similarly my review did not 
include two articles identified by the review conducted by Dubberke and Wertheimer (2009), 
but did identify a further 11 articles not used by Dubberke and Wertheimer (2009). The 
reasons for this are the same as those just described in addition to the inclusion of recent 
publications. Nine articles were common to both reviews. The review by Ghantoji et al. 
(2010) identified four articles not used by Dubberke and Wertheimer (2009). Conversely, 







Summary of included articles in the review examining length of stay and Clostridium difficile infection 
Author Study type Country Statistical analysis  Results 




US Linear regression Three times LOS in person who had CDI and who have IBD compared to 
persons with IBD 
Bajaj et al., 2010 Cohort1 US Logistic regression Mean LOS = 12.7 days in persons who had CDI  
Mean LOS = 6.7 days in persons with cirrhosis (no CDI) 
Dubberke et al., 2008 Cohort US Logistic regression 
 
Median LOS = 9.6 days in persons who had CDI   
Median LOS = 5.8 days in persons who did not have CDI 
Dubberke & Wertheimer, 2009 Review - Review Review 
Ghantoji et al., 2010 Review  -  Review Review  
Kenneally et al., 2007 Cohort US Logistic regression  Mean ICU LOS = 13.7 in persons who had CDI 
Mean ICU LOS  = 11.5 in persons who did not have CDI 
Mean hospital LOS = 27.3 in persons who had CDI 
Mean hospital LOS  =22.8 in persons who did not have CDI 
 
Lawrence et al., 2007 Cohort 
 
US Linear regression Median ICU LOS = 6.1 in persons who had CDI 
Median ICU LOS  = 3.0 in persons who did not have CDI  
Median hospital LOS = 10.1 in persons who had CDI 
Median hospital LOS  =24.5 in persons who did not have CDI 
Lumpkins et al., 2008 Cohort US Linear regression Hospital LOS1 = 34.9 day LOS in persons who had CDI 
Hospital LOS1 = 19 in persons who did not have CDI 
Miller et al., 2002 Case series Canada Not discussed 9% participants with CDI deemed to have mean extension of LOS of 10 days 
(median = 7 days) 




2008 Mean hospital LOS = 6.7 days in persons who had ulcerative colitis 
O'Brien, Lahue, Caro, & Davidson, 
2007; 
Cohort US Descriptive  Mean hospital LOS attributed to CDI = 6.4 days in patients with primary CDI as 
primary diagnosis 
Mean hospital LOS attributed to CDI = 2.9 days in patients with CDI as 
secondary diagnosis 
Pepin, Valiquette, & Cossette, 2005 Cohort Canada Not discussed Mean hospital LOS = 33.7 days in persons who had CDI 
Mean hospital LOS = 23.1 days in persons who did not have CDI 
Song et al., 2008 Cohort US Linear regression 
 
Median hospital LOS = 22 days in persons who had CDI 
Median hospital LOS = 18 in persons who did not have CDI 
Vonberg et al., 2008 Cohort2 Germany Descriptive Median hospital LOS = 27 days in persons who had CDI 
Median hospital LOS = 20 days in persons who did not have CDI 
Zerey et al., 2007; Cohort US Logistic regression 16 days longer LOS (with CDI) 
Zilberberg et al., 2009 Cohort US Logistic regression  CDI correlated significantly with longer LOS (16.0 days, p<0.0001) compared 
to persons without CDI 
Note:  CDI = Clostridium difficile infection. LOS = length of stay. DRG = Diagnosis Related Group. IBD = Inflammatory bowel disease. 1Study did not state whether the LOS was mean or 
median LOS. 1The authors of this study state their study design as case controlled. However persons in this study were selected by their study factor i.e. persons who had CDI, persons who 
had cirrhosis or persons who had both cirrhosis and CDI. Therefore, this study is a cohort study. 2The authors of this study state their study design as case controlled. However, all persons 







Excluding the reviews, only three of the remaining 14 studies were undertaken in 
countries other than the United States. There were no studies identified from an 
Australian setting. The systematic review examining the economic costs of CDI 
undertaken by Ghantoji et al. (2010) also reported that only four of the 13 included 
articles were not from the United States and no study was identified from Australia. In 
the review undertaken by Dubberke and Wertheimer (2009) one Australian study, 
published as a letter to the editor, was identified (Riley, Codde, & Rouse, 1995). A 
separate search for Australian studies examining length of stay and CDI confirmed 




The data collected in the various studies differed considerably. The majority of 
studies collected basic demographic data such as age and gender. Some studies 
collected data on co-morbidities and used a severity index such as the Charslon co- 
morbidity index (Dubberke et al., 2008; Nguyen et al., 2008; Pepin, Valiquette, & 
Cossette, 2005). Data collected on variables such as antibiotic exposure or other drug 
therapy were limited (Kenneally et al., 2007; Lawrence et al., 2007; Pepin et al., 
2005).  
 
Clostridium difficile infection and association with length of stay 
 
Findings from all the studies suggested that CDI contributes to a longer length of stay 
in hospital. It was not possible to pool data as studies varied considerably in design, 
sampling and data analysis. In studies that used a comparison between persons with 
CDI and those without, the difference in the length of stay between the two groups 
ranged from 2.8 days to 16.1 days (Dubberke et al., 2008; Lumpkins et al., 2008). 
These data suggest that CDI may play a role in increasing the length of stay in 






In a cohort of over 18,000 non-surgical patients hospitalised for more than 48 hours, 
Dubberke et al. (2008) undertook an analysis of the nested subset of this population 
(persons who had CDI and did not have CDI) using a matched pairs analysis. The 
authors found that the length of stay attributable to CDI was 2.8 days. Persons without 
CDI were matched to persons who had CDI using a developed propensity score. The 
propensity score was developed by applying logistic regression to the data to predict 
the variables suspected to impact the risk of developing CDI. Median length of stay 
was determined for persons who had and did not have CDI, with the different median 
pairwise length of stay compared using the Wilcoxon signed ranked test. Attributable 
length of stay was calculated as the median pairwise difference between persons who 
had CDI and those who did not (Dubberke et al., 2008). As this study did not include 
surgical patients it is possible that those with severe CDI, requiring colectomies, were 
excluded leading to bias. A propensity score was used for matching, to reduce 
confounding between controls and cases in determining attributable length of stay.  
 
 
A study undertaken by Lumpkins et al. (2008) suggested a considerably higher length 
of stay in hospital due to CDI, compared to the study undertaken by Dubberke et al. 
(2008). In a cohort study consisting of critically injured trauma patients admitted to an 
intensive care unit, those with and without CDI were analysed prospectively. A 
logistic regression model was used for data analysis in comparing the two groups and 
associated variables. The mean hospital length of stay was 15.9 days greater in 
patients who developed CDI, compared to those who did not (34.9 days vs. 19.0 days, 
p = 0.003). When persons who had CDI were compared by extent of antibiotic 
exposure, those with minimal exposure were found to have a shorter length of stay in 
hospital, however antibiotics exposure prior to injury was not obtained in this study 
(Lumpkins et al., 2008). Such a finding would suggest the need to collect data on 









The methods of data analysis varied. In the majority of studies, a regression model 
was developed to attempt to determine the impact that CDI had on length of stay 
(Ananthakrishnan et al., 2008; Bajaj et al., 2010; Dubberke et al., 2008; Kenneally et 
al., 2007; Lawrence et al., 2007; Lumpkins et al., 2008; Nguyen et al., 2008; Song et 
al., 2008; Zerey et al., 2007; Zilberberg et al., 2009). The studies did not report the 
timing of onset of CDI and therefore it is not possible to exclude the possibility of 
reverse causality, in which longer lengths of hospitalisation may have increased the 
risk of CDI. The issues associated with controlling for a potential time-dependent bias 
caused by the length of stay in hospital raises some significant concerns. In order to 
explore this particular issue in more detail, literature, specifically in relation to this 
issue will now be explored. 
 
 
Controlling for length of stay prior to infection onset 
 
Some literature suggests that previously applied models to determine the additional 
length of stay in hospital due to infection result in an overestimation compared to 
newer statistical models (Barnett et al., 2009; Beyersmann, Gastmeier, Wolkewitz, & 
Schumacher, 2008; Beyersmann, Kneib, Schumacher, & Gastmeier, 2009; 
Beyersmann, Wolkewitz, & Schumacher, 2008; Graves et al., 2010; Graves et al., 
2007). The prolongation of hospitalisation due to any infection is an element in 
estimating cost (N. Graves, Halton, K., Jarvis, W., 2009). It is therefore vital that 
studies are designed to evaluate and analyse this effectively. Methods used to evaluate 
costs associated with HAIs are discussed in more detail in Appendix I. The method 
used to determine length of stay should account for the fact that a HAI, such as 
C.difficile, can occur at any point during a hospitalisation and that length of stay is 
affected by other variables such as co-morbidity and primary diagnosis (Graves et al., 
2010). Matched cohort studies suffer from two types of bias. First, some patients are 
predisposed to a longer length of stay and matching is unable to control all bias. 
Second, in an attempt to control for all bias, increasing matching criteria often causes 





The time varying nature of infection also poses an issue in matched studies. Infections 
can occur at any time however data analysis in matched studies often compares 
infected and uninfected patients by their total hospital stay, as evidenced by the 
findings of this review. If the timing of infections is not taken into account, costs 
associated pre and post infection are included and can dramatically amplify 
confounding and lead to time-dependent bias (Graves et al., 2010). Statistical models 
can be used to address this issue at the data analysis stage, rather than at the design 
stage. A model can be built to describe the relationship between length of stay and the 
predictors of that outcome (Beyersmann, 2007; Graves et al., 2010). Previously, 
models that ignored the time of infection often used a linear model assuming a gamma 
distribution of length of stay and an independent variable of infected (yes/no) (Barnett 
et al., 2011).  
 
 
Methods have recently been developed to address this issue when estimating length of 
stay and HAIs. These methods include a multistate model in which the infection is the 
intermediate event between admission and discharge and patients are given three 
states: non-infected, infected, and discharged (Barnett et al., 2009; Barnett et al., 
2011; Beyersmann et al., 2006). Therefore, for future research examining the 
prolongation of length of stay in persons with a HAI such as CDI, data collected on 
the commencement and completion of infection will enable the potential to use a 
multistate model in data analysis.  
 
  
5.2.4 Summary of literature review 
 
Studies examining length of stay attributable to CDI vary considerably in their design 
and data collected. Several studies used administrative codes, such as ICD codes, to 
identify cases of CDI. The use of administrative data for this purpose does have some 
limitations, including the potential for ascertainment bias and lack of sensitivity and 




influence the length of stay in hospital and thus this information should be collected 
where possible.  
 
Despite these differences, there was a clear indication that CDI plays some role in the 
prolongation of length of stay in hospitalised patients. As length of stay in a hospital 
is a major contributor to healthcare cost, it is a logical assumption that CDI has an 
economic cost to the health system, a view shared by Ghantoji et al. (2010). None of 
the studies identified in the literature review or in the two published reviews by 
Ghantoji et al. (2010) and Dubberke and Wertheimer (2009) examined the length of 
stay caused by CDI in an Australian setting. The last published study in an Australian 
setting was published 17 years ago (Riley et al., 1995). The provision of health 
services and the epidemiology of CDI vary among countries and therefore it is vital 
that future studies examining length of stay and CDI are undertaken in a variety of 
countries.  
 
Potential issues in data analysis were identified, as no study fully addresses the issue 
of time-dependent bias when examining the length of stay caused by CDI. More 
specifically, no study identified the onset and cessation of CDI infection and used 
these data to inform data analysis. Recent literature suggests that a multistate model 
should be used to manage the issue of time-dependent bias. In order for a multistate 
model to be used, the timing of CDI infection must be captured. No study identified in 
the literature search undertaken, including the two published reviews examining the 
economic cost of CDI, used or identified a multistate model design. The third study to 
be presented in the next section was informed by the findings of the literature review 








5.3 Objectives and research questions 
 
The objectives for the third and final piece of research for this thesis were to explore 
the incidence of CDI and prolongation of length of stay due to CDI and to analyse 
potential influences of differing data analysis methods in the calculation of any 
prolongation of length of stay. To address these objectives, the following research 
questions were developed: 
In the period 1
st
 January 2007 to 30
th
 December 2010, for all admissions for 
hospitalised patients aged two years or older in a Tasmanian acute public 
hospital: 
1. What is the incidence of CDI? 
2. What impact does CDI have on the prolongation of length of stay, when 
managing time-dependent bias? 
 
In order to answer the second research question, data were available to enable the 
incidence of CDI to be explored. Describing the incidence allowed for a logical flow 





5.4.1 Study design 
 
To address the research questions, an observational design, with dynamic population 






5.4.2 Setting, timeframe and selection of the population  
 
All persons hospitalised more than 48 hours aged two years or older, between the 1
st
 
January 2007 and the 30
th
 December 2010 at the RHH, Hobart, Tasmania, formed the 
study population. In this chapter, persons in the study population will be referred to as 
“admissions” from this point forward. A description of the characteristics of the RHH 
was provided Chapter 4, section 4.5.2. From the available data, those persons who 
developed CDI during their hospital stay were subsequently identified. A person was 
defined as having CDI, based on the national surveillance definition for CDI and as 
previously described in Chapter 4, section 4.5.3.  
 
 
5.4.3 Data collection 
 
This section on data collection is divided into two parts. The first describes the data 
collection process and the second outlines the specific data items collected during 
each step of the process and the rationale for collecting specific items.  
 
Data collection process 
 
Data were retrieved from four different sources. These sources comprised data from 
the Clinical Coding department of the RHH, the TIPCU, the Infection Prevention and 
Control Unit at the RHH, and through a review of the patient administration system 
and medical records of each member of the study population by the researcher.  
 
To identify the population, all admissions aged two years and older admitted to the 
RHH for more than 48 hours during the study period were identified by the Clinical 
Coding department at the RHH at the request of the researcher. To allow for the 
identification of persons who developed CDI during their hospital stay, the TIPCU 
provided the researcher with details on all admissions who had an episode of CDI 
occurring at the RHH during the study period. The identification of admissions with 





Once the researcher had obtained information on the admissions with CDI from the 
TIPCU, further data were collected through a review of the records held on the RHH 
patient information system and medical records of those with CDI. The data items 
collected during this process, including the rationale for collecting some of the items 
are detailed shortly. 
 
The Infection Prevention and Control Unit at the Royal Hobart Hospital collects data 
on the timeframe a person with CDI is isolated under contact precautions. The 
researcher reviewed data provided by this unit for when persons with CDI had contact 
precautions ceased. The rationale for using the cessation of contact precautions as a 
marker for infection cessation is described in more detail in the following section. 
Data using this process were only available from the 1
st
 July 2009 until the 30
th
 
December 2010, as the RHH infection control unit did not collect this data prior to the 
1
st
 July 2009. There were 11 instances within this timeframe where data were not 
available from the RHH infection control unit. Subsequently, specific review of the 
medical notes of these 11 admissions was conducted by the researcher and resulted in 
the date a person was removed from isolation being identified for another six 
admissions. Therefore, data on when a person was removed from isolation could not 
be obtained in five instances. Data on isolation periods for a total of 72 persons (1
st
 
July 2009 until 30
th
 December 2010) were obtained. 
 
Data items collected  
 
This section contains information on the specific data items collected from each of the 
various data collection sources. The rationale for the choice of how data on the 
cessation of CDI was collected will be explored in more detail. Table 12 provides a 
summary of the data items collected, the manner in which they were defined and the 








Data collected and source 
Data field Definition 
 
Source of data 
Admission with CDI Admissions without CDI 
Date of birth Date of birth TIPCU** RHH clinical coding* 
Sex Male, female or intersex 
as stated on the PAS 
TIPCU** RHH clinical coding* 
Age  Age at time of specimen 
collection 
TIPCU** RHH clinical coding* 
Admission date Date of admission to the 
RHH 
TIPCU** RHH clinical coding* 
Discharge date  Date of discharge from the 
RHH or date of death 
(whichever is first) 
Researcher - review of 
medical records & 
PAS*** 
RHH clinical coding* 
Date of death 
(if applicable) 
Date of death up to 180 
days post-date of infection 
commencement 
Researcher - review of 
medical records & 
PAS*** 
RHH clinical coding* 
Date infection 
commenced 





Date contact precautions 
were ceased  
RHH Infection 






Methods used to 
categorise and characterise 
episodes of care received 
by patients admitted to 
hospitals **** 
RHH clinical coding* RHH clinical coding* 
Note: PAS = patient administration system. *Sourced from the PAS by clinical coding. **Originally 
sourced from PAS by the TIPCU and cross checked by the researcher. ***Described in more detail in 
Chapter 6. ****Adapted from “Australian Refined Diagnosis Related Groups Version 6.0 Definitions 
Manual Volume One,” by Australian Government. Copyright 2008 by the Commonwealth of Australia. 
^Only available for the period 1
st
 July 2009 to 31
st
 December 2010 as described in section 5.4.3. 
 
The issue of defining CDI cessation in an individual is challenging. As C.difficile may 
continue to be detected from asymptomatic colonisation, laboratory testing for 
clearance of CDI is not recommended (Stuart et al., 2011). The researcher undertook a 




failed to document a formed stool or cessation of diarrhoea reliably. Based on the 
findings from the review of the 20 medical records, it was considered that the 
cessation of contact precautions for persons with CDI was a simple, reliable and 
practical method of determining cessation of CDI and was consistent with literature 
(Cohen et al., 2010; National Health and Medical Research Council, 2010).  
 
The decision to cease contact precautions at the RHH at the time of the study was 
consistent with recommendations made by the Australian Infection Control 
Association, the National Health and Medical Research Council and the Infectious 
Disease Society of America (Cohen et al., 2010; National Health and Medical 
Research Council, 2010; Stuart et al., 2011). Additionally, the decision to cease 
contact precautions was made after a review by an infection control professional at 
the time of making this clinical decision.  
 
5.4.4 Ethical considerations  
 
Ethical approval for this research was granted by the Tasmanian HREC (H0011484) 
and by Australian Catholic University (N201150). Copies of ethics approvals are 
provided in Appendix P and Appendix Q. The application for ethics approval 
included a request to have consent from participants waived. The same justification 
for consent being waived as described in the previous two case studies was accepted.  
 
The study population for this study differed from that described in study two (Chapter 
4). All persons admitted to the RHH for more than 48 hours, aged two years and older 
were included in this study. Therefore, the size of the study is considerably higher 
than that presented in Chapter 4. Conversely, less personal data were required to be 
obtained for this study.  
 
De-identified data were analysed in this study. All patient identifiable information 




5.4.5 Data analysis 
 
After the provision of an overview on data management, this section will be 
structured by describing the analysis plan for the research questions. 
 
Preliminary data management 
 
Data entered into Microsoft Excel were coded by the researcher from text into 
numerical values ensuring date formats were consistently applied. Data from the 
Microsoft Excel spread sheet were then imported into IBM SPSS Version 20.0 for 
initial data analysis. Further data cleaning in SPSS occurred and included checking 
codes for errors, detecting implausible values and identifying missing values through 
frequency and cross tabulation calculations. New variables were computed in SPSS 
based on raw data collected. These new variables were grouped: CDI or no CDI, 
length of stay,  and discharge outcome. The definition and detail regarding these three 
variables have been previously discussed in Chapter 4 and can be reviewed in Table 
13, Chapter 4. 
 
Statistical analysis   
 
Descriptive analysis on the characteristics of the admissions was performed in IBM 
SPSS Version 20.0 (International Business Machines Corporation, 2011). Data 
analysis included determining the median length of stay and age for all admissions. 
The distribution of length of stay and age were analysed using Q-Q plots and tested 
using the Kolmogorov-Smirnov test. Univariate data analysis was performed 
comparing those with and without CDI. The calculation of relative risk was 
performed to compare occurrence of CDI in different groups. Time to discharge 
(crude length of stay) was described using Kaplan-Meier survival curves. A log rank 
(Mantell-Cox) test was used to compare crude length of stay between persons who 




prolongation of length of stay due to CDI. This specific analysis is described in more 
detail in the remainder of this section.  
 
To determine the prolongation of length of stay due to CDI, data were analysed using 
a multistate model, undertaken in the statistical software program R, version 2.13.2 (R 
Development Core Team, 2011). Multistate models are models for a process, for 
example describing a life history of an individual, which at any time occupies one of a 
few possible states. They can be used to explore several possible events for one 
individual, or the dependence among several individuals (Hougaard, 1999). Events 
are transitions between the different states that a person may undergo. Multistate 
models are useful for modelling different events, which have an event-related 
dependence, like occurrence of HAI (Hougaard, 1999).  
 
The first step in determining the prolongation of length of stay using a multistate 
model is to consider the possible state and paths a person may undergo i.e. the 
multiple states a person may go through during their admission. As described in the 
literature review presented earlier in this chapter, studies have traditionally performed 
data analysis where CDI was considered a time-dependent covariate. The approach 
used in other studies does not permit the calculation of length of stay due to CDI 
explicitly as retrospective stratification of cases (infected) and controls (non-infected) 
are likely to overestimate the effect of CDI, as described in the earlier literature 
review. Even the inclusion of time to infection as a baseline covariate in Cox 
proportional hazard model does not adjust for time-dependent bias as the time to 
infection itself is a time-dependent covariate ( Beyersmann et al., 2009). These issues 
are explored in more detail shortly. 
 
In this study, all admissions were considered to be admissions without infection and 
only progressed to an infected state if and when they were confirmed as having CDI. 
In principle, every individual can move between different states (Wolkewitz, Allignol, 
Schumacher, & Beyersmann, 2010). In the case of my research, individuals could 




in the study were considered as being susceptible to infection until they were either 
discharged or they succumbed to infection. The discharged state could be either 
discharged alive or discharged died. Figure 21 demonstrates the different states that 
an admission in the study could progress through.  
 
 
Figure 21. Model demonstrating the different states a person can transition through in 
my study.  
 
In finalising the above model, a number of other models were explored. The two most 





Figure 22. Potential multistate models. These models were explored before deciding 





Model A (Figure 22) was more accurate in describing the path of a person with CDI 
in hospital, compared to that described in Figure 21. Once a person has ceased having 
CDI, they may either be discharged or they may go back into the ‘no infection’ state. 
In Chapter 9, the number of persons who are discharged the day CDI ceases is 
described and was relatively low in number. The majority of persons with CDI move 
back into a state of ‘no infection’. The researcher had discussions with leading 
biostatisticians responsible for developing multistate models that examine 
prolongation of length of stay due to HAIs. They were unable to assist in the 
development of a code for R that could have been used for data analysis that reflected 
Model A. Therefore, despite being the optimal model, Model A was not able to be 
used for data analysis. 
 
Model B displayed in Figure 22, is an extension of Model A. Model B divides the 
discharged status into discharged alive or discharged died and allows for the transition 
of those persons who had an infection, back into a non-infection status.  
 
The developed model used for this study (Figure 21) assumed that the movements 
between states were Markovian, i.e. the future state only depends on the present state. 
Therefore, analysis on each episode of CDI was considered to represent a separate 
patient. If a person had two episodes of CDI during the study period, they were 
analysed as data for two independent individuals (Beyersmann et al., 2006; Gastmeier 
et al., 2003). The model described in Figure 21 is referred to as a three state model in 
the published literature and has been summarised in the manner displayed in Figure 
23. Despite not being the optimal model, the three state model has been shown to be 
superior in estimating the length of stay due to HAIs, when compared to other 






Figure 23. Three state model. The term ‘susceptible’ refers to persons who are 
susceptible to the given infection. In the case of my study, ‘susceptible’ refers to 
inpatients of a hospital. 
 
The hazard used in data analysis for this study was estimated using the multivariate 
Nelson-Aalen estimator (MVNA) in R. Multistate models require specialised software 
and a multistate model package is available in R (Meira-Machado, de Uña-Álvarez, 
Cadarso-Suárez, & Andersen, 2009). Infection was modelled as a time-dependent 
covariate to avoid time-dependent bias which over-estimates any increased length of 
stay due to infection. This particular issue is discussed in more detail shortly. A 
technical explanation for a multistate model is provided in Appendix J. 
 
The use of a multistate model provides a framework for the display and management 
of length bias and time-dependent bias, which can distort the statistical analysis 
through a misclassification of ‘at risk time’ (Wolkewitz et al., 2010). Using the 
multistate model for my study (Figure 23), a Lexis diagram, displayed in Figure 24 
with fictional data, was developed to demonstrate the potential for length and time-
dependent bias. Lexis diagrams visualise complex survival data, where individuals are 
displayed as lines on a calendar time. Lexis diagrams are particularly useful in 







Figure 24. Lexis diagram demonstrating the potential for time-dependent and length 
bias in my study. Each line represents an individual person’s time in hospital and the 
data they contribute to the study. Three individuals are presented in this diagram, 
labelled A, B and C. Individuals B and C do not ever have CDI during their hospital 
stay. Solid lines indicate the time a person has CDI. Dotted lines the time a person 
does not have CDI. Data are fictitious.  
 
If the time between admission and infection is ignored, then the study has the 
potential to introduce length bias. Length bias occurs if it is incorrectly assumed that 
individuals enter the study at the time of study commencement, that is, the time 
interval between the date of study entry and discharge is incorrectly longer than the 
actual time interval (Asgharian, M'Lan, & Wolfson, 2002). Length bias can be 
overcome by the correct application of data analysis techniques, such as Cox 
Proportional hazards models, assuming data are coded correctly. In my study this 
issue is overcome by persons entering the study on their actual date of hospital 
admission and leaving the study on their discharge date. My study does not assume all 
admissions entered the study on the 1
st
 January 2007. Time-dependent bias occurs in 
data analysis when a time-dependent exposure is incorrectly analysed as a baseline 




exposure or an intermediate event. In the case of my study the event is CDI. To 
explain how time-dependent bias was managed in my study, the following was 
considered. 
 
All persons who were admitted to the RHH were at risk of CDI. In persons who had 
CDI, their data contributed to the risk sets (length of stay) of persons without CDI, 
between the date of admission and infection commencement. Via truncation, persons 
with CDI were then followed up from the time of commencement until discharge 
(Wolkewitz et al., 2010). If the time between admission and infection commencement 
was ignored, it would have incorrectly assumed that a person with CDI contributed to 
the risk set before their infection commenced, thereby resulting in time-dependent 
bias (Wolkewitz et al., 2010). This is represented in the graph labelled “Time-
dependent bias” in Figure 24. The code used in R for data analysis is detailed in 
Appendix K.  
 
In addition to the use of a multistate model, data were analysed using a Cox 
proportional hazard model in IBM SPSS Version 20.0 (International Business 
Machines Corporation, 2011). This was undertaken to demonstrate how different data 
analysis techniques influence results. A Cox proportional hazard regression model 
was developed to estimate the proportional hazard of discharge. Variables found to be 
significant in univariate analysis were entered into the model using a forward stepwise 
condition process.  
 
 
Summary of methods 
 
This section provided an overview of data management and described the analysis 
plan for the research questions. Descriptive statistics and a Cox proportional hazard 
model were undertaken in IBM SPSS Version 20.0. Traditionally, studies that 
calculate excess length of stay due to a HAI do not permit the calculation of length of 




persons without infection is likely to overestimate the effect of CDI. Even the 
inclusion of time to infection as a baseline covariate in Cox proportional hazard 
models has been shown not to adjust for time-dependent bias as the time to infection 
itself is a time-dependent covariate. Therefore, to determine the prolongation of 
length of stay due to CDI using a multistate mode, data were analysed using a 
multistate model, undertaken in the statistical software program R, version 2.13.2 (R 
Development Core Team, 2011). Different multistate models were explored in this 
section and the model used for data analysis in this study provided. 
 
5.5 Results 
5.5.1 Population size and incidence of infection 
 
During the study period, there were 58,942 admissions of persons aged two years and 
older to the Royal Hobart Hospital (RHH) who stayed for 48 hours or longer. These 
58,492 admissions equated to a total of 493,626 bed days, defined as the sum of each 
individual person’s length of stay in hospital. The total number of admissions per 
annum to the RHH increased from 14,055 in 2007 to 15,185 in 2010, representing an 
8% increase over the four years, as demonstrated in Figure 25. Within this four year 
period, the largest seasonal increase in admissions occurred in spring, with a total of 
16.5% more persons being admitted in 2010 compared to 2007.  
 
Figure 25. Distribution of hospital admission dates. Admissions = admissions to the 
RHH hospitalised ≥48 hours and aged ≥2 years old. Total admissions per year = 
























As described in Chapter 4, there were 158 admissions with an episode of CDI in the 
calendar years 2007 to 2010. Despite removing duplicate samples occurring within 
eight weeks of the previous positive sample, there were five instances of a secondary 
infection occurring in the same person during the four year study period. Further 
analysis of these five individuals suggests that secondary cases were unrelated to the 
first case. More information regarding these secondary cases of CDI was provided in 
Chapter 4, section 4.6.1. 
 
The annual incidence of CDI per 1000 admissions for the calendar years 2007 to 2010 
ranged from 1.71, 95% CI [1.12, 2.50] to 3.89, 95% CI [2.96, 5.01] (Figure 26). Raw 
data informing this figure are provided in Appendix L. The incidence of CDI per 1000 
admissions for the entire study period was 2.68, 95% CI [2.28, 3.13]. There was a 
statistically significant increase in the incidence of CDI in 2010 compared to 2007 
(p<0.001). 
 
Figure 26. Incidence of Clostridium difficile infection (CDI) per annum at the Royal 
Hobart Hospital between 2007 and 2010. Admissions = total admissions hospitalised 
≥48 hours and aged ≥2 years old. Admissions with CDI occurring ≥48 hours after 
hospital admission in persons aged ≥2 years old. Errors bars denote 95% confidence 
































5.5.2 Demographic characteristics of the study population 
 
The distribution of age for the study population was not normal: D (58,784) = 0.08, 
p<0.001 (Kolmogorov-Smirnov test). As the size of the study is large, the distribution 
of age was confirmed as non-normally distributed using Q-Q plots. Table 22 displays 
the age and sex characteristics of admissions.  
 
Table 22 
Demographic characteristics of those with and without Clostridium difficile infection 
Characteristic Admissions that 
developed CDI 
(n = 158) 
Admissions that did not 
develop CDI 
(n = 58,784) 
Total 


















































































Age stratification, examining the incidence of CDI per 1000 admissions, was 
performed. The results displayed in Figure 27 and Table 23 demonstrates the 
incidence of CDI by age group. The incidence of CDI increases from the 30-39 year 
age group until the 80-89 year age group. The incidence of CDI stratified by sex and 
age group is provided in Table 23.  
 
 
Figure 27. Incidence of Clostridium difficile infection (CDI) per annum at the Royal 
Hobart Hospital between 2007 and 2010 by age group. Admissions = total admissions 
hospitalised ≥48 hours and aged ≥2 years old. Admissions with CDI occurring ≥48 
hours after hospital admission in persons aged ≥2 years old. Mean = incidence of CDI 






































Incidence of Clostridium difficile infection stratified by sex and age group 














































Note: Admissions = total admissions to the RHH hospitalised ≥48 hours. Admission 
with Clostridium difficile infection occurred ≥48 hours after hospital admission in 
persons aged ≥2 years old. Study period = 2007 to 2010 calendar years. 
 
The probability of a person admitted to the RHH during the study period having CDI 
relative to their age group is displayed in Table 24. In calculating the relative risks 
displayed in Table 24, reference groups were persons aged less than the stated age 
group. Results are displayed in this manner to demonstrate the graduating relative 
risk. The graduating relative risk displayed in this manner can inform a decision as to 
the age groups CDI surveillance should be performed in. This point is discussed 






Comparison of relative risk of Clostridium difficile infection by age group  
Age group Incidence 
Admissions that 
developed CDI / 
Admissions RR 95% CI 
≥80 years old* 4.06 35 / 8610 1.66 1.14-2.40 
≥70 years old* 4.11 73 / 17,769 1.98 1.44-2.70 
≥60 years old* 3.94 104 / 26,378 2.36 1.70-3.27 
≥50 years old* 3.86 128 / 33,137 3.29 2.21-4.90 
≥40 years old* 3.63 141 / 38,885 4.23 2.56-7.00 
≥30 years old* 3.19 146 / 45,813 3.44 1.91-6.19 
≥20 years old* 2.77 149 / 53,790 3.53 1.80-6.88 
≥10 years old* 2.71 155 / 57,261 1.36 0.43-4.24 
 
Note: *Reference group are persons aged less than the stated age group. RR = relative 
risk. CDI = Clostridium difficile infection. Admissions with CDI = number of 
admission with CDI occurring ≥48 hours after hospital admission in persons aged ≥2 
years old. Admissions = number of admissions to the Royal Hobart Hospital in 
persons aged ≥2 years old with a length of stay in hospital ≥48 hours. 95% CI = 95% 
confidence interval. Confidence interval calculated using Taylor series. 
 
Comparisons were made between the DRG category assigned to persons with and 
without CDI (Table 25) Table 25 only details DRG categories where the P value was 






Table 25. Comparison of Diagnosis Related Group in person with and without 
Clostridium difficile infection at the Royal Hobart Hospital, 2007-2010 
 




that did not 
develop CDI 
 (%) 
Total (%) Chi sq. 
statistic 
p value 
Pregnancy 1 (0.6) 7898 (13.4) 7899 (13.4) 22.26 <0.01 
Nervous 20 (12.7) 5007 (8.5) 5027 (8.5) 3.46 0.06 
Digestive 21 (13.3) 4709 (8.0) 4730 (8.0) 5.95 0.02 
Mental health 1 (0.6) 3894 (13.4) 3895 (6.6) 9.17 <0.01 
Kidney 10 (6.3) 1577 (2.7) 1587 (2.7) 8.00 <0.01 
Neoplastic 8 (5.4) 795 (1.4) 803 (1.4) 16.15 <0.01 
Note: DRG = Diagnosis Related Group. Only DRG categories with a p value of ≤0.1 
were included in this table. All DRG categories are provided in Appendix M. Those 
admissions with an “Error” or “Pre” DRG classification were excluded from this 
table. These categories are artefacts of the way DRG are coded and clinically do not 
fit with the above analysis. 
 
 
5.5.3 Timing and duration of infection  
 
For admissions that had an episode of CDI, the median time to infection from 
admission was eight days, with a range of two to 104 days (75
th
 percentile = 13 days). 
As described in the methods section, available data about the length of time 
admissions had infection was incomplete. The time an admission was in isolation in 
hospital was only identified for 72 of the 158 instances of infection. For these 72 
infections, the median time an admission had CDI was five days, with a range of one 
day to 47 days. Twenty-five per cent of these admissions had CDI for 11 days or 
more. The total number of bed days for the time between infection cessation and 






5.5.4 Length of stay using univariate analysis 
 
Using the Kolmogorov-Smirnov test, the length of stay was not normally distributed 
(p<0.001) and this distribution was confirmed by Q-Q plots. The median length of 
stay for all admission was five days. The median length of stay for those who did not 
have CDI at any time during their hospitalisation was five days (range 2-312). For 
those persons who had an episode of CDI during their hospitalisation, the median 
length of stay was 17 days (range 2-214).  
 
Using the Mann Whitney U test, a significant difference was found between the 
median length of stay in those who had an episode of CDI, compared to those who did 
not (x
2 
= 178.3, p<0.001). A Kaplan–Meier survival graph demonstrating the crude 
length of stay in hospital up to 100 days for admissions with and without infection 
CDI is displayed in Figure 28. The proportion of cases with a length of stay of 100 
days or less was 99.8%. There was a significant difference in the length of stay 
between those who had CDI, compared to those who did not (x
2 






Figure 28. Unadjusted length of stay for persons with and without Clostridium 






5.5.5 Prolongation of length of stay using a multistate model 
 
A multistate model was developed to estimate the prolongation of length of stay due 
to CDI. The multistate model used for data analysis was described in section 5.4.5 and 
enabled the time-dependent nature of CDI to be taken into account. Using a multistate 
model, the mean extra length of stay due to infection was calculated to be 0.9 days, p 
= 0.51, 95% CI [-1.8, 3.6] using the empirical transition matrix in the statistical 
package R. Therefore, the increase in length of stay for people who had CDI was not 
statistically significant at the 0.05 level. Figure 29 displays the estimated length of 






The extra length of stay for patients who were ultimately discharged and for those 
who ultimately died was 0.9 days and 0 days, respectively. In considering these 
results however, death was only measured as death on discharge from hospital (in-
hospital mortality). The study presented in Chapter 4 provides a more thorough 
explanation of mortality and CDI.  
 
Figure 29. Estimated length of stay by each day of Clostridium difficile infection in 
persons admitted to the Royal Hobart Hospital, 2007-2010. The red line shows the 
expected length of stay in hospital for each increasing day along the x-axis. The black 
line shows the difference from this length of stay for those with an infection. Only 
person’s aged ≥2 years old admitted to hospital ≥48 hours are included.  
 
Figure 29 demonstrates divergence in the expected length of stay in persons with and 
without CDI from around 80 day’s post-admission to hospital. Further exploration of 
these data indicates that only 308 persons out of 58,942 admissions remained in 








5.5.6 Prolongation of length of stay using a Cox proportional hazard model    
 
A Cox proportional hazard model was developed to estimate the hazard of discharge 
(dead or alive), comparing those with and without CDI. The proposed null hypothesis 
was that CDI does not increase the hazard of discharge. In univariate analysis, there 
was a statistically significant difference for six prognostic variables, when comparing 
those with and without CDI. The six variables were age and the DRG categories of 
digestive, neoplastic disease, mental health, kidney, and pregnancy, which were 
included in the model using a forward stepwise conditional (likelihood ratio) process. 
In contrast to the results in section 5.5.5, the influence of CDI in a proportional hazard 
model was found to be statistically significant, with acquisition of CDI significantly 
reducing the discharge hazard (i.e. it prolonged the length of stay) (Table 26 and 
Figure 30). Overall the model varied from the null hypothesis x




Cox regression model for the hazard of discharge (N= 58,942)  
 Adjusted hazard ratio 95% CI p value 
Person with CDI 
Age  
DRG Mental health (yes) 
DRG Pregnancy (yes) 
DRG Kidney (yes) 



















Note: The Diagnosis Related Group category of neoplastic disease was excluded in 
the final model as p = 0.20. CDI = Clostridium difficile infection. Age was entered as 
a continuous variable; therefore this hazard ratio represents the risk for each 
additional year of age. Only one admission with a DRG category “Mental Health” had 






Figure 30. Effect of Clostridium difficile infection on the hazard of discharge in 
persons admitted to the Royal Hobart Hospital, 2007-2010 as estimated using Cox 
proportional hazard model. Only person’s aged ≥2 years old admitted to hospital ≥48 
hours are included. 
 
 
5.5.7 Summary of results    
 
The incidence of CDI per 1000 admissions for the entire study period was 2.68. The 
annual incidence of CDI increased from 2007 to 2010. When comparing the relative 
risk of CDI by age group, persons aged 40 years and above were at greater risk of 
CDI, compared to persons less than 40 years old. The median length of stay for all 
admissions was five days. For those persons who had an episode of CDI during their 
hospitalisation, the median length of stay was 17 days. Using a multistate model, the 
mean extra length of stay due to infection was calculated to be 0.9 days and this was 
not significant. Applying a proportional hazard model on the same data, acquisition of 








5.6.1 Overview of section 
 
This study examined the incidence of CDI and whether there is prolongation of length 
of stay in hospital in persons with CDI. The challenge faced in determining the length 
of stay due to a healthcare-associated infection was to tease out the independent effect 
that the infection has on outcomes, and make necessary allowances for measured 
confounders. This was achieved using a multistate model for data analysis. The data 
from my study suggest that the incidence of CDI increased during the study period 
and that CDI did not significantly increase the prolongation of length of stay in 
hospital in persons hospitalised at the RHH during the years 2007 to 2010. The latter 
conclusion was made after undertaking data analysis using a multistate model and is 
contrary to findings of other studies. When the same dataset was analysed using a Cox 
proportional hazards model, CDI was associated with an increase length of stay. 
These conflicting findings support recent literature suggesting that data analysis 
methods that do not account for the timing of infection lead to differences and 
arguably a bias in findings when examining infections and length of stay in hospital. 
This is the first known study to examine CDI and prolongation of length of stay in 
hospital using a multistate model.  
 
 
In the discussion to follow, three distinct areas are explored. First, the incidence of 
CDI at the RHH will be discussed in the context of potential influences on that 
incidence. Second, the effect that CDI has on the prolongation of length of stay will 
be explored through comparisons between the findings of my study and the published 
literature. The significance of length of stay in relation to the economics of HAIs will 
be discussed and the implications for future research. To conclude the discussion, the 





5.6.2 Incidence of Clostridium difficile infection at the Royal Hobart Hospital 
 
The following section discusses the incidence of CDI at the RHH. Comparisons 
between the incidence of CDI at the RHH and other Australian hospitals will be 
made, in addition to examining the incidence of CDI in Europe and North America. In 
comparing data from my study to other published literature, challenges and influences 
on the rates of CDI, such as different testing methodologies and exclusion criteria will 
be explored. This section will also examine the age and its impact on the risk of CDI.  
Incidence of Clostridium difficile infection and comparisons to the literature 
 
The incidence of CDI among persons aged two years and older and hospitalised more 
than 48 hours at the RHH increased during the study period. At the same time, the 
number of persons who had a CDI episode increased. When comparing the incidence 
of CDI per 1000 admissions between 2007 and 2010, a significant increase was 
found. These findings were consistent with reports published by the TIPCU, which 
also indicate an increase in healthcare-associated, healthcare facility onset (HCA 
HFO) CDI at the RHH (B. Mitchell, McGregor, A., Brown, S., Wells, A., Wilson, F, 
2011; B. Mitchell, McGregor, A., Wells, A., Wilson, F., 2012). Importantly however, 
there are some distinctions between the reports produced by the TIPCU and the 
research conducted as part of my study. First, the TIPCU do not report on any of the 
characteristics of the persons included in their CDI surveillance, such as age, gender 
or DRG. My study has collected and analysed such data and consequently has enabled 
relative risks to be calculated – according to demographic characteristics. Second, the 
analysis of the characteristics in my study has enabled a robust comparison to the 
literature, whereas the reports by the TIPCU, limited by the data reported, do not 
provide robust comparisons. Third, reports by the TIPCU do not provide denominator 
data nor confidence intervals for individual hospitals, therefore, it is not possible to 
tell from these reports whether the increase at the RHH was statistically significant, as 
demonstrated in my study. Future reports developed by the TIPCU could be improved 





Reports from the TIPCU suggest that the increase in CDI is not isolated to the RHH. 
In Tasmania’s four acute public hospitals, there has been an increase in HCA HFO 
CDI from 1.87 per 10,000 patient care days in 2006-2007 to 3.38 per 10,000 patient 
care days in 2010-2011 (B. Mitchell, McGregor, A., Brown, S., Wells, A., Wilson, F, 
2011). The increase in CDI in Tasmania has been reported in peer reviewed literature 
confirming the results of the TIPCU (Mitchell, Ware, McGregor, Brown, & Wells, 
2011a). In comparing the incidence of CDI in Tasmania to other Australian states and 
the international literature, Mitchell et al. (2011a) highlight inconsistencies in study 
duration, denominator selection, testing effort, and testing methodology. The authors 
concluded that there is a need for national standards for CDI testing and reporting 
(Mitchell et al., 2011a). This is an important point. If HAI data are used to underpin 
infection prevention programs and strategies as discussed in Chapter 2, it is 
imperative that data are collected and reported using consistent and reproducible 
methods. Failure to do so will make the evaluation of interventions to reduce HAIs 
more challenging as it will be difficult to decipher the impact of interventions against 
the effect of issues such as changes in testing methodologies and testing effort.  
 
The incidence of CDI at the RHH appears to be higher than that reported in other 
Australian hospitals. The incidence at the RHH across the four year study period was 
3.20 per 10,000 patient days, 95% CI [2.72, 3.74]. A study examining CDI in nine 
Western Australian hospitals in 2006 found the incidence of CDI to be 1.2 per 10,000, 
95% CI [0.9-1.6] occupied bed days , however the authors note that the short study 
period and marked variations in laboratory diagnostic practices were limitations (Van 
Gessel, 2008). There are limited data with which to compare the incidence of CDI in 
Australia. However, it can be noted that the incidence of CDI at the RHH is lower 
than that reported in many CDI surveillance systems in Europe.  
 
In England, the reported rate for 2009-2010 was 3.7 per 10,000 bed days, down from 
5.5 per 10,000 bed days in 2008-2009 (Health Protection Agency, 2011a). It is 
important to note, however, that only samples from persons hospitalised for four or 
more days are reported in this figure for the English surveillance scheme. If this 
criterion were applied to my study, 25 persons would be excluded from data analysis, 




patient days. This demonstrates the importance of paying attention to exclusion 
criteria when comparing CDI data and the need for a more standardised approach 
(Freeman et al., 2010). The higher incidence of CDI is not only seen with England, 
Scotland had a reported rate of 7.6 per 10,000 occupied bed days for 2010 (Health 
Protection Scotland, 2011a) and there was a reported rate of 4.7 per 1000 admissions 
in Germany in 2007 (Gastmeier, Weitzel-Kage, Behnke, & Eckmanns, 2009). Other 
reported incidence rates of CDI in Europe include Belgium, with 1.52 per 1000 
admissions in 2010 (Viseur, Lambert, Delmée, Broeck, & Catry, 2011) and 1.8 per 
1000 admissions in the Netherlands in 2007 and 2008 (Hensgens, Goorhuis, 
Notermans, Benthem, & Kuijper, 2009). Consistent with my findings, the incidence of 




The incidence of CDI is also higher in North America, where researchers have 
reported an incidence of 22.5 cases of CDI per 1000 admissions (Loo et al., 2005). A 
more recent study in New Jersey demonstrated an increase in CDI from an annual rate 
of 3.7 per 1000 admissions in 2000 to 7.7 per 1000 admissions in 2004 (p = 0.05) 
(Tan, 2007). Increases in the incidence of CDI over the past decade have been 
reported in a number of studies from North America (Chandler, Hedberg, & Cieslak, 
2007; Kazakova et al., 2006; McDonald et al., 2006). Data on the incidence of CDI in 
Asia is limited (Ekma, Yee, & Aziz, 2012), demonstrating the increasing importance 
of this infection worldwide.  
 
Potential influences on an increasing incidence of Clostridium difficile infection 
 
In the literature review presented in this chapter, issues relating to variations in 
laboratory testing and the potential impact these have in research and surveillance 
were discussed. In the methods section I discussed the various methodologies that 
could be applied to the testing of the effects of CDI on length of stay. There are two 
important factors to be taken into account when considering whether an increase in 
the incidence of CDI is ‘real’: the testing effort and testing methodology (Mitchell, 




samples received by a laboratory are tested for CDI. This is dependent on what 
criteria are used before a test for CDI is performed. At the RHH, all diarrhoeal 
samples in hospitalised persons were tested for C.difficile during the study period, so 
this is unlikely to have played a role in the calculated increase in CDI. However, the 
process of testing for CDI can vary considerably among institutions. For example, 
private microbiology laboratories may only test for C.difficile if the test is requested. 
This has the risk of ascertainment bias and is not often accounted for in CDI 
surveillance (Freeman et al., 2010; Mitchell et al., 2011a). Testing methodology or the 
sensitivity of testing can play a role in identifying cases of CDI. This issue was 
discussed in detail in Chapter 4, section 4.2. At the RHH, the methodologies used for 
testing for C.difficile were highly sensitive and, in all situations, the laboratory tested 
for the C.difficile toxin using an assay. Therefore, the increase in HCA HFO CDI over 
time at the RHH was unlikely to have been caused by changes in testing effort or 
testing methodology. Alternatively, given the rigorous testing, there is also little 
chance of underestimation of infection in my study. 
 
 
Age and risk of Clostridium difficile infection 
 
The findings from my study indicate that the incidence of CDI increases with age, 
from 30 years old, up until the age of 90. The reason for the incidence of CDI not 
continuing to increase past 90 years of age is almost certainly an artefact of the small 
number of admission with CDI occurring in this age group in this study. Consistent 
with my study, increasing age is a well-established risk factor of CDI, if there is 
variation in the proportion of a hospitalised population that is older, this may affect 
the incidence of CDI (McFarland et al., 1990; Starr, Martin, McCoubrey, Gibson, & 
Poxton, 2003; Vaishnavi, 2009).  
 
Internationally, there are some surveillance programs that specifically focus on CDI in 
persons aged 65 years and over. The reported incidence of all CDI in this age group in 
England was 9.0 per 10,000 bed days for 2009-2010 (Health Protection Agency, 




aged 65 years and older for 2010-2011 (Welsh Healthcare Associated Infection 
Programme, 2011). In both countries, the incidence of CDI in persons aged 65 and 
over is higher than in all persons aged two years and over. The relative risk of CDI, 
comparing those aged 65 and over to those aged less than 65 years in England was 
2.27 p<0.001, 95% CI [2.20, 2.34]. The relative risks were calculated using raw data 
provided by the Health Protection Agency (Health Protection Agency, 2011a). Due to 
insufficient admission data in persons less than 65 years old from Wales, it was not 
possible to calculate risk by age in this country. The trend of a higher incidence of 
CDI in persons aged 65 and older is repeated in my study, which reports an incidence 
of 4.22 per 1000 admissions, 95% CI [3.41, 5.16] for this age group. The relative risk 
of CDI in persons aged 65 and over in my study, compared to persons less than 65 
years old is 2.42, p<0.001, 95% CI [1.75, 3.38], a similar finding to that from CDI 
surveillance in England.  
 
In my study, relative risks of CDI by age group were compared for each decade of life 
(Table 24). The groups with the highest relative risk were persons aged 40 years and 
older, compared to persons less than 40 years old. The calculated relative risk was 
4.23, 95% CI [2.56-7.00]. It was not possible to calculate the relative risk of CDI in 
different age groups for England and Wales from the available data. Nonetheless, the 
findings of my study pose the question as to whether the ‘65 and over’ age group is 
the most appropriate age group for targeted CDI surveillance because it appears that 
the risk of contracting CDI begins to increase significantly for patients as young as 40 




Noting limitations in comparing incidence of CDI, the incidence of CDI at the RHH is 
lower than that reported in most countries in the northern hemisphere, but higher than 
reports from limited Australian data. The increase in CDI at the RHH is part of a trend 
experienced internationally in recent years. These points are significant as my 




yet experience increases in CDI as have occurred in other countries. In order to better 
interpret trends and the epidemiology of CDI, the issue of variation in microbiological 
testing methodologies becomes an important issue. Differences in testing 
methodologies make comparisons intrinsically difficult and there is a need for 
standardised practice in this area both in Australia and internationally. This point is 
taken up in the recommendations section. 
 
5.6.3 Estimating the effect of Clostridium difficile infection on length of stay  
 
My study found no significant increase in the length of stay in hospital caused by CDI 
if a multistate model was used for estimation. At the time of writing, no reports of 
studies examining the prolongation of length of stay due to CDI using multistate 
modelling were found in the peer reviewed literature; however, one study did use the 
principles of managing time-dependent bias in their study (Forster et al., 2012). This 
study is explored in more detail later in this section. As no other study has explored 
length of stay and CDI using multistate modelling, limited comparisons between my 
study and others were possible. There are many studies that examine the prolongation 
of length of stay due to CDI using different approaches; these are discussed below. 
Furthermore, studies have examined length of stay caused by other HAIs using 
multistate modelling and where relevant to this discussion, they are explored.  
 
All the studies identified in the literature review presented earlier in this chapter, 
suggested that CDI contributes to a longer length of stay in hospital for patients when 
compared to people without infection. In studies that used a comparison between 
persons with CDI and those without, the difference in length of stay between the two 
groups ranged from 2.8 days to 16.1 days (Dubberke et al., 2008; Lumpkins et al., 
2008). In the majority of studies a regression model was used in examining the impact 
that CDI had on length of stay, (Ananthakrishnan et al., 2008; Bajaj et al., 2010; 
Dubberke et al., 2008; Kenneally et al., 2007; Lawrence et al., 2007; Lumpkins et al., 
2008; Nguyen et al., 2008; Song et al., 2008; Zerey et al., 2007; Zilberberg et al., 
2009). None of these studies reported on the timing of CDI infection relative to 




causality as a longer length of stay in hospital may increase the risk of CDI. Reverse 
causation ordinarily refers to situations where the outcome precedes and causes the 
exposure instead of the exposure preceding and causing the outcome (Flegal, 
Graubard, Williamson, & Cooper, 2010). 
 
 
A retrospective cohort study was undertaken in Canada to determine the effect that 
hospital acquired CDI had on length of stay and attempted to manage CDI as a time-
varying covariate (Forster et al., 2012). Only persons who had CDI that commenced 
72 hours after admission were included in the study; persons less than 15 years old 
were excluded. The authors attempted to account for the time varying nature of CDI 
onset by describing times to discharge from hospital by C.difficile status using 
Kaplan–Meier curves. The authors employed two different processes for data analysis 
to demonstrate the impact of not accounting for the timing of infection. 
First, a patient who acquired CDI had two items of data collected: the time between 
admission and acquisition of C.difficile, and the corresponding time to discharge or 
death. Acquisition of CDI was censored; therefore, median times to discharge and the 
probabilities of remaining in hospital at various endpoints could be calculated. Using 
this first method, the authors calculated the crude median length of stay by CDI status 




The second method used in data analysis in this study was the calculation of median 
times for length of stay. Only days between CDI acquisition and discharge were 
attributed to the group with CDI (Forster et al., 2012). In persons with CDI, the time 
from admission to CDI was attributed to the group that did not ever acquire CDI 
whilst in hospital. All persons who did not have CDI had all days between admission 
and discharge counted as not having CDI. The unadjusted and adjusted associations 
between CDI and time to discharge were estimated using Cox proportional hazards 
regression models (Forster et al., 2012). Using this process, CDI was still found to 
significantly decrease the hazard of discharge (i.e. increased the length of stay in 




discharge was 0.55, 95% CI [0.39, 0.70] (Forster et al., 2012). The median increase in 
length of stay attributed to CDI was six days. 
 
Although not stated as a multistate model, the authors in this study clearly used a 
process that attempted to control for the time varying nature of infection. Similar to 
my study, they demonstrated that not accounting for the time to infection could result 
in an overestimation of the length of stay attributable to CDI. However, in contrast to 
my study, even when accounting for timing of infection, they found that CDI did 
significantly increase length of stay in hospital. The findings from both Forster’s 
study (Forster et al., 2012) and mine suggest the failure to account for the time 
varying nature of infection can lead to bias, are confirmed by others. Studies have 
demonstrated the same over-estimation of effect using other HAIs as examples 
(Barnett et al., 2009; Beyersmann et al., 2008). 
 
The challenge faced in determining the length of stay due to a healthcare-associated 
infection is to tease out the independent effect that the infection has on outcomes, and 
make necessary allowances for observable confounders. This challenge can be 
addressed to some extent by using data collected from a cohort of hospitalised 
patients and either selecting a subset of infected patients or building multivariable 
statistical regression models that describe the relationship between HAI and cost 
outcomes, while controlling for other factors thought likely to affect outcomes (Katz, 
2003).
 
Such a process is called comparative attribution (Graves & Weinhold, 2006). 
All of the studies identified in the literature review informing this research used a 
comparative attribution approach. In contrast to my study however, these studies did 
not use a statistical method to control for the time varying nature of CDI in data 
analysis. Like my study, several of these used administrative data to evaluate the 
effect that CDI has on length of stay (Lesperance, Causey, Spencer, & Steele, 2011; 
Nguyen et al., 2008). In doing so, there are limitations on the amount of information 
available from administrative databases and, therefore, the ability to control for 
potential confounders. This demonstrates the need to have robust and preferably 
prospective data collection that includes influences on HAI data. These influences 
could be either characteristics of the infection itself, for example the time of infection 




for example co-morbidities. The limitations for my study and their implications are 
discussed later. 
 
One alternative to comparative attribution is direct attribution of length of stay. This 
requires an expert reviewer to assess the extra cost of each case of a healthcare-
associated infection. An example of a study using this method examined the direct 
costs of healthcare associated catheter associated urinary tract infection (CAUTI). In 
this study, researchers prospectively reviewed patient’s records and made a judgment 
on which diagnostic tests, treatments and length of stay could be reasonably ascribed 
to the episode of CAUTI (Tambyah, Knasinski, & Maki, 2002). This method has been 
criticised as being subjective and not reproducible. Accordingly, comparative 
attribution studies have been preferred by the research community (Graves et al., 
2007; McGowan, Jr., 1981). The criticism that direct attribution is subjective and not 
reproducible would only have merit in situations where definitions used were not 
clear.  
 
The multistate models used in my study and that of others (Bajaj et al., 2010;  Barnett, 
Graves, Rosenthal, Salomao, & Rangel-Frausto, 2010; Beyersmann et al., 2006; 
Beyersmann et al., 2009; Graves et al., 2010), do not account for variables such as co-
morbidity. This is a limitation of multistate models. Further, comparisons between 
regression models such as Cox proportional hazards and multistate models need to be 
undertaken with some caution, as regression models may account for confounders that 
multistate models do not consider. The issue of not adjusting for other variables such 
as co-morbidity in a multistate model may not necessarily be relevant to all HAIs.  
 
5.6.4 Contribution of length of stay as part of the economics of healthcare 
associated infections  
 
There are different methods used to evaluate the economic cost of HAIs (Appendix I), 
the accountants’ model and the economists’ model. The accountants’ model for 
determining the cost of HAIs is to count fixed and variable costs. According to 




informing decisions as the assumption of an accountant model is that by reducing or 
eradicating a specific infection, a fixed figure could be saved. This model does not 
account for the increased investment associated with reducing infections and fails to 
consider what costs actually change with infections where many fixed costs remain 
(N. Graves, Halton, K., Jarvis, W., 2009). An economist’s approach in evaluating the 
cost of HAIs is supported by the argument that the majority of the costs associated 
with hospital care are fixed (Plowman, 1999; Roberts et al., 1999). Therefore, in 
describing how costs change in relation to HAIs, it is important to demonstrate the 
number of bed days caused by HAIs (N. Graves, Halton, K., Jarvis, W., 2009). A 
decision on how these additional bed days will be utilised can then be considered. For 
example, the consumables may be reduced with a reduction in HAIs. The capacity 
gains associated with reduction in HAIs are valuable as this creates an opportunity for 
savings or for redeployment of resources. The redeployment of resources could be 
used for tasks such as elective surgery and, in turn, cause other variable costs to 
increase (N. Graves, Halton, K., Jarvis, W., 2009). In using either the accountants’ or 
economists’ model for evaluating costs of HAI, a fundamental issue is that an 
accurate assessment of the prolongation of length of stay due to the infection must 
occur.  
 
Reviews examining the economic costs of CDI have primarily focussed on studies 
that have evaluated costs through the eyes of an accountant, primarily because studies 
included in these reviews have used this approach (Dubberke & Wertheimer, 2009; 
Ghantoji et al., 2010). Both of these reviews acknowledged this limitation and called 
for a more accurate measure of the cost of CDI. To address this issue, an economic 
computation simulation model was developed by McGlone et al. (2011) to evaluate 
the costs of CDI from three different perspectives: hospital, third party payer, and 
societal. The hospital perspective determines the opportunity cost of lost bed days 
from extended length of stay and considered a model proposed by Graves (2004). The 
third party payer perspective considers only direct costs, whilst the societal 
perspective includes both direct and indirect costs. As such, the study by McGlone et 
al. (2011) was the first known study to determine the cost of CDI from different 
perspectives. Results from this study suggest that the cost of CDI ranges from 




2011) . These figures are consistent with previous reports and suggest that, regardless 
of severity and the method used to evaluate cost, there are significant costs associated 
with CDI (Ananthakrishnan et al., 2008; Dubberke & Wertheimer, 2009; Ghantoji et 
al., 2010; Zerey et al., 2007).  
 
The use of accurate methods to determine length of stay due to CDI and HAIs more 
generally, combined with specific economic models used to evaluate cost, can assist 
decision makers in formulating informed choices about investing in infection 
prevention and control prevention activities. The use of direct costs may be valuable 
in helping healthcare managers with insurance related issues and reimbursement 
decisions. These reimbursement decisions may evolve, as is the current trend in the 
United States, where there has been a decision not to reimburse for certain HAIs 
(Rosenthal 2007; Stone et al., 2010). Finally, having accurate information on the cost 
of CDI and other HAIs may assist manufacturers and drug companies in their decision 
to invest in products, and the choice of price for these products and treatments 
(McGlone et al., 2011). All these points highlighted in this paragraph demonstrate the 
need for accurate data to influence and shape infection prevention and control 
programs and strategies as discussed in Chapter 2.  
 
Using a multistate model for data analysis, the findings of my study suggest that CDI 
has little impact on length of stay in hospital, noting my study did not adjust for other 
variables in this model. As these findings contradict published literature, it can be 
argued that this work is not supportive of infection prevention and control activities. 
On the contrary, I believe my study aims to present data to policy makers that is 
credible and able to withstand critical examination. Overinflated suggestions of the 
impact that CDI has on length of stay may have short-term benefits; however once it 
becomes clear that these data have limitations, there is a risk of loss of credibility in 
the broader field of infection prevention and control research. In turn, this may have 
effects for future investment in infection control activities. The use of sound data 
analysis techniques and study design that account for time-dependent bias are 
required for studies that evaluate the impact that HAIs have on length of stay in 




CDI has on length of stay and does not consider the human cost, which is difficult to 
quantify. The impact the CDI has on mortality was found to be significant, as 
described the second study of this thesis. 
 
5.6.5 Implications for future studies examining length of stay   
 
Various statistical models were discussed in the data analysis section 5.4.5. One 
model, suggested as optimal, Figure 22 on page 174 of this thesis, was not viable 
because code for this data analysis technique had not yet been developed in R. 
Further, it became clear after data collection that the infection cessation data for all 
admissions with CDI in the study was incomplete. Even if this model was available, 
given that my study only had data on CDI cessation from 72 persons, the value in its 
use could be questionable. This model accommodated the possibility of an infected 
person returning to a susceptible state upon infection cessation prior to discharge from 
hospital. This is important as in many instances of HAIs there is little or no immunity. 
Therefore, a person who recovers from an infection may be susceptible to being 
infected again. Five people in the current study had more than one infection, although 
these occurred during different admissions to hospital so did not pose an issue with 
respect to this point. Further, research examining the prolongation of length of stay 
due to a HAI typically focuses on one infection, such as CDI and the current 
multistate models do not account for multiple or concurrent infections during the 
same admission period.  
 
Future studies may wish to examine the impact of more than one infection in a study 
cohort. For this to occur, a model not only needs to allow a person who had an 
infection to return to a susceptible status again, but also allow for the possibility of 
other or concurrent healthcare-associated infections. Specific patient groups such as 
those who are severely immuno-compromised are at a greater risk of infection, 
therefore multiple infections are possible. There were 30 instances where CDI ceased 
prior to discharge that could be identified in my study, equating to 286 bed days, 
These 30 instances are considered an underestimate as data on infection cessation was 
only available for 18
 




it is possible that up to 762 patient days across the entire study period, were attributed 
to an ‘infected status’ when the person may in fact have recovered from CDI. 
Although small relative to the total number of bed days under observations, it does 
underline the potential for improvement in the multistate modelling techniques used. 
Further, with improvements in data aggregation and surveillance programs collecting 
data on more and more HAIs, the need for data analysis to consider this model is 
becoming more important. As datasets become larger through increased surveillance 
and improved data aggregation, the effect of using substandard methods for data 
analysis will compound bias further.  
 
A future consideration for the development of future multistate models is the need to 
adjust for other variables, such as co-morbidity, in the model. This is a limitation of 
current multistate models. Until such time, direct comparisons between regression 
models and multistate models should be undertaken with caution, as the methods used 
analyse the data differently. To the best of my knowledge, this point has not yet been 
articulated in the peer reviewed literature. Paradoxically, the use of multistate models 
does account for the timing of infection and the potential bias this can lead to when 
not managed in data analysis.  
 
My study has contributed to testing relatively new statistical methods, namely 
multistate modelling and in doing so has proposed that these models can be further 
enhanced through an ability to account for persons returning to a non-infective status 





My study does have some limitations. First, the inability to identify the infection 
cessation date on all admissions that had CDI was a limitation. This did not affect the 
results however, as the multistate model used for data analysis did not require this 
information. Further, the study used a novel approach to determine infection cessation 




discussed in section 5.4.3. In deciding to cease contact precautions, staff members 
from the RHH Infection Prevention and Control Unit examined each person with CDI 
and the decision was made after consultation with the Director of the unit. Therefore, 
there was a level of consistency in the data. Although infection cessation data were 
not required for data analysis, if the multistate model included the timing of infection 
cessation, as proposed in Figure 22 (Model B), there may be value in using the 
approach taken in this study to collect these data.  
 
In my study, variables such as age and co-morbidities were not included in the 
multistate model. As previously discussed in this chapter, this issue is not unique to 
this study but is a broader limitation of using multistate modelling for data analysis.  
 
A further limitation in this study is ascertainment bias, caused by approaches taken in 
laboratory testing and therefore subsequent identification of admissions with CDI. 
The effect of ascertainment bias in this study is low due to two main points. First, the 
RHH microbiology department tested all diarrhoeal samples from hospitalised 
patients for C.difficile. Second, all the methods employed by the RHH microbiology 
department during this study period are highly sensitive.  
 
In this study, the date of infection commencement was obtained using the collection 
date of faeces subsequently found to be positive for C.difficile. It is possible that 
persons with CDI did not have a faecal specimen taken immediately, although there is 
no way of quantifying this. If this has occurred, the infection commencement dates in 
some persons with CDI may have been earlier therefore extending the time a person 
had infection. The effect this would have in calculating the prolongation of length of 
stay is unknown. This limitation is not unique to this study.  
 
Finally, this study only examined admission with CDI occurring in persons 
hospitalised for more than 48 hours, i.e. healthcare associated, healthcare facility 




study, for example persons who acquired C.difficile from a recent admission or visit 
to hospital and subsequently succumbed to infection. Therefore, we cannot determine 
the wider impact that HCA CDI may have on length of stay. Paradoxically, the use of 
data from admissions with HCA HFO CDI in also a key strength of this study, as this 
study had a very succinct and clear dataset. Further, interventions can be put in place 
to reduce the incidence of healthcare associated, healthcare facility onset CDI; 
therefore, the findings of this study are relevant when determining the cost benefit of 
any intervention given the closed population.  
 
5.7 Recommendations  
 
From the findings of this study, a number of recommendations can be developed. Not 
accounting for the timing of infection can result in spurious results i.e. an 
overestimation of the prolongation of length of stay due to CDI. With this in mind, 
several recommendations are made for future research examining CDI and HAIs: 
1. Future research examining the length of stay caused by a healthcare-associated 
infection must take into account the timing, including both onset and end of 
infection.  
2. Data analysis must account for the time varying nature of infection. 
 
Interventions aimed at reducing or preventing healthcare-associated infections are 
often implemented for two reasons: to improve the quality of care and to improve 
efficiency (reduce cost). As resources in healthcare are limited, a decision to 
implement an intervention to reduce a healthcare-associated infection should include a 
cost benefit analysis. Currently, the data used to inform a decision may not be as 
accurate or complete as possible and the limitations of data analysis techniques need 
to be understood. The following recommendation is made: 
3. Policy makers and healthcare managers must carefully critique the data that 
underpin decisions relating to interventions that have a potential cost benefit. 




undertake this, healthcare epidemiologists and biostatisticians should be 
employed to assist in analysing and interpreting data.  
 
In the methods, potential multistate models were identified but could not be used as 
specific codes for these models have not yet been developed. In considering a 
multistate model that examines HAIs and length of stay, there are infections other 
than CDI that result in a person moving back to susceptible status once an infection 
has ceased. Future studies may wish to examine the effect of more than one infection 
on length of stay in a given timeframe. In both these examples, there is a need for a 
multistate model to be able to return to a susceptible state. Additionally, in the 
discussion section of this chapter, a further limitation of multistate models, not yet 
explored in the literature was identified. This limitation refers to the current inability 
of these models to adjust for other variables, such as co-morbidity. Noting the 
limitations of multistate models described in the paragraph, the following 
recommendations for future research and development are now provided. 
4. A code for the following multistate model needs to be developed to better 
reflect how healthcare-associated infections affect hospitalised patients.  
 
Figure 31. Suggested multistate model for future studies examining length of stay due 
to a healthcare associated infection. Identical figure presented in section 5.4.5 but is 
provided again in this section for clarity.  
5. Multistate models that have the capacity to adjust for variables such as co-








This chapter presented the results and discussed findings from the third piece of 
research for this thesis. The research questions addressed in this chapter reported both 
the incidence of CDI at RHH over a four year period and the potential impact of CDI 
on prolongation of length of stay in hospitalised persons. The calculated incidence 
was higher than other published Australian data but lower than internationally 
reported incidence. This study is, to the best of the author’s knowledge, the first to use 
multistate data analysis techniques to determine the potential prolongation of length 
of stay due to CDI. From the findings, it can be inferred that Clostridium difficile 
infection does not significantly contribute to a longer hospital length of stay, (p = 
0.51). Conversely, the influence of CDI in a proportional hazard model was found to 
be statistically significant, with acquisition of CDI significantly reducing the 
discharge hazard (p<0.001). These findings have a number of implications for future 
researchers exploring the consequences of HAIs and for senior healthcare managers 
responsible for policy and practice in this area. In essence, the findings of my study 
demonstrate limitations of both data collected and data analysis techniques currently 
available. Multistate models may manage the issue of time-dependent bias, but there 
is further refinement still required in these methods. Nonetheless, in this chapter, a 







Chapter 6: Conclusion 
 
6.1 Introduction to the chapter 
 
There were two overarching aims for this thesis: to explore the epidemiology of two 
serious HAIs and to examine the methodological influences on reliable and valid HAI 
data collection and analysis. This final chapter summarises the key findings of the 
three studies addressing these aims. A model is presented which elaborates influences 
on reliable and valid HAI data and implications for use of the proposed model are 
discussed. Finally, contributions made as a result of this work are presented. 
 
6.2 Findings from the studies 
 
This section summarises the key findings of the three studies presented in this thesis. 
Through an exploration of the epidemiology of SAB and CDI and the examination of 
mortality and prolongation of length of stay associated with CDI, key methodological 
influences on reliable and valid HAI data collection and analysis were identified. 
Additionally, a model that summarises these influences is proposed and the 
implications for this model are discussed. The purpose of this discussion is to elicit 
the themes relating to the burden of disease from SAB and CDI, and the potential 
methodological influences on reliable and valid HAI data collection and analysis – a 
foundation of many HAI prevention activities. 
 
The burden of healthcare associated infections  
 
The studies presented in this thesis clearly identify a proportion of the burden that 
HAIs pose in an Australian setting. For SAB, the burden of HA SAB remains high 
with 41.6% of SAB being HA. The findings from the first study indicate that of these 
HA cases of SAB, an intravascular device was implicated in some way in 55% of 




management, an argument supported in the literature (P. Collignon, Dreimanis, D., 
Beckingham, W., Roberts, J., Gardner, A, 2007; Maki, et al., 1991). For CDI, the 
burden of this infection is demonstrated in the findings from the second study, 
suggesting that CDI is associated with increased mortality. However, the findings 
from the third study call into question the extent to which length of hospital stay is 
influenced by CDI.  
 
The second aim of the thesis was to examine methodological influences on reliable 
and valid HAI data collection and analysis. Through the three studies, four broad 
influences on reliable and valid HAI data were identified: ‘host’, ‘definitional’, 
‘environmental’ and ‘data analysis’. These four influences will now be explored in 
more detail. 
 
Host influences  
 
The term ‘host’ has been assigned to describe individual intrinsic patient risks that 
may in turn influence the interpretation of incidence data, because they are potential 
confounders. From the studies conducted three host influences were identified: age, 
sex, and co-morbidities.  
 
In the study examining SAB, age was identified as a risk factor. This finding has been 
supported by other studies examining SAB (Asgeirsson, et al., 2011; Laupland, et al., 
2008; Morin & Hadler, 2001; J. Turnidge, Nimmo, G., Pearson, J., Gottlieb, T., 
Collignon, P.,  Australian Group on Antimicrobial Resistance, 2007) and was also 
identified in the third study in which the risk of CDI increased with age. In the first 
study, gender was identified as a risk factor with males at greater risk of SAB than 
females. This finding has been reported in other studies (Easton, 2010; Huggan et al., 
2010). The second study also identified other important ‘person specific’ issues that 
influenced outcomes. In this study, co-morbidities were identified as playing an 




morbidity data is something that should be considered for future HAI surveillance. 
The ability to control for co-morbidities permits an assessment of the independent 
effect of HAIs and allows for the potential of risk adjustment. Where co-morbidity 
data are not available, this should be noted when interpreting results. 
 
These examples demonstrate that there are individual (host) factors that can influence 
the likelihood of acquiring and surviving a HAI. The need to measure and adjust for 
patient risk in HAI surveillance has been previously identified in the literature (Haley, 
1995). In targeted research, the influence of these host factors is often explored as a 
matter of course. However, in HAI surveillance programs, such data are not always 
collected or reported, as was evidenced through the three literature reviews presented 
in this thesis.  
 
Definitional influences  
 
‘Definitional’ is the broad term used to describe factors such as case definitions and 
laboratory testing. Case definitions, comprising inclusion and exclusion criteria, have 
been recognised as important elements in surveillance programs. 
 
In the first study examining SAB, 42% of all 214 cases of SAB were HA. Of these 
HA cases of SAB, 68% occurred in people hospitalised for more than 48 hours, whilst 
32% were hospitalised less than 48 hours but had other clinical criteria which resulted 
in them being defined as HA. Therefore, in cases where there were no criteria other 
than timeframe used to define cases of SAB, approximately 30% of HA SAB cases 
would not be identified and could in turn be incorrectly identified as CA. The practice 
of using timeframes to define cases of HA SAB is used in both surveillance and 
research, as identified in the SAB literature review in Chapter 3. This finding 
demonstrates how the application of different case definitions can cause significant 
variation. The impact of case definitions was also identified in the second study of 





The second study identified that CDI was associated with mortality at a relatively late 
stage. I argued that the removal of cases of CDI occurring within eight weeks of the 
previous case from data analysis may explain this (Chapter 4, section 4.7.3). The 
removal of cases occurring within eight weeks of the previous case is common in CDI 
surveillance as identified in the CDI literature review in Chapter 4 and is consistent 
with international CDI surveillance definitions. Nonetheless, findings from this 
second study raise the question that even accepted and commonly used case 
definitions may influence results.  
 
Making comparisons is challenging, where case definitions vary, as demonstrated in 
the third study. In this study, admissions with healthcare associated, healthcare facility 
onset CDI were identified, i.e. infections that commenced more than 48 hours after 
admission. This surveillance definition of healthcare associated, healthcare facility 
CDI is internationally accepted and was the basis for the calculation of the incidence 
of CDI. In comparing the incidence of CDI in this study with the literature, it was 
found that not all CDI programs use the same case definition. For example, if the 
same case definition criteria were applied to data in this study as they are in England, 
persons would have been excluded from data analysis, leading to a reduction in the 
incidence of CDI. This demonstrates the importance of carefully monitoring exclusion 
criteria when comparing CDI data. It also demonstrates the need for a more 




The third study, which explored the incidence of CDI and the prolongation of length 
of stay due to CDI, identified influences that differing data analysis methods have in 
the calculation of any prolongation of length of stay associated with a HAI. The major 
issue faced in studies examining length of stay and HAIs is controlling for the time-
dependent nature of infections. Relatively new data analysis techniques such as 




When conducting this study, I identified that multistate models have limitations. One 
limitation that was current at the time of writing was that these models could not 
adjust for possible additional risk, such as co-morbidities. Until this can occur, direct 
comparisons between regression models and multistate models should be undertaken 
with caution because these methods analyse data differently. In this study, it was 
possible to demonstrate different results using different data analysis techniques 
applied to the same data—each had advantages and disadvantages. Importantly, the 
results between the two different techniques—namely, the prolongation of length of 
stay due to CDI—varied considerably. 
 
Environmental influences  
 
The term ‘environmental’ is used to encapsulate other factors identified in the three 
studies that may influence the reliability and validity of HAI surveillance data. The 
study examining CDI and mortality identified notable differences in exposure to 
antibiotics between persons who had and did not have CDI. This supported the 
argument that antibiotics influence the likelihood of acquiring CDI. Such an argument 
is supported by the wider literature suggesting antibiotics are an important risk factor 
for CDI (Bignardi, 1998; J. Pépin, Saheb, N., Coulombe, M., Alary, M., Corriveau, 
M., Authier, S., Leblanc, M., Rivard, G., Bettez, M., Primeau, V., Nguyen, M.,  
Jacob, C., Lanthier, L, 2005; Polgreen, et al., 2007; Thomas, et al., 2003). 
 
 
6.3 A model displaying influences on reliable and valid healthcare 
associated infection surveillance 
 
Using the three studies presented in this thesis, this section brought together 
influences on reliable and valid HAI data. The four broad themes that arose were 
identified, namely: host, definitional, data analysis, and environmental. A model that 











Figure 32. Model demonstrating the influences on reliable and valid healthcare 
associated infection surveillance data. HAI = healthcare associated infection. 
 
The four themes identified and discussed above have similarities to the areas of 
concern proposed by Masterton (2000) in which he suggested that there are three 
areas of dilemma in surveillance programs: laboratory, organism source, and patient 
selection. ‘Laboratory’ describes variables such as laboratory performance and quality 
assurance. ‘Organism source’ refers to clinical factors, environmental factors, repeat 
isolates and organism species. ‘Patient selection’ refers to inclusion and exclusion 
criteria and community versus hospital acquisition. The model proposed in Figure 32 
builds on that proposed by Masterton (2000). Further, in describing the National 
Nosocomial Infection Surveillance System of the Centre for Disease Control and 
Prevention (R. Gaynes, Richards, C., Edwards, J., Emori, G., Horan, T., Alonso-
Echanove, J., Fridkin, S., Lawton, R., Peavy, G., Tolson, J.., National Nosocomial 
Infection Surveillance (NNSI) System Hospitals, 2001), it has been suggested that a 
successful system must satisfy three requirements, each of which have been addressed 
in the model proposed in this thesis. A successful system must: 
1. Have a clear purpose; 
2. Use standard definitions, data fields and protocols; 
3. Use an institution (specialist unit) to standardise definitions, assess for quality, 
risk adjust and interpret and disseminate data (R. Gaynes, Richards, C., 




R., Peavy, G., Tolson, J.., National Nosocomial Infection Surveillance (NNSI) 
System Hospitals, 2001). 
 
The four methodological influences on HAI data presented in this section—as a result 
of the three studies conducted—will require further refinement and validation by 
future researchers and commentators. However, the model proposed presents a 
method for articulating the major influences on the reliability and validity of HAI 
data. The potential implications of this model will now be discussed. 
 
 
Implications for a model describing the importance of reliable and valid healthcare 
associated with infection surveillance data 
 
In Chapter 2, surveillance was described as the collection, collation, analysis and 
dissemination of data in order to improve health. Improvements in the surveillance of 
HAIs, such as more surveillance and improved processes and definitions have been 
called for, so that the size, burden, and understanding of the effect of HAIs can be 
improved. Improving the rigor of surveillance of HAIs makes it possible to provide 
more valid and reliable information, to design and plan future programs, as well as 
provide a measure for evaluating interventions. The biopsychosocial framework for 
infection prevention and control proposed in Chapter 2 relies on the use of HAI data 
underpinned by HAI surveillance. If the role of HAI surveillance is deemed so 
important that it is identified as a critical element for infection prevention, then it 
would be logical to assume that an understanding of the influences on reliable and 
valid HAI—as proposed in Figure 32—is also important. To the researcher’s 
knowledge, no one has yet arranged the influences on reliable and valid HAI data in a 
model.  
 
There are four main implications for displaying the influences on HAI data, as 




influences on HAI data permits infection control professionals, researchers and 
planners of surveillance to consider how these elements can be best managed when 
designing a surveillance program or piece of research. 
 
Second, when attempting to compare existing surveillance data or HAI research, the 
model can serve as a prompt for potential factors that need to be considered. Indeed, 
this concept can be extended further to the case of public reporting. The general 
public and media, who are unaware of the complexities that surround HAI data 
collection and analysis, should be provided with the necessary information to 
demonstrate that data are not always comparable, and to inform them of the reasons 
for this. Consequently, for professionals responsible for producing reports that are 
made publically available, the model may serve as a useful reference tool for 
informing the public about reports’ potential limitations. 
 
Third, as described in Chapter 2, HAI data are often used within a safety and quality 
framework to drive improvements in practice, and reduce the risk of HAIs. The data 
can also be used in performance management, with targets set for specific HAIs 
(Duerden, 2009). For those health planners responsible for developing and monitoring 
HAI as part of a performance management framework, it is vital, at both the design 
stage and monitoring stage, that limitations of the data are articulated and appreciated. 
For example, there is no credibility in holding hospital executives accountable for 
apparently excessive levels of HAIs that are beyond their control due to the 
application of inconsistent case definitions. 
 
Finally, by considering influences on reliable and valid HAI data, risk adjustment may 
be possible to make the data more comparable, as happens in surgical surveillance 
undertaken by the VICNISS coordinating centre (Russo et al., 2006). Further, 
considering as many influences as possible on the data may enable their relative 





The value of surveillance in infection control programs is crucial, as was discussed in 
detail in Chapter 2. Importantly, regarding the issue of reliability and validity of data, 
healthcare professionals must also perceive value in the data. They are more likely to 
rely on data when making decisions and will hopefully alter their behaviour in order 
to reduce the risk of HAIs (R. Gaynes, Richards, C., Edwards, J., Emori, G., Horan, 
T., Alonso-Echanove, J., Fridkin, S., Lawton, R., Peavy, G., Tolson, J.., National 
Nosocomial Infection Surveillance (NNSI) System Hospitals, 2001). 
 
6.4 Thesis contribution 
 
This thesis has made four significant contributions to the broader understanding of 
HAIs:  
 First, a revised framework for HAI prevention that incorporates the role of 
surveillance in infection prevention and control activities was proposed in 
Chapter 2.  
 Second, the first known Australian study to capture and analyse data from all 
cases of SAB at a jurisdictional level was undertaken, allowing for an accurate 
representation of the incidence of SAB. As a result, the burden of HA SAB at 
a population level was articulated, in addition to being able to identify the 
potential for under reporting of SAB where data are only collected from public 
hospitals. This has implications not only for SAB but for the design of future 
national HAI surveillance programs in Australia.  
 Third, a study examining mortality and CDI was undertaken in the southern 
hemisphere for the first time in 15 years. The findings suggested CDI is 
associated with increased mortality and the findings have the potential to 
influence local, state and national policy direction in the area of CDI 
prevention by demonstrating the impact that CDI may have on hospitalised 
individuals.  
 Fourth, the third study examining CDI and its impact on prolongation of 
length of stay in hospitalised persons, is, to the best of the author’s knowledge, 
the first to apply multistate data analysis techniques to CDI data. Findings 




techniques produce significantly different results. These findings have a 
number of implications for future researchers exploring the consequences of 
HAIs and length of stay more broadly. In conducting this study refinements 
for multistate models were proposed to enhance the reliability of data analysis. 
Finally, by conducting three studies, influences on reliable and valid HAI data 
collection and analysis were articulated and a new model proposed that 





The two overarching aims for this thesis were to explore the epidemiology of two 
serious HAIs and to examine methodological influences on reliable and valid HAI 
data collection and analysis. At the beginning of this thesis, I discussed the emergence 
of HAIs as a safety and quality issue, explored strategies to reduce the effect of HAIs 
and examined the role of surveillance in HAI prevention and control activities. In this 
thesis I proposed a revised framework that incorporated the role of surveillance into a 
biopsychosocial framework for infection prevention and control. Three studies, which 
examined two HAIs, were presented in Chapters 3 to 5. Each of the three studies had 
objectives and research questions related to the aims of the thesis.  
 
The first study explored the epidemiology of SAB using a descriptive, observational, 
population-based study design. This is the first known Australian study to capture and 
analyse data from all cases of SAB at a jurisdictional level and represent this as an 
incidence. The findings of this study can be summarised into four themes: 
 First, the incidence of SAB at a population level could be accurately 
determined for the first time in Australia.  
 Second, a large proportion of HA SAB was associated with intravascular 




 Third, case definitions for HA SAB influence detection, for example, if only 
timeframe from admission to hospital and infection onset are used to 
determine cases of HA SAB, approximately 30% of HA SAB will be 
incorrectly classified as CA SAB.  
 Fourth, that a measurable proportion of SAB were identified in private 
hospitals and these fall outside the scope of almost all SAB surveillance 
programs in Australia.  
  
The second and third studies were conducted on CDI. Results from the second study 
indicated that CDI was associated with increased mortality a considerable time after 
initial infection commencement, although the exact relationship between infection and 
subsequent mortality is still not clear; this was the first known study in 15 years to 
examine CDI and mortality in the southern hemisphere.  
 
The third study examined the incidence of CDI and prolongation of length of stay in 
hospitalised patients. This study is, to the best of the author’s knowledge, the first to 
use multistate data analysis techniques to determine the potential prolongation of 
length of stay due to CDI. In doing so, the calculations suggest that CDI does not 
significantly contribute to a longer hospital length of stay. Conversely, when other 
methods for data analysis were used on the data, a significant increase in length of 
stay was found for people infected with C.difficile. These findings have a number of 
implications for future researchers exploring the consequences of HAIs and for senior 
healthcare managers responsible for policy and practice in this area. In essence, the 
findings demonstrate the limitations of both data collected and data analysis 
techniques currently available. Multistate models may manage the issue of time-
dependent bias, but there is further refinement still required in these methods. 
Nonetheless, in this chapter, a new model for data analysis was proposed to further 
enhance the reliability of data. 
 
The three studies each provided a significant and unique contribution to the literature, 




these studies, as well as new epidemiological knowledge, influences on reliable and 
valid data collection and analysis were identified. A new model summarising 
influences on reliable and valid HAI surveillance has been presented in this chapter. 
Overall, this thesis made a number of significant contributions to the broader 
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Appendix A  
Sources of infectious agents in the chain of infection model 
 
Exploring endogenous transmission further, it has been shown that persons with nasal 
carriage of Staphylococcus aureus have an increased risk of HAI caused by this 
organism, compared to persons without or with low level carriage (Kluytmans et al., 
1995; Luzar et al., 1990; Nouwen et al., 2006). Further, more than 80% of HAIs 
caused by Staphylococcus aureus are thought to be endogenous (von Eiff et al., 2001; 
Weinstein, 1959; Wertheim et al., 2005).  
 
The role of other source of infections, namely from environmental or other inanimate 
objects remains less clear, however there is increasing evidence of its role in infection 
transmission. From the data available, it has been suggested that contaminated 
surfaces can lead to HAIs indirectly (Weinstein & Hota, 2004). This is possible  as 
microorganisms can survive for long periods in the environment (Kramer, 2006; 
Wagenvoort, 2011) and unless  processes such as cleaning are performed, these 
microorganisms can persist in the healthcare environment and hence pose a source of 
infection, for example, via the hands of healthcare workers, as described earlier in this 
section (Barker, Vipond, & Bloomfield, 2004; Bhalla et al., 2004; Dancer, 2011; B. 
Mitchell, Wilson, F., McGregor, A., Dancer, S. , 2012). To demonstrate this point 
further, studies have shown that persistence of organisms in the environment leads to 
an increased risk of acquiring an infection in a patient who is admitted to a room 
previously occupied by a patient colonised or infected with that particular organism 






Appendix B  
Further detail on standard precautions and their application 
 
Standard precautions are used because: 
 people may be placed at risk of infection from others who carry infectious 
agents; 
 people may be infectious before signs or symptoms of disease are recognised 
or detected, or before laboratory tests are confirmed in time to contribute to 
care; 
 people may be at risk from infectious agents present in the surrounding 
environment; and 
 there may be an increased risk of transmission associated with specific 
procedures and practices. 
(National Health and Medical Research Council, 2010) 
Standard precautions consist of hand hygiene, the use of personal protective 
equipment, the safe use and disposal of sharps, routine environmental cleaning and 
reprocessing of reusable medical equipment and instruments, respiratory hygiene and 
cough etiquette, aseptic non-touch technique, waste management and appropriate 
handling of linen. Standard precautions should be used in the handling of blood, all 
other body substances, secretions and excretions (excluding sweat), non-intact skin 







Appendix C  
Examples of applying transmission based precautions 
 
Contact precautions refer to processes that should be implemented when there is a risk 
of direct or indirect contact with an infectious agent, such as MRSA. Droplet 
precautions are intended to prevent transmission of infectious agents that are spread 
through close respiratory or mucous membrane contact with respiratory secretions, 
whilst airborne precautions prevent transmission of microorganisms that remain 
infectious over time and distance when suspended in the air (National Health and 
Medical Research Council, 2010). The modes of transmission vary by type of 
organism; some organisms, such as influenza, can be transmitted by more than one 
route (National Health and Medical Research Council, 2010). If the agent is 
transmitted to another person, infection can result. The table below provides examples 
of applying contact, droplet, and airborne precautions. These three processes fall 
under the umbrella term called ‘transmission based precautions’.  
 
Type of transmission 
based precaution 
Examples of processes that need to be applied 
Contact precautions* 1. When working with patients who require contact 
precautions. Contact precautions include performing hand 
hygiene; use of gloves and gown upon entry to the patient-
care area; ensuring clothing and skin do not contact 
potentially contaminated environmental surfaces; and 
removing gown and gloves and performing hand hygiene 
before leaving the patient-care area. 
2. Use patient-dedicated equipment or single-use non-critical 
patient-care equipment. 
3. If common use of equipment for multiple patients is 
unavoidable, clean the equipment and allow it to dry 
before use on another patient. 
4. A single-patient room is recommended for patients who 
require contact precautions.  




reduce the risk of environmental contamination.  
Droplet precautions* 1. When entering the patient-care environment, put on a 
surgical mask. 
2. Patients on droplet precautions should be placed in a 
single-patient room. 
3. When transfer of a patient on droplet precautions within or 
between facilities is necessary, the patient should wear a 
mask while they are being transferred and to follow 
respiratory hygiene and cough etiquette. 
Airborne precautions* 1. Use of P2 respirators (mask). Mask should be applied 
before entering the patients’ room and removed upon 
leaving the room.  
2. Patients on airborne precautions should be placed in a 
negative pressure room or in a room from which the air 
does not circulate to other areas.  
3. When transfer of a patient on airborne precautions within 
or between facilities is necessary, the patient should wear a 
mask while they are being transferred and follow 
respiratory hygiene and cough etiquette. 
Note: Adapted from “Australian Guidelines for the Prevention and Control of 
Infection in Healthcare,” by National Health and Medical Research Council. 
Copyright 2010 by the National Health and Medical Research Council. *Standard 
precautions always apply, in addition to the examples listed in the table. Transmission 
based precautions are applied to patients suspected or confirmed to be infected with 
agents transmitted by the contact, droplet or airborne routes. A person with an 
infection can have a combination of transmission based precautions applied to prevent 
the transmission of infection. For example contact and droplet precautions can be 






Appendix D  
Relating the biomedical model to infection control 
Concept Infection control example 
The concepts of health and illness are seen to exist 
separately. 
HAI and the interventions made by health and social care professionals are seen as existing in isolation; they are 
not perceived as impacting upon each other. 
Disease or infection is external to the body and is not the 
result of an individual’s behaviour. 
The behaviour of health and social care professionals has no impact upon the risk of cross infection. 
Individuals have no responsibility to ensure the 
maintenance of their own or others’ health and wellbeing. 
Despite failing to adopt standard precautions, health and social care professionals are not responsible for the 
consequences of such a failure. 
Although it is acknowledged that they exist, the mind and 
body are perceived as being separate, with neither having 
consequences for the other. 
A health professional who is experiencing stress will demonstrate a greater propensity toward becoming 
cognitively economic and unrealistically optimistic in his/her perception of the importance of standard 
precautions. Despite this, there will be no impact upon his/her behaviour. Therefore, a failure to carry out 
standard precautions according to a biomedical perspective is not a consequence of the way a health professional 
thinks, but simply a physical action. 
Psychosocial factors have no part to play and healthcare 
intervention should centre around the physical aspects in 
isolation. 
HAI has nothing to do with how health and social care professionals think or the social context within which they 
are practising. Cross infection is simply a consequence of physical factors, such as the cleanliness of equipment 
or the environment. 
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Appendix F  
Percentage of population by age group and region in Tasmania 
 
Age group Region 
South North North-west 
0-14 19.10% 19.43% 20.07% 
15-24 13.41% 13.32% 12.35% 
25-39 18.55% 17.62% 17.13% 
40-64 34.25% 33.99% 34.30% 
65-84 12.79% 13.72% 14.21% 
>85 1.89% 1.92% 1.94% 
Note: Adapted from “Tasmanian State and Regional Indicators” by Australian 










Appendix G  
Algorithm used to match ICD-10-AM codes against Charlson co-morbidity index 
Condition Weight ICD-10-AM Codes 
Acute myocardial infarction 1 I21, I22, I252 
Congestive heart failure 1 I50 
Peripheral vascular disease 1 I71, I790, I739, R02, Z958, Z959 
Cerebral vascular accident 1 I60, I61, I62, I63, I65, I66,G450, G451, G452, G458, G459, G46,I64, G454, I670, I671, I672, I674, I675, I676, I677 
I678, I679, I681, I682, I688, I69 
Dementia 1 F00, F01, F02, F051 
Pulmonary disease 1 J40, J41, J42, J44, J43, J45, J46, J47, J67, J44, J60, J61, J62, J63, J66, J64, J65 
Connective tissue disorder 1 M32, M34, M332, M053, M058, M059, M060, M063, M069, M050, M052, M051, M353 
Peptic ulcer 1 K25, K26, K27, K28 
Liver disease 1 K702, K703, K73, K717, K740, K742, K746, K743, K744, K745 
Diabetes 1 E109, E119, E139, E149, E101, E111, E131, E141, E105, E115, E135, E145 
Diabetes complication 2 E102, E112, E132, E142 E103, E113, E133, E143 E104, E114, E134, E144 
Paraplegia  2 G81 G041, G820, G821, G822 
Renal disease 2 N03, N052, N053, N054, N055, N056, N072, N073, N074, N01, N18, N19, N25 
Cancer 2 C0, C1, C2, C3, C40, C41, C43, C45, C46, C47, C48, C49, C5, C6, C70, C71, C72, C73, C74, C75, C76,C80, C81, C82, 
C83, C84, C85, C883, C887, C889, C900, C901, C91, C92, C93, C940, C941, C942, C943, C9451, C947, C95, C96 
Metastatic cancer 3 C77, C78, C79, C80 
Severe liver disease 3 K729, K766, K767, K721 
HIV 6 B20, B21, B22, B23, B24 
Note: Charlson diagnostic categories and corresponding ICD-10 AM codes. Adapted from “New ICD-10 version of the Charlson co-morbidity 
index predicted in-hospital mortality,” by V. Sundararajan, T. Henderson, C. Perry, A. Muggivan, H. Quan, and W. Ghali, 2004. Journal of 
Clinical Epidemiology, 57, p.1290. Copyright 2004 by Elsevier B.V.  
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Appendix H  
Time between first and second cases of Clostridium difficile infection for 
persons with more than one infection 
 
Person Time between first and second infection 
1 3 years 
2 9 months 
3 4 months 
4 6 months 





Appendix I  
Models used to evaluate the cost of healthcare associated infections  
 
This appendix briefly explores the different models used to evaluate the economic 
cost of a HAI. By exploring these models, it becomes evident that length of stay in 
hospital is an important element of cost and that this variable underpins models used 
to evaluate cost. As demonstrated in a recent published systematic review examining 
the economic costs of CDI, the focus of many studies is to view costs through the eyes 
of an accountant (Ghantoji et al., 2010). An accountant’s model for determining the 
cost of HAIs is to count fixed and variables costs. Variable costs may include items 
such as dressings, personal protective equipment and costs of laboratory test 
materials. Fixed costs include such things as salary, electricity and heating. As fixed 
costs are often jointly shared, for example one doctor does not treat one patient, the 
accountants’ model determines a measure of usage for these fixed costs (cost per unit) 
and allocates this to patients or the health provider accordingly. Comparisons between 
the average cost per infected patient and average cost per non-infected patient are 
often used to attribute the cost of HAIs, however this maybe misleading (N. Graves, 
Halton, K., Jarvis, W., 2009). According to Graves, using such a model is not suitable 
for economic appraisal or informing decisions on the best use of scarce healthcare 
resources. An implication of the accountant model is that by reducing or eradicating a 
specific infection, a fixed figure could be saved. An accountant model ignores the cost 
of increased investment associated with reducing infections and fails to consider what 
costs actually change with infections, where many fixed costs remain (N. Graves, 
Halton, K., Jarvis, W., 2009). 
 
An economist model uses a cost analysis approach to determine any savings. For 
example, the consumables may be reduced with a reduction in HAIs. The capacity 
gained by a reduction in HAIs is valuable and should thus be redeployed for other 
uses. The redeployment of resources could be used for tasks such as elective surgery 
which in turn may cause other variable costs to increase (N. Graves, Halton, K., 
Jarvis, W., 2009). An economist’s approach in evaluating the cost of HAIs is 




are fixed (Plowman, 1999; Roberts et al., 1999). Therefore, in describing how costs 
change in relation to HAIs, it is important to demonstrate the number of bed days 
caused by HAIs (N. Graves, Halton, K., Jarvis, W., 2009) before deciding who will 
utilise these extra bed days released. This concept of accurately determining the 
prolongation of length of stay due to CDI will assist in developing an economic model 






Appendix J  
Technical explanation of a multistate model 
 
A technical explanation for a multistate model is provided by Wolkewitz et al (2010): 
 
The hazard (u) depends on time u and is considered to be the probability of 
changing states in the next short time interval divided by the length of the 
interval, noting that individuals have been in the current state up to that time. 
In the equation below, Y(u) is denoted as the size of the risk sets and N(u) as 
the number of observed events at time u. The time-dependent cumulative 
hazard can be estimated by the following formula (Nelson–Aalen estimator). 
The formula shows that the size of the risk sets (denominator) is crucial to 
estimate the death hazards. Survival analysis is based on hazards because the 
cumulative hazard (and the hazard itself) remains ‘undisturbed’ by right 
censoring/left-truncation if the truncation as well as the censoring time is 









Appendix K  
Code used for multistate model data analysis in R 
 
# MVNA3state.R 
# september 2011 
# analyse Brett's data using MVNA, use a 3 state model (Susceptible, infected, 
death/discharge) 
setwd(lib$brett) # move to the folder 
load('Brett.RData') # load the data 
library(mvna) # R library to run multistate models 
 




## set up entry and exit times 
# susceptible -> death/discharge 
not.infected$entry=0 # start at time zero 
not.infected$exit=as.numeric(not.infected$Discharge-not.infected$Admission) # exit 
at discharge, add 0.001 day for same day entry/exit 
not.infected$from=0 # from susceptible 
not.infected$to=2 # to death/discharge 
not.infected=subset(not.infected,select=c(id,from,to,entry,exit)) # remove extra 
variables from the data 
# susceptible -> infected 
StoI=infected 
StoI$entry=0 # start at time zero 
StoI$exit=as.numeric(StoI$Infection.start-StoI$Admission)# exit at infection date 
StoI$from=0 # from susceptible 
StoI$to=1 # to infected 
StoI=subset(StoI,select=c(id,from,to,entry,exit)) # remove extra variables from the 
data 





ItoD$entry=as.numeric(ItoD$Infection.start-ItoD$Admission)# entry at infection date 
ItoD$exit=as.numeric(ItoD$Discharge-ItoD$Admission) # exit at discharge 
ItoD$from=1 # from infected 
ItoD$to=2 # to death/discharge 
ItoD=subset(ItoD,select=c(id,from,to,entry,exit)) # remove extra variables from the 
data 
# concatenate the three data sets 
for.analysis=rbind(not.infected,StoI,ItoD) 
with(for.analysis,table(from,to)) # table of the transitions 
 
# Modification for patients entering and leaving a state at the same date 
for.analysis <- for.analysis[order(for.analysis$id, for.analysis$entry, 
for.analysis$exit), ] 
for (i in 2:nrow(for.analysis)) { 
  if (for.analysis$id[i]==for.analysis$id[i-1]) { 
    if (for.analysis$exit[i]==for.analysis$exit[i-1]) { 
      for.analysis$exit[i-1] <- for.analysis$exit[i-1] - 0.5 # move forward in time by half 
a day 
      for.analysis$entry[i] <- for.analysis$entry[i] - 0.5 # change to match above move 
    } 
  } 
} 




# Matrix of logical giving the possible transitions 
tra <- matrix(ncol=3,nrow=3,FALSE) 
tra[1, 2:3] <- TRUE 
tra[2, 3] <- TRUE 
 
# Computation of the Nelson-Aalen estimates 





# plot to a jpeg 
jpeg(filename = "3State.jpg", width = 9, height = 9, res=300, 
     units = "cm", pointsize = 12, quality = 100, bg = "transparent") 
par(mai=c(0.9,0.9,0.05,0.2),las=1) # set up margins 
plot(na, tr.choice=c("0 2", "1 2"), xlab = "Days in hospital",xlim=c(0,80),ylim=c(0,6), 
     ylab = "Cumulative Hazard", lwd=2, curvlab=c("Not infected","Infected")) 
dev.off() 
 
### Biased estimate based on ignoring time-dependence 







tdepLower <- exp(model$coefficients[1,1]+lower)-exp(model$coefficients[1,1]) 
tdepUpper <- exp(model$coefficients[1,1]+upper)-exp(model$coefficients[1,1]) 














Appendix L  
Incidence of Clostridium difficile infection per 1000 admissions by calendar 
year at the Royal Hobart Hospital 
 
Year Number of cases 
of CDI 
Incidence per 1000 
admissions 


























Note: Admissions = total admissions to the RHH hospitalised ≥48 hours. CDI = 





Appendix M  
Comparison of Diagnosis Related Group in person with and without 
Clostridium difficile infection at the Royal Hobart Hospital, 2007-2010 
 






Total (%) Statistic p value 
Pregnancy 1 (0.6) 7898 (13.4) 7899 (13.4) 22.26^ <0.01 
Circulatory 12 (7.6) 6851 (11.7) 6863 (11.6) 2.52^ 0.11 
Musculoskeletal 16 (10.1) 5877 (10.0) 5893 (10.0) 0.003^ 0.96 
Nervous 20 (12.7) 5007 (8.5) 5027 (8.5) 3.46^ 0.06 
Respiratory 9 (5.7) 4711 (8.0) 4720 (8.0) 1.15^ 0.28 
Digestive 21 (13.3) 4709 (8.0) 4730 (8.0) 5.95^ 0.02 
Health status 15 (9.5) 4278 (7.3) 4293 (7.3) 1.15 ^ 0.28 
Mental health 1 (0.6) 3894 (13.4) 3895 (6.6) 9.17^ <0.01 
Injury 3 (1.9) 1957 (3.3) 1960 (3.3) N/A* 0.50 
Skin 3 (1.9) 1799 (3.1) 1802 (3.1) N/A* 0.64 
Endocrine 3 (1.9) 1623 (2.8) 1626 (2.8) N/A* 0.81 
Kidney 10 (6.3) 1577 (2.7) 1587 (2.7) 8.00^ <0.01 
Hepatobiliary 4 (2.5) 1525 (2.6) 1529 (2.6) N/A* 1.00 
ENT 1 (0.6) 1477 (2.5) 1478 (2.5) N/A* 0.20 
Female reproduction 2 (1.3) 1190 (2.0) 1192 (2.0) N/A* 0.78 
Infectious 4 (2.5) 895 (1.5) 899 (1.5) N/A* 0.31 
Neoplastic 8 (5.4) 795 (1.4) 803 (1.4) 16.15^ <0.01 
Blood 3 (1.9) 615 (1.0) 618 (1.0) N/A* 0.23 
Male reproduction 0 (0.0) 601 (1.0) 601 (1.0) N/A* 0.42 
Alcohol 0 (0.0) 335 (0.6) 335 (0.6) N/A* 1.00 
Burns 0 (0.0) 288 (0.5) 288 (0.5) N/A* 1.00 
Eye 0 (0.0) 165 (0.3) 165 (0.3) N/A* 1.00 
Pre  19 (12.0) 547 (0.9) 566 (0.9) 203.95^ <0.01 
Error 3 (0.3) 170 (1.9) 173 (0.3) 13.95^ <0.01 








Appendix N  
Ethics approval from the Tasmanian Human Research Ethics Committee 







Appendix O  
Ethics approval from Australian Catholic University for Staphylococcus 








Appendix P  
Ethics approval from the Tasmanian Human Research Ethics Committee 













Appendix Q  
Ethics approval from Australian Catholic University for the Clostridium 
difficile infection studies 
 
 
 
